Interní Med. 2009; 11(Suppl.1)

Racionální přístupy k léčbě osob s diabetem

pořadatel: doc. MUDr. Rudolf Chlup, CSc.

Terapeutická edukace ve 3. miléniu

Published: January 20, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chlup PR. Racionální přístupy k léčbě osob s diabetem. Interní Med. 2009;11(Suppl.1):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Berger M, Jörgens V, Chlup R. Léčba inzulinem v každodenním životě. Victoria Publishing, Praha, 1995: s. 293.
    2. Bruns W, Seige K, Menzel R, Panzram G. Die Entwicklung der Diabetologie im Osten Deutschlands von 1945 bis zur Wiedervereinigung. Deutsche Diabetesgesellschaft, WECOM, Hildesheim, ISBN 3-936453-31-4, 55 s.
    3. Diabetes Education Study Group. Basic curriculum for health professionals on diabetes therapeutic education. Report of DESG Working Group 2001, 62 stran.
    4. Goleman D. Emotional inteligence, Bloomsbury paperbacks, Great Britain, 1996, 352 s.
    5. Howorka K: Pícháte si inzulín? Kirchheim, Mainz, 1996: 155 s.
    6. Chlup R, Holešinská P, Chlupová L, Komenda S. Assessment of Postgraduate Education of Therapeutic Educators (PETE) at a university diabetes centre. In. Diabetes Metabolism. 18th Interantional Diabetes Federation Congress. Poster Displays. France: Paris, 24-29 August 2003.
    7. Chlup R, Janů K, Menzel R, Bruns W, Venháčová J. Léčba diabetu pomocí ručního dávkovače inzulínu MADI. Univerzita Palackého Olomouc, 1985: 63 s.
    8. Chlup R, Taton J, Neoral L, Day JL. The changing role of physician nurse dietitian teacher and social environment in the self-treatment of a diabetic patient. Vth European Workshop of Medical & Teaching Staff. Olomouc, 1991.
    9. Chlup R, Navrátilová L, Řehořová J, Vaverková H, Venháčová J, Bartek J, Ficker L, Slezáková L. Programová léčba diabetu. Galén, Praha 1996: 194 s.
    10. Jirkovská A, a kol. (1998) Jak (si) kontrolovat a léčit diabetes. Ed. PANAX Praha.
    11. Jörgens V, Grüsser M, Perger M, Kreze-Spirová E. Moja kniha o cukrovke. Eli Lilly, 1997: 121 s.
    12. Kodadský J. Praktické rady pro nemocné cukrovkou. GEUM Běstvina, 1999: 80 s.
    13. Kolektiv autorů: Diabetes mellitus - příčiny komplikace léčba. Příručka pro pacienty. IKEM, Praha, 1992.
    14. Kudlová P, Tomanová D. Didaktická vybavenost edukační lekce. In. Trendy v ošetřovatelství III. - Trends in Nursing III. Ostrava: Ostravská univerzita, Zdravotně sociální fakulta, 2004a: 93-102.
    15. Kudlová P, Tomanová D. Strukturní elementy edukace. In Kudlová, P. (Ed.) Ošetřovatelství perspektivní věda i umění. 1. vyd. Olomouc: Grada Publishing, 2004b: 388 s. 182-192.
    16. Menzel R. Insulin zum Leben. MEDICUS Verlag Gesundheit, Berlin, 1997: 204 stran.
    17. Mühlhauser I., Bruckner I, Berger M, Cheta D, Jörgens V, Ionescu-Tirgoviste C, Scholz V, Mincu I (1987) Evaluation of an intensified insulin treatment and teaching programme as routine management of type I (insulin-dependent) diabetes. Diabetologia 30: 681-690. Go to original source... Go to PubMed...
    18. Vávrovi H aj. Poezie dospívání. GEUM Praha, 2006.
    19. World Health Organisation. Therapeutic patient education. 1998: 76 s.
    20. ###
    21. Bartoš V, Pelikánová T. a kolektiv. Praktická diabetologie. 3. rozšířené vydání. Praha: Maxdorf, 2003: 479 s.
    22. Holešinská P. Edukace diabetika II. typu léčeného, mimo jiné, inzulinem. In Holešinská, P. (Ed.) Multioborová, interdisciplinární a mezinárodní kooperace v ošetřování. 1. vyd. Praha: GRADA Publishing, 2002; 376 s.
    23. Chlup R, a kol. Úvod do diagnostiky a léčby diabetu. Olomouc: VUP, 2000.
    24. Chlup R, et al. Programová léčba diabetu. 1. vyd. Praha: Galén, 1996: 196 s.
    25. Kalhous Z. Základy školní didaktiky. 1. vyd. Olomouc: VUP, 1995: 122 s.
    26. Kudlová P. Edukační program, distanční text v předmětu Ošetřovatelský proces u vybraných chorob. Olomouc: ÚTPO LF UP, LMS Unifor, 2003. Staženo 19. 02. 04. Dostupný z: http://serverl.upol.cz.
    27. Kudlová P, Tomanová D. Didaktická vybavenost edukační lekce. In. Trendy v ošetřovatelství III. - Trends in nursing III. Ostrava: Ostravská univerzita, Zdravotně sociální fakulta, 2004a: s. 93-102.
    28. Kudlová P, Tomanová D. Strukturní elementy edukace. In Ošetřovatelství perspektivní věda i umění. Kudlová, P. (Ed.) 1. vyd. Olomouc: Grada Publishing, 2004b: 388 s.
    29. Rybka J. Saintvincentská deklarace - váš průvodce k lepší léčbě diabetu. 1. vyd. Praha: Svaz osob s diabetem České republiky, 1994.
    30. Tomanová D. Edukační kompetence zdravotní sestry. In Multioborová, interdisciplinární a mezinárodní kooperace v ošetřování. Holešinská P. (Ed.) 1. vyd. Praha: GRADA Publishing, 2002. 376 s.
    31. ###
    32. Bartoš V, Pelikánová T. a kolektiv. Praktická diabetologie. 3. rozšířené vydání. Praha: Max dorf, 2003; 479 s.
    33. Chlup R, et. al. Programová léčba diabetu. 1. vyd. Praha, Galén, 1996; 194 s.
    34. Chlup R, a kol. Úvod do diagnostiky a léčby diabetu. Olomouc: VUP, 2000.
    35. Kudlová P, Chlup R. Pomůcky k aplikaci inzulinu. Interní Med. 2006; 8(6): 302-306.
    36. Vízner K, et al. Pomocník diabetologa 2008 - Informační katalog. Praha: Geum, 2008. 1. vyd.
    37. ###
    38. Expert committee on the diagnosis and classification of diabetes mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
    39. Silverstein J, et al. Care of children and adolescents with type 1 diabetes mellitus: a statement of the American Diabetes Association. Diabetes Care 2005; 28: 186-212. Go to original source... Go to PubMed...
    40. Standards of Medical Care in Diabetes - 2007. Diabetes Care 2007; 30 (Suppl. 1): S4-S41.
    41. Praktická diabetologie. Eds. V. Bartoš, T. Pelikánová a kol., Maxdorf 2003.
    42. ###
    43. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006; 49: 1711-1721. Go to original source... Go to PubMed...
    44. Praktická diabetologie. Eds. V. Bartoš, T. Pelikánová a spol., Maxdorf 2003. (3. vydání)
    45. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Cor Vasa 2005; 47: 3-14.
    46. Recommendations for the management of patients with type 2 diabetes mellitus in the central, Eastern and Southern European Region. Int. J. Posttrad. Train. Med. 2000: 8.
    47. Standards of medical care in diabetes - 2007, Diabetes Care 2006; 30 (Suppl. 1): S4-S41.
    48. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. European Heart Journal 2007; 28: 88-136.
    49. ###
    50. Anděl M, et al. Diabetes mellitus a další poruchy metabolismu. 1. vyd Galén Praha 2001: 210 s.
    51. Assal JP. The Diabetes Education Study Group of the European Association for the Study of Diabetes: 15 years devoted to improving patient management. 1994.
    52. Bakx J. Editorial: Health promoting hospitals. Patient Education and Counseling 2001; 45: 237-238. Go to original source...
    53. Berger M, Jörgens V, Chlup R. Léčba inzulinem v každodenním životě. Victoria Publishing. Praha 1995: 293 s.
    54. Bruns W. Zur Therapie des Typ-2 Diabetes - Ansätze für eine frühzeitig beginnende pathophysiologisch begründete Therapie mit Insulin. Diabetes Dialog 1998; 1-98: 9-13.
    55. Chlup R, et al. Programová léčba diabetu. Galén 1996; 194 s.
    56. Chlup R, Možíšová L. Léčba diabetiků pomocí inzulinové pumpy - teorie a praxe. Diabetologie-Metabolismus-EndokrinologieVýživa 2000; 3 (1): 3-17.
    57. Diabetes Education Study Group: Basic curriculum for health professionals on diabetes therapeutic educatioon. Report of a DESG Working Group, DESG 2001; 62 s.
    58. IDF Consultative Section on Diabetes Education: International Consensus of Practice for Diabetes Education. Class Publishing Barb House Berb Mews London W67PA UK 1997.
    59. Jirkovská A. Jak (si) kontrolovat a léčit diabetes: manuál pro edukaci diabetiků. Praha Panax 1999: 200 s.
    60. Kvapil M. Edukace diabetika - nezbytná součást léčby. Vnitřní lékařství 2001; 5: 293-297.
    61. Menzel R. Insullin zum Leben. Medicus Verlag Gesundh 1997: 204 s.
    62. Mlčák P, Chlup R, Boudová E, Bartek J, Zapletalová J. Vývoj koncentrace glukosy v intersticální tekutině u nediabtetiků s ohledam na detekci fenoménu svítání - pilotní studie. Klin. Metab 2003; 1: 44-49.
    63. Musil D, Heřman J. Přínos barevné duplexní ultrasonografie k předoperačnímu vyšetření nemocných s chronickou žilní insuficiencí. Vnitř. lék. 2001; 4: 227-231.
    64. Osterbrink B. für Ausschüssen und Arbeitsgruppen der Deutschen Diabetes-Gesellschaft. Neue Qualitätsstandards zur Anerkennung einer Behandlungseinrichtung für Typ 1- und Typ 2 - Diabetes mellitus. Diabetologie-Informationen (DDG) 2002; 24(6): 173-179.
    65. Perušičová J, Šmahelová A, Kvapil M, Rušavý Z. Inzulinová léčba diabetiků 1. typu - závěry workshopů českých diabetologů 1. část. Diabetologie-Metabolismus-Endokrinologie-Výživa 2002; 5 (4): 251-253.
    66. Rosak C. Insulinanaloga: Struktur, Eigenschaften und therapeutische Indikationen Teil 1: Kurzwirkende Insulinanaloga. Internist 2001; 42: 1523-1535. Go to original source... Go to PubMed...
    67. Rušavý Z, et al. Diabetická noha: diagnostika a terapie v praxi. Galén Praha 1998: 189 s.
    68. Škrha J. Standardy péče o diabetes mellitus 1. typu. Diabetologie-Metabolismus-Endokrinologie-Výživa 1999; 2 (2): 81-85.
    69. Šmahelová A, Perušičová J. Akutní komplikace diabetes mellitus. Interní medicina pro praxi 2000; 2 (10): 491-496.
    70. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruynink F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367. Go to original source... Go to PubMed...
    71. Weber P, Polcarová V. Jak léčíme diabetes (zejména s pozdními komplikacemi) ve vyšším věku? In: Čs. gerontologická a geriatrická společnost, Čs. společnost pro aterosklerózu, Společnost parenterální a enterální výživy, metabolismu a stárnutí: V. celostátní kongres s mezinárodní účastí na téma, ,Účelná farmakoterapie ve stáří". Hradec Králové 25.-26.11.1999. Souhrny přednášek a posterů. 1999.
    72. World Health Organization Regional Office for Europe: Therapeutic patient education. Report of a WHO working group 1998; 77s.
    73. World Health Organization, International Diabetes Federation: Saintvincentská deklarace - Váš průvodce k lepší léčbě diabetu. Svaz diabetiků České republiky Praha 1994.
    74. ###
    75. Vaverková H, Soška V, Rosolová H, Češka R, Cífková R, Freiberger T, Piha J, Poledne R, Štulc T, Urbanová Z, Vráblík M. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracovaná výborem české společnosti pro aterosklerózu. Vnitřní lék 2007; 53(2): 181-197.
    76. Cífková R, Býma S, Češka R, Horký K, Karen I, Kunešová M, Králíková E, Rosolová H, Roztočil K, Soška V, Škrha J. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Cor Vasa 2007; 49(3): K73-K86.
    77. Cífková R, Býma S, Češka R, Horký K, Karen I, Kunešová M, Králíková E, Rosolová H, Roztočil K, Soška V, Škrha J. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Čas Lék čes 2007; 146(6): I-XV.
    78. Cífková R, Býma S, Češka R, Horký K, Karen I, Kunešová M, Králíková E, Rosolová H, Roztočil K, Soška V, Škrha J. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. DMEV 2007; 10(2): 106-120.
    79. Cífková R, Býma S, Češka R, Horký K, Karen I, Kunešová M, Králíková E, Rosolová H, Roztočil K, Soška V, Škrha J. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Vnitřní lék 2005; 51: 1021-1036.
    80. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Four Joint Task Force of European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehab 2007; 14 (Suppl 2): E1-E40.
    81. ###
    82. Berger M, Jörgens V, Chlup R. Léčba inzulinem v každodenním životě. Victoria Publishing, Praha, 1995; 293 s.
    83. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Y, Shahinfar S, for the RENAAL Study Investigators (... Chlup R...). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001; 345 (12): 861-869. Go to original source... Go to PubMed...
    84. Bruns W, Chlup R, Philipp A, Worms F, Lundershausen R. Pathophysiologisch begründete Therapie der postprandialen Hyperglykämie - unter Berücksichtigung der zirkadianen Insulindefizite bei Typ-2-Diabetes - Untersuchungen unter Nutzung des sogenannten Basalratentests. Diabetes Stoffw 2001; 10 (Suppl 2): 7 (Abstrakt).
    85. Felsing W, Menzel R, Alt P, Chlup R, Bruns W. Erste Erfahrungen mit dem MADI in der DDR. In: W Bruns (ed) Lehrgang über aktuelle Probleme des Diabetes mellitus Berlin 24.-28. 11. 1986 (Kongressberichte) Edn Akademie für ärztliche Fortbildung der DDR, p 60.
    86. Holešinská P, Chlup R. Kdo má edukovat diabetiky? Zprav klin Farmakol Farmac 1998; 12 (4): 29-33. Go to original source...
    87. Hřebíček J, Janout V, Malinčíková J, Horáková D, Čížek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index Quicki for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002; 87 (1): 144-147. Go to original source... Go to PubMed...
    88. Chlup R. Přínos a praktické provádění intenzivní léčby u diabetiků 1. a 2. typu. In: Abstrakta XI. Diabetologické dny v Trenčíně s medzinárodnou účasťou 7.-9. 6. 2001, (nestr) (Abstrakt).
    89. Chlup R, Bartek J, Malá E, Doubravová B, Pukowietz L, Zatloukal P, Chlupová L, Zapletalová J. Uživatelská studie o správnosti a přesnosti měření glukometrů Advance, Card a Optium. Klin Biochem Metab 2004; 12 (3): v tisku.
    90. Chlup R, Bartek J, Řezníčková M, Zapletalová J, Doubravová B, Chlupová L, Sečkař P, Dvořáčková S, Šimánek V. Determination of glycaemic index of selected foods (white bread and cereal bars) in healthy persons. Biomed Papers 2003; 147: v tisku. Go to original source...
    91. Chlup R, Beránková I, Boudová E, Ďurajková E, Faltýnková J, Fišarová S, Gajdošová M, Grecmanová M, Holá J, Holešinská P, Hrubá V, Kmoníčková A, Konštacká L, Pevná Z, Řehořová J, Strnadová J, Šeflová L. Doporučení pro léčbu inzulinem u dospělých diabetiků při hospitalizaci - návrh standardu. Klin Farmakol Farm 2003; 17 (1): 34-42.
    92. Chlup R, Holešinská P, Chlupová L, Komenda S. Assessment of postgraduate education of therapeutic educators (PETE) at a university diabetes centre. Diabetes Metab 2003; 29: 4S385 (Abstract).
    93. Chlup R, Janů K, Menzel R, Bruns W, Venháčová J. Léčba diabetu pomocí ručního dávkovače inzulinu MADI. Univerzita Palackého v Olomouci, Olomouc, 1985; 64 s.
    94. Chlup R, Janů K, Venháčová J, Bartek J. Six models of a new insulin pen (MADI): description and first clinical trial. Practical Diabetes International 1995; 12 (1): 32-35. Go to original source...
    95. Chlup R, Křikal Z, Flašarová B, Gazárek F. Diabetes a těhotenství matky. Čes Gynek 1976; 41: 113-115.
    96. Chlup R, Maršálek E, Bruns W. Prospective study of the hazards of multiple use of disposable syringes and needles in intensified insulin therapy. Diabetic Medicine 1990; 7: 624-627. Go to original source... Go to PubMed...
    97. Chlup R, Menzel R, Hildmann W, Eisner B, Heinke P, Jutzi E. Co přináší noční dávka insulinu? In: Abstrakta XXVI. diabetologické dny v Luhačovicích, 24.-27. dubna 1990, 20 s.
    98. Chlup R, Menzel R, Kolesár P, Rybka J, Svoboda Z, Škarpová O, Venháčová J, Zander E, Abel P, Rosenfeld R, Hildebrandt R, Janů K, Jutzi E. Erste Erfahrungen mit dem MADI - multizentrische technische und klinische Studie. VIII. internationales DonauSymposium über Diabetes mellitus, Bratislava, 18.-21. Juni 1985. Wien: Robidruck 1985; Abstrakt 79 P, (nestr).
    99. Chlup R, Mlčák P, Boudová E, Fialová J, Bartek J. Kontinuální monitorování koncentrace glukosy v intersticiální tekutině - naše první zkušenosti. Klin Biochem Metab 2003; 11 (32): 37-43.
    100. Chlup R, Možíšová L. Léčba diabetiků pomocí inzulinové pumpy - teorie a praxe. Diabet Metabol Endokrin Výž 2000; 3 (1): 3-17.
    101. Chlup R, Navrátilová L, Řehořová J, Vaverková H, Venháčová J, Bartek J, Ficker L, Slezáková L. Programová léčba diabetu. Galén, Praha 1996: 196 s.
    102. Chlup R, Neoral L. Methods for retrospective assessment of the unusual behavior of a person with diabetes: ebrietas alcoholica and/or hypoglycaemia? Biomed Papers 2003; 147: v tisku.
    103. Chlup R, Rancová A, Both P, Axmannová M, Vaverková H, Bartek J. Intensive komplementäre Insulintherapie bei adipösen Typ-2Diabetikern hat meistens eine Gewichtsreduktion zur Folge. Diabetes und Stoffwechsel 1999; 8 (Suppl): 17 (Abstrakt).
    104. Chlup R, Táncosová S, Malá E, Boudová E. Co stojí léčba diabetu? In: Abstrakta XII. Diabetologické dni v Trenčíně s medzinárodnou účasťou 5.-8. 6. 2002, (nestr) (Abstrakt).
    105. Chlup R, Vaverková H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. I. Effects on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105 (Suppl 2): 70-73. Go to original source... Go to PubMed...
    106. Chlup R, Vaverková H, Bartek J. Long-Term Benefits of Complementary Insulin Therapy on Body Mass and Hemoglobin A1c in Obese Type 2 Diabetic Patients. Diabetes Research and Clinical Practice 2000; 50 (Suppl 1): S66-S67 (Abstract). Go to original source...
    107. Chlup R, Zander E, Hildmann W, Bartek J, Jutzi E. Vliv tělesného tréninku na metabolizmus sacharidů a tuků u diabetiků 1. typu. In: E Horniak (ed) Sport ve zdraví a nemoci: Práce IV. Evropského kongresu sportovního lékařství, Praha 25. 3.-28. 3. 1985, 1. díl, 245-251.
    108. Chlup R, Zapletalová J, Sečkař P, Chlupová L, Táncosová S, Řezníčková M. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 diabetes treated by means of an insulin pump. Biomed Papers 2003; 147: v tisku. Go to original source...
    109. Janů K, Chlup R. Konstrukční řešení ručního dávkovače inzulinu MADI. Jemná mechanika a optika 1992; 37 (1): 14-15.
    110. Loyková V, Chlup R, Pumprla J, Bartek J. Intenzivní inzulinová léčba pomocí MADI u dospělých. In: Abstrakta XXIV. diabetologické dny v Luhačovicích, 24.-27. dubna 1990, 30 s.
    111. Menzel R, Chlup R, Felsing W, Witte K, Alt E, Jutzi E. Insulininjection devices connected to the body by subcutaneous catheter - a cheap alternative to highly sophisticated insulin pumps? Diabetologia 1988; 31: 520 A (Abstract).
    112. Menzel R, Chlup R, Jutzi E, Hildmann W., ,Catheter-Pens" - an alternative to insulin pump treatment? Exp Clin Endocrinol 1990; 95: 157-64. Go to original source... Go to PubMed...
    113. Nakládalová M, Kapoun S. Zdravotní způsobilost k práci u osob s diabetem. Pracov Lék 2004; 56: 13-16.
    114. Neoral L, Chlup R, Loyková V, Franková M, Zedníková K, Bartek J, Mazochová J. Vliv inzulinu na metabolizmus etylakoholu a vliv etylalkoholu na glykemii u diabetiků 1. typu. Protialkoholický obzor 1991; 26 (6): 329-337.
    115. Rybka J, Brázdová L, Jirkovská A, Chlup R, Lacigová S, Lebl J, Vavřinec J, Podroužková B, Šimurda J, Rušavý Z. Edukace diabetika. In: Sborník XXX. jubilejní diabetologické dny v Luhačovicích, 21.-23. 4. 1994, 40-49.
    116. Vaverková H, Chlup R, Ficker L, Novotný D, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients: II. Effects on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997; 105 (Suppl 2): 74-77. Go to original source... Go to PubMed...
    117. World Health Organization Regional Office for Europe. Therapeutic patient education. Continuing education programmes for healthcare providers in the field of prevention of chronic diseases. Report of a WHO Working Group 1998: 77 s.
    118. Zander E, Bruns W, Wulfert P, Besch W, Lubs D, Chlup R, Schulz B. Muscular Exercise in Type 1-Diabetics. Exp Clin Endocrinol 1983; 82 (1): 78-90. Go to original source... Go to PubMed...
    119. Zander E, Schulz B, Chlup R, Woltansky P, Lubs D. Muscular exercise in Type-1-Diabetics: II. Hormonal and metabolic responses to moderate exercise. Exp Clin Endocrinol 1985; 85 (1): 95-104. Go to original source... Go to PubMed...
    120. ###
    121. Cox DR, Oakes D. Analysis of survival data. Chapman & Hall, USA 1998.
    122. Faber E, Koza V, et al. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry. Neoplasma 2007; 54 (5): 443-446. Go to PubMed...
    123. Faber E, Vondráková J, et al. Prognostic factors for survival of patiens with non-Hodgkin's lymphoma (NHL) after autologous peripheral stem cell transplantation (APSCT) - dingle center experience. Biology of Blood and Marrow Transplantation 2006; 12 (2): 344. Go to original source...
    124. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203-223. Go to original source... Go to PubMed...
    125. Hanefeld M, Julius U, et al. Die Diabetesinterventionsstudie (DIS) Diabetesverlauf und Mortalität, eine Bilanz 11 Jahre nach Diagnosestellung, Diabetes und Stoffwechsel 1996; 5: 39-45.
    126. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Ass 1958; 53: 457-481. Go to original source...
    127. Karvonen M, Tuomilehto J, et al. A review of the recent epidemiological data on the worldwide incidence of Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 883-892. Go to original source... Go to PubMed...
    128. Klein JP, Moeschberger ML. Survival analysis: Techniques for censored and truncated data. Springer, New York 1997.
    129. Kleinbaum DG. Survival analysis. Springer-Verlag, New York 1996. Go to original source...
    130. Michaelis D, Jutzi E, Heinke P. 30jährige Inzidenz - und Prävalenztrend des juvenilen Typ I - Diabetes in der ostdeutschen Bevölkerung. Diab Stoffw 1993; 2: 245-250.
    131. Perušičová J, Neuwirt K. Epidemiology of diabetes mellitus in Prague. Kvarta 1992, Praha.
    132. Procházka V, Trněný M, et al. Peripheral T-cell lymphoma, unspecified - the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomed Pap 2007; 151 (1): 103-107. Go to original source... Go to PubMed...
    133. Ratzmann K, Gorr K, Schneider H. Prävalenz diabetesbedingter Erblindungen. Diabetes und Stoffwechsel 1994; 3: 261-264.
    134. Schneider H, Lischinski M, Jutzi E. Survival time after onset of diabetes: 29-year follow-up mortality study in a diabetes cohort from a rural district. Diabete & Metabolisme 1993; 19: 152-158. Go to PubMed...
    135. Schneider H, Lischinski M, Jutzi E. Überlebenszeit von Diabetikern im 30-Jahres-Follow-up innerhalb einer geschlossenen Population. Diabetes 1993; 87: 323-327.
    136. Snedecor GW, Cochrane WG. Statistical Methods. Ames, The Iowa State University Press, 1967.
    137. Škrha J. Diabetes mellitus 2002 v České republice - epidemiologická studie. Diabetol Metab Endokrinol výž 2005; 8 (1): 5-12.
    138. Ústav zdravotnických informací a statistiky ČR. Péče o nemocné cukrovkou 2006 in.: Zdravotnická statistika http://www.uzis.cz.
    139. Zvárová J. Základy statistiky pro biomedicínské obory, Karolinum, Praha 2004.
    140. ###
    141. Standardy péče o diabetes mellitus v těhotenství, Diab Metabol Endokrin Výž., 2007; 10(4): 229-231.
    142. Bartoš V, Pelikánová T, et al., Praktická diabetologie, II. vydání 2000: 345-365.
    143. Barron MW, Lindheimer MD. Medical disorders during pregnancy, Mosby 2000, 3rd edition, 71-101.
    144. James DK, Steer PJ, Werner CP, Gonik B, High risk pregnancy management options, W. B. Saunders II.nd edition, London, 665-685.
    145. Chlup R, Gazárek F, Křikal Z, Flašarová B. Diabetes a těhotenství matky, Čes. Gynekol. 1976; 41(2): 113-115.
    146. Čech E. a kol. Porodnictví. Grada 2006, II. vydání.
    147. Kudela M, a kol. Základy gynekologie a porodnictví pro posluchače lékařské fakulty, LF UP Olomouc, 2004: 242-243.
    148. Winn NH, Hobbins JC. Clinical Maternal-Fetal Medicíně, Parthenon Publishing, New York 2002: 395-402.
    149. Queenan JT, Spong CY, Lockwood CJ, Management of High-Risk Pregnancy, Blackwell Publishing, Vth edition, 2007, 182-186. Go to original source...
    150. Boulvain M, Stan C, Irion O. Elective delivery in diabetic pregnant women. Cochrane Pregnancy and Childbirth Group. Cochrane Databáze Syst rev 2006; 2: CD 000451.
    151. Unzeitig V, Andělová K, Stará S. Doporučený postup k provádění screeningu poruch glukózové tolerance v graviditě, www.perinatologie.cz, 2009.
    152. ###
    153. Bartoš V, Pelikánová T, a kol. Praktická diabetologie, 3. vydání. Maxdorf, Praha 2003: 479 s.
    154. Cinek O, Šumník Z, Vavřinec J. Dětský diabetes mellitus v České republice: stále více a čím dál dříve. Čas. Lék. čes. 2005; 144: 266-271.
    155. Eurodiab ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000; 355 (9207): 873-8763. Go to original source...
    156. Frier BM. Defining hypoglycaemia: What level has clinical relevance? Diabetologia 2009; 52: 31-34. Go to original source... Go to PubMed...
    157. IS3 Clinical Practice Consensus Guidelines 2006-2007. www.ispad.org.
    158. Lebl J, Průhová Š, a kol. Abeceda diabetu. 3. rozšířené vydání, Maxdorf, Praha 2008: 184 s.
    159. Phillip M, Batelino T, Rodriguez H, et al. Use of Insulin Pump Therapy in the Pediatric Age-Group. Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007; 30(6): 1653-1662. Go to original source... Go to PubMed...
    160. Workgroup on Hypoglycemia ADA. Defining and reporting hypoglycemia in diabetes: a report from American Diabetes Association Workgroup on hypoglycemia. Diabetes Care 2005; 28: 1245-1249. Go to original source... Go to PubMed...
    161. ###
    162. Chlup, R. et al. Programová léčba diabetu. Praha: Galén, 1996. 190 s.
    163. Chlup, R., Možíšová, L. Léčba diabetiků pomocí inzulinové pumpy - teorie a praxe. DMEV. 2000, 3(1).
    164. Jirkovská, A. a kol. Jak si léčit a kontrolovat diabetes - Manuál pro edukaci diabetiků. Praha: PANAX, 2003.
    165. Kupčík, V. Implantabilní inzulinová pumpa s dálkovým ovladačem. Prezentace firmy Medtronic Minimed - únor 2006.
    166. Perušičová, J. Analoga Inzulinu. Klinická Farmakologie a Farmacie, 2006; 20 (1).
    167. Pomocník diabetologa 2005 - Informační katalog. Praha: Geum, 2005. 1. vyd.
    168. ###
    169. Abraira C, Henderson WG, Colwell JA, Nuttall FQ, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998; 21: 574-579. Go to original source... Go to PubMed...
    170. Berger M, Jörgens V, Chlup R. Léčba inzulinem v každodenním životě. Victoria Publishing Praha 1995.
    171. Bruns W. Zur Therapie des Typ-2-Diabetes - Ansätze für eine früzeitig beginnende pathophysiologisch begründete Therapie mit Insulin. Diabetes Dialog 1998; 1: 9-13.
    172. Bruns W, Heinz F, Altmann B, Lundershausen R, Menzel R, Worms F, von Kriegstein E. Insulintherapie bei Typ 2 - Diabetes. Science. 1. 2004 Auflage - Bremen: UNI-MED.
    173. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marrat G, Quagliaro L, Piconi L, Assaloni R, Motz E. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabetea UK Diabetic Medicine 2004; 21: 171-175. Go to original source... Go to PubMed...
    174. Consensus Statement. Recxommendation for the management of patients with type 2 diabetes mellitus in the central, eastern and southern european region. Int J Postgr Train Med 2001; 13: 1-20.
    175. Davies MJ, Metcalfe J, Gray JL, et al. Insulin deficiency rather than hyperinsulinemia in newly diagnosed type-2 diabetes mellitus. Diab. Med. 1992; 10: 305-312. Go to original source...
    176. Del Prato S, Bruttomesso D. Clinical aspects of beta-cell dysfunction in NIDDM. Exc. Med. Boehringer Mannheim 1996; 17 (1): 1-5.
    177. Fischer S, Bruns W, Kohler C, Melchert P, Gudat U, Frank M, Hanefeld M. Substitution der Frühphase der postprandialen Insulinsekretion mit Lispro bzw. Normalinsulin bei Typ-2-Diabetikern. Abstrakt. Diabetes und Stoffwechsel 1999; 8 (Suppl 1): 22.
    178. Gerich JE. Novel insulins: Expanding options in diabetes management. Am J Med 2002; 113: 308-316. Go to original source... Go to PubMed...
    179. Gudat U, Kühn C, Kazda C, Lehnert H. Insulin lispro bei übergewichtigen Patienten mit Diabetes mellitus Typ 2. Diabetes und Stoffwechsel 2003; 12: 3-7.
    180. Chapman TM, Noble S, Goa KL. Insulin aspart: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 2002; 62: 1945-1981. Go to original source... Go to PubMed...
    181. Chlup R, Bruns W. Patofyziologický přístup k léčbě diabetu 2. typu. Interní Med. 1999; 4: 27-35.
    182. Chlup R, et al. Programová léčba diabetu. Galén, Praha 1996.
    183. Chlup R, Vaverková H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipids parameters in type 2 (non-insulin-dependent) diabetic patients. I. Effects on blood glucose control. Exp. Clin. Endocrinol. Diabetes 1997; 105 (Suppl. 2): 70-73. Go to original source... Go to PubMed...
    184. Kalfhaus J, Berger M. Supplementare Insulintherapie (SII) - wie effektiv und sicher ist die Gabe von praeprandialem Normalinsulin als Therapie-Alternative bei Typ-2-Diabetes? Abstrakt. Diabetes und Stoffwechsel 1999; 8 (Suppl 1): 44.
    185. Kazlauskaite R, Fogelfeld L, Orlowski JM. Insulin therapy in type 2 diabetes. Dis. Mon., 2003; 49: 373-420. Go to original source... Go to PubMed...
    186. Klimeš I. Súčasné možnosti prevencie diabetu 2. typu. Diabetes a obezita 2004; 4 (7): 13-38.
    187. Koehler C, Fischer S, Bruns W, Melchert J, Gudat U, Pfuetzner A, Frank M, Hanefeld M. Einfluss des Koerpergewichts auf die Glykaemielage bei Typ-2-Diabetikern nach kleinen Dosen Lispro-Insulin oder Normalinsulin. Abstrakt. Diabetes und Stoffwechsel 1999; 8 (Suppl 1): 49.
    188. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin. Pharmacokinet. 2001; 40: 641-659. Go to original source... Go to PubMed...
    189. Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp. Clin. Endocrinol. Diabetes, 2002; 110: 416-419. Go to original source...
    190. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patints with diabetes mellitus. DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Brit med. 1997; J 314: 1512-1515. Go to original source... Go to PubMed...
    191. Ohkubo Y, Kishikawa H, Araki E, Miyata R, et al. Intensive insulin therapy prevents the progressions of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pact. 2000; 28: 103-117. Go to original source... Go to PubMed...
    192. Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diab. Med. 1996; 13: 19-24. Go to original source...
    193. Ratzmann KP. Kumulative Häufigkeit des Sekundärversagens einer Sulfonylharnstoff Therapie. Diabetes Stoffw 1994; 3: 348-352.
    194. Sawicki PT, Berger M. Pharmacological treatment of diabetic patents with cardiovascular complications. J. Intern. Med. 1998; 243: 181-189. Go to original source... Go to PubMed...
    195. Scherbaum WA, Landgraf R. Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Diabetes und Stoffwechsel, 2003; 12: 13-31.
    196. Standl E. Insulin analogues - State of the art. Horm. Res., 2002; 57: 40-45. Go to original source... Go to PubMed...
    197. UK Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998; 352: 854-865. Go to original source... Go to PubMed...
    198. UK Prospective Diabetes Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352: 837-853. Go to original source... Go to PubMed...
    199. UK Prospective Diabetes Study (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit. med. J. 1998; 317: 703-713. Go to original source...
    200. Vaverková H, Chlup R, Ficker L, Novotný D, Bartek J. Complementary insulin therapy improves blood glucose and serum lipids parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins. Exp. Clin. Endocrinol. Diabetes 1997; 105 (Suppl. 2): 74-77. Go to original source... Go to PubMed...
    201. Vozár J, Uličiansky V, Tkáč I, Martinka E, Michálek J, Krahulec B, Porubská M, Okapcová J (2004) Racionálna liečba diabetes mellitus 2. typu. Diabetes a Obezita 4 (7): 79-91.
    202. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, et al. (1992) Comparison of insulin regimens in patients with nen-insulin-dependent diabetes mellitus. N Engl J Med 327: 1426-1433. Go to original source... Go to PubMed...
    203. ###
    204. Chlup R, Zapletalová J, Sečkař P, Malá E, Doubravová B, Táncosová S, Chlupová L, Pukowietz L, Zatloukal P. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. Diab Technol Therap 2006; 9(3): 223-231. Go to original source... Go to PubMed...
    205. Kvapil M, Rušavý Z, Olšovský J. DM II z hlediska klinické praxe. Nakl. Adéla Plzeň 2007; 173 s.
    206. Nathan D, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. (Léčba hyperglykemie u diabetu 2. typu: konsenzuální algoritmus pro zahájení a úpravu léčby). Diabetologia 2006; 49: 1711-1721. [Český překlad: Revue Endokrinologie 2006; 2(1): 1-15]. Go to original source...
    207. Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE(TM) study. Int J Clin Pract 2009; 63(3): 425-452. Go to original source... Go to PubMed...
    208. www.diab.cz
    209. www.diazivot.cz
    210. www.diabetik.cz
    211. www.dm2t.cz
    212. www.athero.cz
    213. www.tigis.cz/dmev/index.htm
    214. ###
    215. DeVries JK, et al. Refining basal unsulin therapy: what have we learned in the age of analogues? Diabetes Metabolism Research&Reviews 2007. Go to original source...
    216. Dornhorst A et al. Safety and efficacy of insulin detemir in clinical practice: 14week follow-up data from type 1 and 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007; 61: 523-528. Go to original source... Go to PubMed...
    217. Hermansen K, et al. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007; 9 (3): 209-217. Go to original source... Go to PubMed...
    218. Klein O, et al. Albumin bound basal insulin analogues (insulin detemir and NN 344): Comparable time-action profiles, but less variability than glargine in type 2 diabetes. Diabetes, Obesity and Metabolism 2006. Go to original source... Go to PubMed...
    219. Luddeke HJ, Sreenan S, et al, PREDICTIVE Study Group. PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes, baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab. 2007; 9: 428-434. Go to original source... Go to PubMed...
    220. Muggeo M, et al, Diabetes Care 2006.
    221. Philis-Tsimikas, et al. Comparison of once daily insulin detemir added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin. Ther., 2006; 28 (10). Go to original source... Go to PubMed...
    222. Raslova T, et al. Insulin detemir results in less weight gain than NPH insulin when in basal-bolus therapy for type 2 diabetes mellitus. Clin Drug Investig. 2007; 27 (4): 279-285. Go to original source... Go to PubMed...
    223. SPC Levemir, 2007.
    224. Standard léčby diabetu 2. typu, Česká diabetologická společnost, Výbor 2007-08-16.
    225. Stratton IM, Adler AI, et al. Association of glycaemia with macrovascular and microvascular complications of type diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321 (17258): 405-412. Go to original source... Go to PubMed...
    226. ###
    227. ADA. National Standards for Diabetes Self-Management Education. Diabetes Care, 2006, vol. 29, p. 78-85. Go to original source...
    228. ADA. Standards of Medical Care in Diabetes. Position Statement. Diabetes Care, January 1, 2006, vol. 29 (suppl. 1), p. 4-42. ISSN 0149-5992. Go to original source...
    229. Bartoš V. et al. Praktická diabetologie. 2. vyd. Praha: Maxdorf, 2000. 473 s. ISBN 80-8591217-1.
    230. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J, Langová K, Chlupová L. Continuous glucose monitoring - a novel upproach to the determination of the glycaemic index of foods (DEGIF 1). Exp Clin Endocrinol Diabetes 2006, 114: 68-74. Go to original source... Go to PubMed...
    231. Chlup R, Mlčák P, Boudová E, Bartek J. Kontinuální monitorování glukosy v intersticiální tekutině - naše první zkušenosti. Klin. Biochem. Metab., 2003, roč. 11, s. 37-43. Go to original source...
    232. Kožnarová R. Kontinuální senzory glykemie. Sestra v diabetologii, 2005, roč. 1. č. 1, s. 15-16.
    233. Kudlová P, Stanislavová A. Edukace zdravých probandů v souvislosti s určováním glykemického indexu potravin (Education of healthy volunteers for the determination of glycaemic index of foods). In Čáp J, Žiaková K, Nemčeková M, Holmanová E. (eds.). Teoria, výskum a vzdelávanie v ošetrovatelstve, First Edition. S. 363-372, Martin: JLF UK Martin, 2005. ISBN 80-88866-32-4.
    234. Ladýř M. Velký přehled glukometrů. Diastyl, 2005, roč. 2, č. 1, s. 30-31.
    235. Perušičová J, et al. Diabetes mellitus 2. typu. 1. vyd. Praha: Galén, 1996. 127 s. ISBN 8085824-33-7.
    236. Pomocník diabetologa 2005 - Informační katalog. Praha: Geum, 2005. 1. vyd. ISBN 8086256-42-1.
    237. Úhrady VZP (online). (Cit. 2006-02-20). Dostupný z: <http://www.mte.cz/vzp.htm.
    238. Výbor České diabetologické společnosti. Standardy péče o diabetes mellitus 1. typu, 2. typu, o diabetes mellitus v těhotenství. Laboratorní diagnostika a sledování stavu diabetu mellitu (online). (Cit. 2006-02-20). Dostupný z: <http://www.diab.cz/modules.php?name=Standardy.
    239. ###
    240. Amir O, Cihen O, Zilberstein S, Gabis E, Karasin A. The First Non-Invasive CGMS Profiler. Diabetes 2007; 56 (Suppl 1): A118 (P442).
    241. Bailey T. Diabetes data management in the clinic. J Diab Sci Tech 2007; 1 (6): 888-891. Go to original source... Go to PubMed...
    242. Bernhardt JKM, Block U, Freeman B, Lenosky T, Lipson J, Lipson JM, McNamara RP, Petrasek D. Noninvasive continuous monitoring of glucose concentration using Raman spectroscopy: Result of a glucose clamp study. VII. Diab Technol Meeting, San Francisco, 2007: A9.
    243. Brauker J, Kamath A, Li Y, Zisser H, Schwartz S, Ratner R, Wise J, Bailey T. Time Lag of a Seven-Day Transcutaneous Glucose Sensor Compared to YSI Blood Glucose Values. Diabetes 2007; 56 (Suppl 1): A119 (P448).
    244. Bugler JR, Pryor H, Harris C. Performance of FreeStyle Navigator against standards for continuous glucose monitoring system and ISO 15197 system accuracy blood glucose meter guidelines. Diabetologia 2007; 50 (Suppl. 1): S419 (A1014).
    245. Burgler J, Buell H. MAGE analysis of the FreeStyle Navigator continuous glucose monitoring system. Diabetes 2007; 56 (Suppl 1): A111 (P419).
    246. Caduff A, Talary M, Donath M, Dewarrat F, Huber D, Stahel WA, Falco L, Klisic J. Tracking glucose excursion with a multisensor platform for noninvasive glucose monitoring. VII. Diab. Technol. Meeting, San Francisco, 2007: A17. Go to original source...
    247. Cameron BD, Li Y. Polarization-based diffuse reflectance imaging for noninvasive measurement of glucose. J Diab Sci Tech 2007; 1 (6): 873-878. Go to original source... Go to PubMed...
    248. Chase JG, Hann CHE, Shaw GM, Wong J, Lim J, Hons BE, Lotz T, LeCompte A, Lonergan T: Overview of glycemic control in critical care: Relating performance and clinical results. J Diab Sci Tech 2007; 1 (1): 82-91. Go to original source... Go to PubMed...
    249. Chlup R, Janů K, Venháčová J, Bartek J. Six models of a new insulin pen (MADI): description and first clinical trial. Practical Diabetes International 1995,12 (1): 32-35. Go to original source...
    250. Chlup R, Payne M, Zapletalová J, Komenda S, Doubravová B, Řezníčková M, Chlupová L, Sečkař P. Results of selfmonitoring on glucometer systems Advance and Optium in daily routine. Biomed Papers 2005; 149: 127-139. Go to original source...
    251. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Chlupová L, Bartek J. Function and accuracy of glucose sensors beyond their stated expiry date. Diabetes Technology et Therapeutics. 2005; 8 (4): 495-504. Go to original source... Go to PubMed...
    252. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J. Continuous glucose monitoring - a novel approach to the determination of the glycaemic index of foods (DEGIF 1). Exp Clin Endocrinol Diabetes. 2006; 114: 68-74. Go to original source... Go to PubMed...
    253. Chlup R, Sečkař P, Zapletalová J, Langová K, Kudlová P, Chlupová K, Bartek J, Jelenová D. Automated computation of glycaemic index for foodstuffs using continuous glucose monitoring. J Diabetes Sci Technol 2008; 2 (1): 67-75. Go to original source... Go to PubMed...
    254. Chlupová K, Kohnert KD, Heinke P, Augstein P, Chlup R. Salzsieder E. Resultate kontinuerlicher Glukosemessungen (CGMS) unter ambulanten Bedingungen zur Beurteilung der Stoffwechseleinstellung bei T2DM. Diabetologie und Stoffwechsel. 2006; 1 (Suppl 1): 94 (Abstract). Go to original source...
    255. Clarke WL, Kovatchev B. Continuous glucose sensors: continuing questions about clinical accuracy. J Diab Sci Tech 2007; 1 (3): 669-675. Go to original source... Go to PubMed...
    256. Cooke D, Steed L, Hurel SJ, Nunn A, Ahlquist J, Weaver J, Kerr D, Barnard M, Newman S. Use and acceptability of two minimally invasive continuous blood monitors. Diabetologia 2007; 50 (Suppl. 1): S418 (A1012).
    257. DeBlock CH, Keenoy BM, Rogiers P, Van Gaal L. Continuous glucose monitoring highlights stress hyperglycemia at the intentive care unit: need for expert diabetes supervision? Diabetes 2007; 56 (Suppl. 1): A118 (P443).
    258. Deiss D, Bolinder J, Riveline JP, Battelino T, Bost E, Tubiana-Rufi N, Kerr D, Phillip M. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diab. Care 2006; 29 (12): 2730-2732. Go to original source... Go to PubMed...
    259. Ellis SI, Voelmle M, Gottlieb P, Gutin R, Garg S.. Improved glycemic control with real-time continuous glucose sensors in patients with type 1 diabetes. Diabetologia 2007; 50 (Suppl. 1): S418 (A1010).
    260. Fachinetti A, Sparacino G, Cobelli C. Recontruction of glucose in plasma from interstitial fluid continuous glucose monitoring data: role of sensor calibration. J Diab Sci Tech 2007; 1 (5): 617-623. Go to original source... Go to PubMed...
    261. Fajkusová Z, Jadviščoková T, Pallayová M, Luža J, Kuzmina G. Glycaemic index of selected foodstuffs in healthy persons. Biomed Papers 2007; 151 (2): 257-261. Go to original source... Go to PubMed...
    262. Farrell B. Microformats: Three proposed standards for solving the need for standard data presentation. J Diab Sci Tech 2007; 1 (2): 245-250. Go to original source... Go to PubMed...
    263. Freckmann G, Hagenlocher S, Baumstark A, Jendrike N, Gillen RC, Rössner K, Haug C. Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals. J Diab Sci Tech 2007; 1 (5): 695-703. Go to original source... Go to PubMed...
    264. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values. Diab Care 2006; 29 (12): 2644-2649. Go to original source... Go to PubMed...
    265. Garraugh GV. Detection of hypoglycaemia in patients with TIDM using the FreeStyle Navigator continuous monitoring system and traditional blood glucose monitoring. Diabetologia 2007; 50 (Suppl.1): S417 (A1009).
    266. Ge X, Lam H, Modi SJ, LaCourse WR, Rao G, Tolosa L. Comparing the performance of the optical glucose assay based on glucose binding protein with high-performance anion-exchange chromatography with pulsed electrochemical detection: effors to design a low-cost point-of-care glucose sensor. J Diab Sci Tech 2007; 1 (6): 864-872. Go to original source... Go to PubMed...
    267. Ghevondian N, Nguyen H, Jones T, Skladnev V. Comparison of the overnight and daytime physiological responses of children with type 1 diabetes using the HypoMon - results of the glucose-vlamp studies. Diabetes 2007; 56 (Suppl1): A117 (P439).
    268. Gravesen P, Poulsen KR, Dirac H. Lab-on-a-chip technology for continuous glucose monitoring. J Diab Sci Tech 2007; 1 (3): 372-374. Go to original source... Go to PubMed...
    269. Heinemann L, the Glucose monitoring study group: Continuous glucose monitoring by means of the microdialysis technique: underlying fundamental aspects. Diabetes Technol Ther 2003; 5: 545-561. Go to original source... Go to PubMed...
    270. Heinemann L. Noninvasive glucose monitoring systems: will we ever have such sensors for practical use? J Diab Sci Tech 2007; 1(6): 936-939. Go to original source... Go to PubMed...
    271. Hsieh YCH, Zahn JD. On-chip microdialysis system with flow-through glucose sensing capabilities. J Diab Sci Tech 2007; 1 (3): 373-383. Go to original source... Go to PubMed...
    272. Jadviščoková T, Fajkusová Z, Pallayová M, Luža J, Kuzmina G. Occurence of adverse events due to continuous glucose monitoring. Biomed Pap Med Fac Univ Palacký Olomouc Czech Rep. 2007; 151 (2): 263-266. Go to original source... Go to PubMed...
    273. Klonoff DC. The benefits of implanted glucose sensors. J Diab Sci Tech 2007; 1 (6): 797-800. Go to original source... Go to PubMed...
    274. Kudlová P, Chlup R. Pomůcky k aplikaci inzulinu. Interní Med 2006; 8 (6): 302-306.
    275. Kudlová P, Chlup R. Selfmonitoring u osob s diabetem. Interní Med 2006; 8 (12): 539-544.
    276. Kudlová P, Stanislavová A. Edukace zdravých probandů v souvislosti s určováním glykemického indexu potravin (Czech: Education of healthy volunteers for the determination of glycemic index of foods). 1st ed. In: Čáp J, Žiaková K, Nemčeková M, Holmanová E, ed. Teoria, výskum a vzdelávanie v ošetrovatelstve (Theory, research and education in nursing). Univerzita Komenského Bratislava, Jeseniova Lekárska Fakulta Martin, Ústav ošetrovatelstva, SR, Lékařská fakulta Univerzity Palackého Olomouc, Ústav teorie a praxe ošetřovatelství, ČR, Občianské združenie pre rozvoj zdravotníckeho vzdelávania v Martine.2005: 363-372.
    277. Lee SW, Sweeney T, Clausen D, Kolbach C, Haasen A, Firek A, Brinegar Ch, Petrofsky J. Combined insulin pump therapy with real-time continuous glucose monitoring significantly improves glycemic control compared to multiple daily injection therapy in pump na ve patients with type 1 diabetes; Single center pilot study experience. J Diab Sci Tech 2007; 1 (3): 400-404. Go to original source... Go to PubMed...
    278. Mastrototaro J, Soundararajan G, Cooper K, Shah R. Accuracy of real-time continuous glucose monitoring in the MiniMed Paradigm System. Diabetes 2007; 56 (Suppl. 1): A112 (P422).
    279. Miller M, White NH, Chase H. Continuous glucose monitoring system glycaemic variability in pediatric type 1 diabetes patients in basal insulin prandial insulin: utility of Fourier analysis. Diabetologia 2007; 50 (Suppl. 1): S420 (A1015).
    280. Mlčák P, Fialová J, Trnková K, Chlup R. A continuous glucose monitoring system (CGMS) - A promising approach for improving metabolic control in person with type 1 diabetes mellitus treated by insulin pumps. Biomed Pap Med Fac Univ Palacký Olomouc Czech Rep. 2004; 148: 33-38. Go to original source...
    281. Nichols JH, Klonoff DC. The need for performance standards for continuous glucose monitors. J Diab Sci Tech 2007; 1 (1): 92-74. Go to original source... Go to PubMed...
    282. Nielsen JK, Gravholt CH, Djurhuus CHB, Brandt D, Becker J, Heinemann L, Christiansen JS. Continuous subcutaneous glucose monitoring shows a close correlation between mean glucose and time spent in hyperglycemia and hemoglobin A1c. J Diab Sci Tech 2007; 1 (6): 857-963. Go to original source... Go to PubMed...
    283. Peterson K, Chlup R, Langová K, Zapletalová J, Kudlová P, Přibylová H. Benefits of continuous glucose monitoring transmitted to Paradigm 722. Diabetes 2006; 55 (Suppl. 1): A531.
    284. Sacks DB. Correlation between hemoblobin A1c (HbA1c) and average blood glucose: can HbA1c be reported as estimated blood glucose concentration. J Diab Sci Tech 2007; 1 (6): 801-803. Go to original source... Go to PubMed...
    285. Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGerraugh GV. Accuracy of the 5-day FreeStyle Navigator continuous glucose monitoring system. Diabetes Care 2007; 30 (5): 1125-1130. Go to original source... Go to PubMed...
    286. Wriss R, Lazar I. The need for continuous blood glucose monitoring in the intensive care unit. J Diab Sci Tech 2007; 1 (3): 412-414. Go to original source... Go to PubMed...
    287. Zoupas CS, Kefaloyannis N, Pappas A, Kepaptzoglou O, Kyrlaki E, Taraoune I, Giannakopoulos F, Garoutsou P, Vasilopoulos H. Evaluation of continuous use of real-time glucose monitoring, alone and after combined insulin pump therapy, as a mean to normalise glycaemic control in IDDM. Diabetologia 2007; 50 (Suppl. 1): S418 (A1011).
    288. www.abbott.com
    289. www.dexcom.com
    290. www.minimed.com
    291. ###
    292. Bartoš V, et al. Praktická diabetologie. 2. vyd. Praha: Maxdorf, 2000; 473 s.
    293. Brand-Mileler J, Wolever TMS, Colagiuri S, Foster-Powell K. The glucose revolution. The autoritative guide to the glycemic index. 3th ed., New York: Marlowe and company, 1999.
    294. ČDS. Doporučení k edukaci diabetika [online]. [Cit. 2005-12-15]. Dostupný z: <http://www.diab.cz/modules/Standardy/edukace.pdf>.
    295. FAO/WHO. Carbohydrates in human nutrition. Report of a joint FAO/WHO report. Rome 144 - 18. 4. 1997, Paper 66. 1998. FAO Food and Nutrition.
    296. Foster H. Dieta GI. Glykemický index - nižší hmotnost a více energie. 1. vyd. Praha: Ottovo nakladatelství, s. r. o., 2004; 128 s.
    297. Foster-Powell K, Holt S, Brand-Miller JC. International table of glycemic index and glycemic load. American Journal of Clinical Nutricion, 2002; July 76: 5-56. Go to original source... Go to PubMed...
    298. Frost G, Leeds AA, Dore CJ, Madeiros S, et al. Glycemic index as a determinant of serum HDL-cholesterol concentration. Lancet, 1999; 353: 1045-1048. Go to original source... Go to PubMed...
    299. Chantelau E. Diät-Liberalisierung bei Typ-I-Diabetes mellitus. Ergebnisse intensivierter Insulintherapie. Urban&Schwarzenberg München-Wien-Baltimore, 1988: 120 s.
    300. Chlup R, Bartek J, Řezníčková M, Zapletalová J, Doubravová B, Chlupová L, Sečkař P, Dvořáčková S, Šimánek V. Determination of glycaemic index of selected foods (white bread and cereal bars) in healthy persons. Biomed Papers, 2004; 148: 17-25. Go to original source...
    301. Chlup R, et al. Úvod do diagnostiky a léčby diabetu. 1. vyd. Olomouc: Univerzita Palackého v Olomouci, 2000.
    302. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Bartek J. Function and accuracy of glucose sensors beyond their stated expiry date. Diabetes, 2005; 54 (Suppl 1), A138 (Abstract).
    303. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J, Langová K, Chlupová L. Continuous glucose monitoring - a novel approach to the Determination of the Glycaemic Index of Foods (DEGIF 1). Exp Clin Endocrinol Diab, 2006; 114: 68-74. Go to original source... Go to PubMed...
    304. Lebl J, Burgerová R. Velká dia knížka o jídle. Praha: Sdružení rodičů a přátel diabetických dětí v ČR, 2004.
    305. Ludwig DS. Dietary glycemic index and obesity. J Nutr, 2000; 130: 280S-283S. Go to original source... Go to PubMed...
    306. Kudlová P, Chlup R. Nové trendy ve výživě u osob s diabetem. Diagnóza v ošetřovatelství, 2006, 2(7): 259-262.
    307. Páv J, Klusoňová H, Štorková H. Jak žít a co jíst při cukrovce. 4. vyd. Praha: Avicenum, 1985; 269 s.
    308. Pelikánová T. Diabetologie a vybrané kapitoly z metabolismu. 1. vyd. Praha: Triton, 2003; s. 18-19, 25-27, 34-36, 38-40, 44, 47-50, 51-57.
    309. Rušavý Z, Kreuzbergová J. Glykemický index potravin. Postgraduální medicína, 2002; 6.
    310. Výbor ČDS. Standardy dietní léčby pacientů s diabetem [online]. [Cit. 2005-12-15]. Dostupný z: <http://www.diab.cz/modules/Standardy/dieta.pdf>.
    311. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999; 354: 617-621. Go to original source...
    312. Turek B, Ježková D, Procházková R. Glykemický index. Praha: SZÚ, 2003.
    313. Wolever TMS, Jenkins DJA, Jenkins AL, Josse RG. The glycemic index: metodology and clinical implications. Am J Clin Nutr, 1991; 54: 846-854. Go to original source... Go to PubMed...
    314. ###
    315. Ball SD, Keller KR, Moyer-Mileur LJ, Ding YW, Donaldson D, Jackson WD. Prolongation of satiety after low versus moderately high glycemic index meals in obese adolescents. Pediatrics 2003; 111: 488-494. Go to original source... Go to PubMed...
    316. Berger M. Diabetes mellitus I. First Edition, p. 135-157, Urban & Schwarzenberg, München Wien Baltimore, 1995.
    317. Brand-Miller JC, Holt SH, Pawlak DB, McMillan J. Glycemic index and obesity. American Journal of Clinical Nutrition 2002; 76: 2815-2855. Go to original source...
    318. Chlup R, Bartek J, Malá E, Doubravová B, Pukowietz L, Zatloukal P, Chlupová L, Zapletalová J. User-oriented study on accuracy and precision of glucometer systems Advance, Card and Optium. Klin Biochem Metab 2004; 12: 171-178.
    319. Chlup R, Bartek J, Řezníčková M, Zapletalová J, Doubravová B, Chlupová L, Sečkař P, Dvořáčková S, Šimánek V. Determination of glycaemic index of selected foods (white bread and cereal bars) in healthy persons. Biomed Papers 2004; 148: 17-25. Go to original source...
    320. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Bartek J. Function and accuracy of glucose sensors beyond their stated expiry date. Diabetes 2005; 54 Suppl 1: A138 (Abstract).
    321. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J, Langová K, Chlupová L. Continuous glucose monitoring - a novel approach to the Determination of the Glycaemic Index of Foods (DEGIF 1). Exp Clin Endocrinol Diab 2006: in press. Go to original source... Go to PubMed...
    322. Food and Agriculture Organization/World Health Organization: Carbohydrates in human nutrition: report of a Joint FAO/WHO expert consultation. FAO Food and Nutrition Paper 1998; 66: 1-140. Go to PubMed...
    323. Foster-Powell K, Holt SH, Brand-Miller JC. International table of glycemic index and glycemic load values. American Journal of Clinical Nutrition 2002; 76: 5-56. Go to original source... Go to PubMed...
    324. Gannon MC, Nuttall FQ, Krezowski PA, Billington CJ, S. Parker. The serum insulin and plasma glucose responses to milk and fruit products in type-2 (non-insulin-dependent) diabetic patients. Diabetologia 1986; 29: 784-791. Go to original source... Go to PubMed...
    325. Heilbrann LK, Noakes M, Clifton PM. The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. Journal of the American College of Nutrition 2002; 21: 120-127. Go to original source... Go to PubMed...
    326. Hodge AM, English DR, O&Dacute;ea K, Giles GG. Glycemic index and dietary fiber and the risk of type 2 diabetes. Diabetes Care 2004; 27: 2701-2706. Go to original source... Go to PubMed...
    327. Jenkins AL, Jenkins DJ, Zdravkovitz U, Wursch P, Vuksan V. Depression of glycemic index by high levels of beta-glucan fiber in two functional foods tested in type 2 diabetes. Europan Journal of Clinical Nutrition 2002; 56: 622-628. Go to original source... Go to PubMed...
    328. Jenkins DJ, Kendall CW, Augustin LS, Franceschi S, Hamidi M, Marchie A, Jenkins AL, Axelsen M. Glycemic index: overview of implications in health and disease. American Journal of Clinical Nutrition 2002; 76: 2665-2673. Go to original source...
    329. Jenkins DJ, Kendall CW, Augustin LS, Vuksan V. High-complex carbohydrate or lente carbohydrate foods? American Journal of Medicine 2002; 113 Suppl 98: 30S-37S. Go to original source... Go to PubMed...
    330. Kabir M, Oppert JM, Vidal H, Bruzzo F, Fiquet C, Wursch P, Slama G, Rizkalla SW. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. Metabolism. Clinical & Experimental 2002; 51: 819-826. Go to original source... Go to PubMed...
    331. Kudlová P, Stanislavová A. Edukace zdravých probandů v souvislosti s určováním glykemického indexu potravin (Education of healthy volunteers for the determination of glycaemic index of foods). In: Čáp J, Žiaková K, Nemčeková M, Holmanová E (eds.). Teoria, výskum a vzdelávanie v ošetrovatelstve, First Edition. pp. 363-372, Univerzita Komenského Bratislava, Jeseniova Lekárska Fakulta Martin, Ústav ošetrovatelstva, SR, Lékařská fakulta Univerzity Palackého Olomouc, Ústav teorie a praxe ošetřovatelství, ČR, Občianské sdruženie pre rozvoj zdravotníckeho vzdelávania v Martine, Martin, 2005.
    332. Liu S, Willett WC. Dietary glycemic load and atherotrombotic risk. Current Atherosclerosis Reports 2002; 4: 454-61. Go to original source... Go to PubMed...
    333. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002; 287: 2414-2423. Go to original source... Go to PubMed...
    334. Nakládalová M, Kapoun S. Zdravotní způsobilost k práci u osob s diabetem. Pracovní Lék 2004; 56: 13-6.
    335. Payne M. Hypoguard Advance Micro-draw performance. Klin Biochem Metab 2004; 12: 202 (Letter).
    336. Raben A. Should obese patients be counselled to follow a low-glycemic index diet? No. Obesity Reviews 2002; 3: 245-256. Go to original source... Go to PubMed...
    337. Sheard NF, Clark NG, Brand-Miller JC, Franz MJ, Pi-Sunyer FX, Mayer-Davis E, Kulkarni K, Geil P. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the American Diabetes Association. Diabetes Care 2004; 27: 2266-2271. Go to original source... Go to PubMed...
    338. Sievpiper JL, Jenkins AL, Whitham DL, Vuksan V. Insulin resistance: concepts, controversies, and role of nutrition. Canadian Journal of Dietetic Practice & Research 2002; 63: 20-32. Go to original source... Go to PubMed...
    339. Wolever TMS, Mehling C. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr 2002; 76: 5-56.
    340. Zemlin C, Lüder W, Vetter K, Bruns W, Menzel R. Diät bei Diabetes mellitus. Med aktuell 1989; 15: 49-52.
    341. ###
    342. Fajkusová Z, Jadviščoková T, Pallayová M, Matušková V, Luža J, Kuzmina G. Glycaemic index of selected foodstuffs in healthy persons. Biomed Pap Med Fac Univ Palacky Olomouc. 2007; 151(2): 257-261. Go to original source... Go to PubMed...
    343. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Chlupová L, Bartek J. Function and Accuracy of glucose sensors beyond their stated expiry date. Diab Technol Therap 2006; 8(4): 495-504. Go to original source... Go to PubMed...
    344. Chlup R, Sečkař P, Zapletalová J, Langová K, Kudlová P, Chlupová K, Bartek J, Jelenová D. Automated computation of glycemic index for foodstuffs using continuous glucose monitoring. J Diab Sci Techn 2008; 2(1): 67-75. Go to original source... Go to PubMed...
    345. Jadviščoková T, Fajkusová Z, Pallayová M, Luža J, Kuzmina G: Occurence of adverse events due to continuous glucose monitoring. Biomed Pap Med Fac Univ Palacký Olomouc. 2007; 151(2): 263-266. Go to original source... Go to PubMed...
    346. Lippaiová N, Pallayová M, Kuzmina G, Peterson K, Fajkošová L, Luža J. Safety of new algorithms for premeal insulin boluses in high glycaemic index meals in persons with type 1 diabetes mellitus using insulin pumps. Biomed Pap Med Fac Univ Palacky Olomouc. 2008; 152(I): 73-77. Go to original source... Go to PubMed...
    347. Peterson K, Lippaiová N, Chlup R, Pallayová M, Langová K. Efficiency of simple algorithms for premeal boluses in high glycemic index meals in persons with type 1 diabetes mellitus using insulin pumps and sensors. Diabetes 2008; 57 (Suppl 1): A471 (Abstract). Go to original source... Go to PubMed...
    348. Přibylová H, Pallayová M, Hučíková J, Luža J. Evaluation of the new software program DEGIFXL4 in the determination of the glycaemic indices of foodstuffs. Biomed Pap Med Fac Univ Palacky Olomouc. 2008; 152(I): 65-71. Go to original source... Go to PubMed...
    349. Chlup R, Peterson K, Zapletalova J, Langova K, Seckar P, Kudlova P. Relation between glycemic index of ingested foods and mean plasma glucose concentration measured by CGMS in healthy persons. Abstracts 2nd International Conference on Advanced Techologies and Treatments for Diabetes (Athens 2009). www.kenes.com/attd: Abstract No 204. Go to original source...
    350. ###
    351. Brand-Miller JC, Pang E, Bramall L. Rice - a low or high glycaemic food. Am J Clin Nutr 1991; 56: 1034-1036. Go to original source... Go to PubMed...
    352. Brand-Miller JC, Pang E, Broomhead L. Glycaemic index of foods containing sugars: comparison of foods with naturally occuring versus added sugars. Br J Nutr 1995; 73: 613-623. Go to original source... Go to PubMed...
    353. Brand-Miller J, Colagiuri S, Foster-Powell K. The glycaemic index is easy and works in practice. Letter Diabetes Care 1997; 2: 1628-1629. Go to original source... Go to PubMed...
    354. Buyken EA, Heitkamp G, Toeller M. and the EURODIAB Complications Study Group. Dietary glycemic indices in European outpatients with type-1 diabetes: Relations to HbA1c, and serum lipids. Abstracts. Booklet of abstracts. Versailles/France: 17th Annual Symposium of the Diabetes and Nutrition Study Group of the EASD; 1999.
    355. Capani F, Casalini G, Consoli A, DÉmilio A, Lanave GF, Loragno M, Vitacolonna E, Zappone G, Sensi S. Variability of the efficacy of a small subsucateous insulin bolus in CSII-treated type-1 diabetic subjects. Diab Nutr Metab 1988; 1: 297-301.
    356. Capani F, Casalini G, Consoli A, DÉmilio A, Lanave G, Loragno M, Vitacolonna E, Zappone G. Insulin requirement of simple and complex carbohydrate foods in type-1 (insulin-dependent) CSII-treated diabetic subjects obtained by Biostator. Correlation with glycaemic index. Acta diabetol Lat 1991; 28: 47-53. Go to original source... Go to PubMed...
    357. Chantelau E. The glycaemic index of carbohydrate foods: an update from a diabetologistś perspective. Aktuel Ernaehr Med 2000; 25: 176-185.
    358. Chantelau E, Kronsbein P, Kempf U, Berger M. Untersuchung zum Mahlzeiten-bezogenen Insulinbedarf von Linsen und Kartoffeln bei Patienten mit Typ-1 Diabetes mellitus. Aktuel Ernaehr Med 1989; 14: 175-178.
    359. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J, Langová K, Chlupová L. Continuous Glucose Monitoring - A Novel Approach to the Determination of the Glycaemic Index of Foods (DEGIF 1). Exp Clin Endocrinol Diabetes 2006; 114: 68-74. Go to original source... Go to PubMed...
    360. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Chlupová L, Bartek J. Function and Accuracy of Glucose Sensors beyond their stated Expiry Date. Diabetes Technology & Therapeutics 2006; 8 (4) 495-504. Go to original source... Go to PubMed...
    361. Chlup R, Kudlová P., Bartek J, Sečkař P, Langová K. Základní předpoklady a ekonomika pro stanovení glykemického indexu potravin. Diabet Metabol Endokrin Výž 2006; 9 (Suppl 2): 24-26 (Abstract).
    362. Chlup R, Zapletalová J, Jelenová D, Chlupová K, Bartek J, Řehořová J. Glykemický index hořké čokolády, ovocného jogurtu, jablečné přesnídávky a rýžových chlebíčků u zdravých osob. Diab Obezita 2006; 11: 103-112.
    363. Chlup R, Jelenová D, Kudlová P, Bartek J, Nakládalová M, Sečkař P, Zapletalová J Langová K, Pukowietz L, Chlupová K. Konventionelle Bestimmung des glykämischen Indexes verschiedener Nahrungsmittel (Schokolade, Apfelmuss, Reisbrot, Yoghurt) bei pumpenbehandelten Typ-1 Diabetikern. Diabetologie und Stoffwechsel 2006; 1 (Suppl 1): 154 (Abstract). Go to original source...
    364. Chlup R, Kudlová P, Sečkař P, Zapletalová J, Bartek J, Chlupová K, Luža J. Glycaemic index of foods in healthy persons vs persons with type 1 diabetes mellitus. Diabetes 2006; 55 (Suppl 1): A593 (Abstract).
    365. Frost G. The relevance of the glycaemic index to our understanding of dietary carbohydrates. Diabetic Med 2000; 17: 336-345. Go to original source... Go to PubMed...
    366. Goldschmied A, Shani J, Zurkowski S. Range-related glycaemic response to increasing load of carbohydrates. Pharmacology 1980; 21: 355-362. Go to original source... Go to PubMed...
    367. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21: 1910-1914. Go to original source... Go to PubMed...
    368. Hollenbeck CB, Coulston AM, Donner CC, Williams RA, Reaven GM. The effect of variations in percent of naturally occuring complex and simple carbohydrates on plasma glucose and insulin response in individuals with non-insulin-dependent diabetes mellitus. Diabetes 1985; 34: 151-153. Go to original source... Go to PubMed...
    369. Ionescu-Tirgoviste C, Popa E, Santu E, Mihalache N, Cheta D, Mincu I. Blood glucose and plasma insulin responses to various carbohydrates in type 2 (non-insulin-dependent) diabetes. Diabetologia 1983; 24: 80-84. Go to original source... Go to PubMed...
    370. Ionescu-Tirgoviste C. Reproducibility of a standard test meal in type 2 diabetic patients. Letter to the Editor. Klin Wochenschr 1991; 69: 91. Go to original source... Go to PubMed...
    371. Jenkins DJA, Wolever TMS, Taylor RH, Barker H, Fielden H, Baldwin JM, Bowling AC, Newman HC, Jenkins AL, Goff DV. Glycemic index of foods: a physiological basis for carbohydrate exchange. Amer J Clin Nutr 1981; 34: 362-366. Go to original source... Go to PubMed...
    372. Katan MB. Are there good and bad carbohydrates for HDL-cholesterol? The Lancet 1999; 353: 1029-1030. Go to original source... Go to PubMed...
    373. LeFloch JP, Baudin E, Escuyer P, Wirquin E, Nillus P, Perlemuter L. Influence of non-carbohydrate foods on glucose and insulinresponses to carbohydrates of different glycaemic index in type-2 diabetic patients. Diab Med 1992; 9: 44-48. Go to original source... Go to PubMed...
    374. Ludwig DS, Majzoub JA, Al-Zahrani A, Dallal GE, Blanco I, Roberts SB. High glycaemic index foods, overeating and obesity. Pediastrics 1999; 103: E 26. Go to original source... Go to PubMed...
    375. Nielsen PH, Nielsen GL. Preprandial blood glucose values: influence on glycaemic response studies. Am J Clin Nutr 1989; 49: 1243-1246. Go to original source... Go to PubMed...
    376. Otto H, Bleyer M, Pennartz M, Sabin G, Schauberger G, Spaethe R. Kohlenhydrat-Austausch nach biologischen Äquivalenten. In: Otto H, Spaethe R (Hrsg): Diätetik bei Diabetes mellitus. Bern, Stuttgart, Wien: Verlag Hans Huber; 1973: 41-50.
    377. Otto H, Niklas L. Differences dáction sur la glycemie dáliments contenant des hydrates de carbone. Consequences pour le traitement dietetique du diabete sucre. Med et Hyg 1980; 38: 3424-3429.
    378. Rasmussen O, Hermansen K. Preprandial blood glucose values and glycemic responses in insulin-dependent diabetes mellitus at constant insulinaemia. Am J Clin Nutr 1991; 53: 520-523. Go to original source... Go to PubMed...
    379. Rasmussen O. Dose-dependency of the glycemic response to starch-rich meals in non-insulin-dependent diabetic subjects: studies with varying amounts of white rice. Metabolism 1993; 42: 214-217. Go to original source... Go to PubMed...
    380. Rasmussen O. Dose-dependency of the glycemic response to starch-rich meals in insulin-dependent diabetic subjects: studies at constant insulinemie. Metabolism 1993; 42: 710-713. Go to original source... Go to PubMed...
    381. Samanta A, Burden AC, Jones GR. Plasma glucose responses to glucose, sucrose, and honey in patients with diabetes mellitus: an analysis of glycaemic and peak incremental indices. Diab Med 1985; 2: 371-373. Go to original source... Go to PubMed...
    382. Weyman-Daum M, Fort P, Recker B, Lanes R, Lifshitz F. Glycemic response in children with insulin-dependent diabetes mellitus after high- or low-glycemic-index breakfasts. Am J Clin Nutr 1987; 46: 798-803. Go to original source... Go to PubMed...
    383. Wolever TMS, Jenkins DJA, Jenkins AL, Josse RG. The glycamic index: methodology and clinical implications. Am J Clin Nutr 1991; 54: 846-854. Go to original source... Go to PubMed...
    384. ###
    385. Astrand PO, Rodahl K. Texbook of work physiology. Physiological base of exercise. McGrawHill Book Company, N. York, London, Düsseldorf 1977; IInd edition: 331-365.
    386. Berger M, Berchtold P, Cüppers HJ, Drost H, Kley HK, Müller WA, Wiegelmann W, Zimmermann-Teschlow H, Gries FA, Krüskemper HL, Zimmermann H. Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. Diabetologia 1777; 13: 355. Go to original source... Go to PubMed...
    387. Brož J. Sportování s inzulínem. Sanvitalia s.r.o. 2007, 1. vydání: 46 s.
    388. Chassin LJ, Wilinska ME, Hovorka R. Intense exercise in type 1 diabetes: Exploring the role of continuous glucose monitoring. J Diab Sci Technol 2007; 1 (4): 570-573. Go to original source... Go to PubMed...
    389. Chlup R, Bartek J, Hildmann W, Lubs D, Wodrig W, Jutzi E, Zander E. Die Effektivität eines Trainingsprogramms auf den Insulinbedarf und die Stoffwechseleinstellung von Typ-1-Diabetikern. In: Wiedermann B, Bibergeil H (eds), Symposium Diabetes a fyzická zátěž - Diabetes und Muskelbelastung, Olomouc, ČSSR, 21.-23. 1. 1982. Univerzita Palackého v Olomouci, Olomouc, pp.36-37.
    390. Chlup R, Zander E, Hildmann W, Bartek J, Jutzi E Vliv tělesného tréninku na metabolismus sacharidů a tuků u diabetiků I. typu. In: E Horniak (ed) Sport ve zdraví a nemoci: Práce IV. Evropského kongresu sportovního lékařství, Praha 25. 3. - 28. 3. 1985, 1. díl, pp.245-251.
    391. Felig P. Glucose-Alanin-Zyklus. Metabolism 1973; 22: 179. Go to original source... Go to PubMed...
    392. Lefebvre PJ. Naturally labeled 13C-glucose: A new tool to measure oxidation rates of exogenous glucose. Diabetes 1979; 28: 63. Go to original source... Go to PubMed...
    393. Lopata L, Piroch V, Techlová R. Při diabetu cvičte denně. Olympia, Praha, 1977, 2. vyd.
    394. Pirnay F. et al. Eur J Appl Physiol. 1977; 36: 247. Go to original source... Go to PubMed...
    395. Ribisl PM, Lang W, Jaramillo S, Jakicic JM, Stewart KJ, Bahnson J, Bright R, Curtis J, Crow R, Soberman JE. On behalf on the Look AHEAD Research Group: Exercise capacity and cardiovascular/metabolic characteristic of overweight and obese individuals with type 2 diabetes. Diabetes Care 2007; 30 (10): 2679-2689. Go to original source... Go to PubMed...
    396. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients. Diabetes Care 2006; 29 (11): 2518-2527. Go to original source... Go to PubMed...
    397. Vranic M, Berger M. Exercise and diabetes mellitus. Diabetes 1979; 28: 147. Go to original source... Go to PubMed...
    398. Zander E, Bruns W, Wulfert P, Besch W, Lubs D, Chlup R, Schulz B. Muscular Exercise in type 1-diabetics. Exp Clin Endocrinol 1983; 82 (1): 78-90. Go to original source... Go to PubMed...
    399. Zander E, Schulz B, Chlup R, Woltansky P, Lubs D. Muscular exercise in type-1-diabetics: II. Hormonal and metabolic responses to moderate exercise. Exp Clin Endocrinol 1985; 85 (1): 95-104. Go to original source... Go to PubMed...
    400. ###
    401. Almdal T, Scharling H, Jensen JS, et al. Type II diabetes is an independent risk factor for myocardial infarction and death from ischemic heart disease in man and women. Abstract. Diabetologia 2002; 2: 94.
    402. American Diabetes Association: Concensus development conference on insulin resistance. Diabetes Care 1998: 310-314. Go to original source... Go to PubMed...
    403. Balletshofer BM, et al. Endothelial dysfunction is detectable in young normotensive first - degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784. Go to original source... Go to PubMed...
    404. Bergman RN, et al. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236: 667. Go to original source... Go to PubMed...
    405. Cauza E, Hanusch-Enserer U, Strassser B, et al. Effects of resistence training on glycemic control in type 2 diabetes mellitus. Diabetologia 2002; 2: 34.
    406. Cífková R. za členy společné pracovní skupiny: Prevence ischemické choroby srdeční v dospělém věku. Diab Metab Endokr Výž 2001; 1: 13-27.
    407. Češka R. Léčba diabetické dyslipoproteinémie. Kapitoly Kardiol 2001; 3/2: 14-19.
    408. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    409. De Fronzo RA, et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223. Go to original source... Go to PubMed...
    410. Despres JP, LaMarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957. Go to original source... Go to PubMed...
    411. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project randomised trial (CAPP). Lancet 1999; 353: 611-616.
    412. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116. Go to original source...
    413. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistence in essential hypertension. N Engl J Med 1987; 317: 317-350. Go to original source... Go to PubMed...
    414. Feskens EJM, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arterioscler Tromb 1994; 14: 1641-1647. Go to original source... Go to PubMed...
    415. Gaede P, Vedel P, Larsen N, et al. The Steno-2 study: intensified multifactorial intervention reduced the risk of cardiovascular disease in patients with Type 2 diabetes and microalbuminuria. Abstract. Diabetologia 2002; 45/2: 63.
    416. Haffner SM, Kennedy E, Gonzalez C, et al. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19/10: 1138-1141. Go to original source... Go to PubMed...
    417. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. Go to original source... Go to PubMed...
    418. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardivascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259. Go to original source...
    419. Helge JW, Dela F. Training and insulin sensitivity: effect of muscle phospholipid and triacylglycerol fatty acid composition and total muscle triacylglycerol content. Abstract. Diabetologia 2002; 45/2: 34.
    420. Hřebíček J, Janout B, Malinčíková J, et al. Detection of insulin resistence by simple quantitative sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metabol 2002; 87: 144-147. Go to original source...
    421. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25/7: 1129-1134. Go to original source... Go to PubMed...
    422. Hypertension Optimal Treatment Trial (HOT). Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    423. Chen W, Srinivasan SR, Elkasabany A, et al. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (syndrome X) between young parents and their offspring: the Bobalusa Heart Study. Atherosclerosis 1999; 145: 197-205. Go to original source... Go to PubMed...
    424. Chlup R. Současné možnosti prevence diabetes mellitus 1. a 2. typu. Kapitoly Kardiol 2001; 3/2: 36-39.
    425. Chlup R, Bruns W. Patofyziologický přístup k léčbě diabetu 2. typu. Intern Med 1999; 4: 27-35.
    426. Chlup R, Vaverková H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid perameters in type 2 (non-insulin-dependent) diabetic patients. I. Effect on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105/2: 70-73. Go to original source... Go to PubMed...
    427. Imperatore B, Ricardi G, Iovine C, et al. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998; 21: 549-654. Go to original source... Go to PubMed...
    428. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-865.
    429. Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: A simple, accurate method for assessing insulin sensitivity in humans. Clin Endocrinol Metabol 2000; 85/7: 2402-2410. Go to original source... Go to PubMed...
    430. Kernan WN, Inzucchi SE, Viscoli CM, et al. Insulin resistence and risk for stroke. Neurology 2002; 59/6: 809. Go to original source... Go to PubMed...
    431. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456. Go to original source... Go to PubMed...
    432. Lemieux I, Lamarche B, St-Pierre A, et al. Low HDL cholesterol without vs. with features of the atherogenic metabolic triad and its impact on IHD risk: the Québec cardiovascular study. Abstract. Diabetologia 2002; 45/2: 63-64.
    433. Lichnovská R, Gwozdziewiczová S, Hřebíček J. Gender differences in metabolic variables related to insulin resistance in elderly hyperlipemic non-diabetic subjects. Cardiovascular Diabetology v tisku.
    434. Linhart A, Paleček T, Aschermann M. Koronární postižení při diabetu - prevence a léčba. Kapitoly Kardiol 2001; 3/2: 20-26.
    435. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28/7: 412-419. Go to original source... Go to PubMed...
    436. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. J Amer Med Ass 2000; 283: 221-228. Go to original source... Go to PubMed...
    437. Meigs JB, Nathan DM, DÁgostino RB, et al. Fasting and postchallenge glycemia and cardiovascular disease risk. Diabetes Care 2002; 25: 1845-1850. Go to original source... Go to PubMed...
    438. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-1820. Go to original source... Go to PubMed...
    439. Nilsson PM. Hypertention in diabetes - favourable trends in clinical control in repeated national surveys from Sweden. Abstract. Diabetologia 2002; 45/2: 64.
    440. Oerry C. Report of 6th Scientific Meeting of the Hypertension in Diabetes (HID). Study Group of the EASD in Edinburgh. Abstract. Diabetologia 2001; 44/11: 57.
    441. Olšovský J. Vliv antihypertenzní terapie na inzulinovou rezistenci. Vnitřní Lék 1999; 45/11: 670-672.
    442. Pelikánová T. Ischemická choroba srdeční u nemocných s diabetem 2. typu. Diab Metab Endokr Výž 1999; 2/4: 161-169.
    443. Piarulli FN, Marolla ME, Bax G, et al. Insulin reduce progression of carotid stenosis in type 2 diabetes mellitus: a three years prospective study. Abstract. Diabetologia 2002; 45/2: 95.
    444. Reaven GM, Chen YDI, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92: 141-146. Go to original source... Go to PubMed...
    445. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistence and the sympathoadrenall system. N Engl J Med 1996; 334: 374-381. Go to original source... Go to PubMed...
    446. Ruige JB, Assendelft WJJ, Dekker JM, et al. Insulin and risk of cardiovascular disease. A meta-analysis. Circulation 1998; 97: 996-1991. Go to original source... Go to PubMed...
    447. Rybka J, Adamíková A. Syndrom diabetické nohy. Kapitoly Kardiol 2001; 3/2: 28-31.
    448. Shulman GI. Cellular mechanism of insulin resistence. J Clin Invest 2000; 106: 171-176. Go to original source... Go to PubMed...
    449. Scheen AJ, Van Gaal LF, et al. Need to optimize cardiovascular prevention in type 2 diabetic patients: the Belgian OCAPI Survey. Diabetologia 2002; 45/2: 63.
    450. Solerte SB, Fioravanti M. Human insulin up-regulates the release of Vascular Endothelial Growth Factor (VEGF) from immune cells in hyperinsulinemic microalbuminuria type 2 diabetic patients. Diabetologia 2002; 45/2: 35.
    451. Stout RW. Overview of the association between insulin and atherosclerosis. Metabolism 1985; 34/12 (Suppl. 1): 7-12. Go to original source... Go to PubMed...
    452. Turner R, Tchobroutsky G, Slama G, et al. Vascular complications of diabetes. Éditions pradel Paris 1994: 1-166.
    453. Šejda T. Rostlinné steroly a stanoly v prevenci ischemické choroby srdeční. Diab Metab Endokr Výž 2001; 4/2: 140-144.
    454. The Framingham Study. Circulation 1979; 59: 8-13. Go to original source... Go to PubMed...
    455. The UK Prospective Diabetes Study (UKPDS): Effect of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...
    456. The UK Prospective Diabetes Study (UKPDS): Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720. Go to original source...
    457. The UK Prospective Diabetes Study (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. Go to original source...
    458. The UK Prospective Diabetes Study (UKPDS) (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713. Go to original source...
    459. Vaverková H, Chlup R, Ficker L, et al. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effect on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997; 105/2: 74-77. Go to original source... Go to PubMed...
    460. Welborn TA, Knuiman MW, Ward N, et al. Serum insulin is a risk marker for coronary heart disease mortality in men but not in women. Diabetes Res Clin Pract 1994; 26: 51-59. Go to original source... Go to PubMed...
    461. ###
    462. Adámková R. Akutní infarkt myokardu a diabetes mellitus. Interní Med 2008; 10(9): 402-406.
    463. Kvapil M. Těsná kompenzace glykemie a vaskulární komplikace u pacientů. Interní Med. 2008; 10(10): 479-480.
    464. Kvapil M. Studie Advance v kontextu ostatních morbi-mortalitních studií u pacientů s diabetem 2. typu. Interní Med. 2008; 10(12): 583-587.
    465. Mokáň M, Martinka E, Galajda P. Diabetes mellitus a vybrané metabolické ochorenia. Vydavateľstvo P+M, Martin 2008.
    466. Rybka J. Diabetes mellitus II. typu, co víme a v co věříme (stručný nástin etiopatogenetických poznatků). Diabetes a obezita 2008; 8(16): 31-39.
    467. Sucharda P. Obezita a metabolický syndrom. Od syndromu inzulinové rezistence k, ,syndromu centrální obezity". Interní Med. 2008; 10(4): 165-166.
    468. Weber P. Diabetes mellitus - specifika a komplikace ve stáří. Interní Med. 2008; 10(10): 456-460.
    469. www.dm2t.cz
    470. www.athero.cz
    471. www.tigis.cz/dmev/index.htm
    472. ###
    473. Almdal T, Scharling H, Jensen JS, et al. Type II diabetes is an independent risk factor for myocardial infarction and death from ischemic heart disease in man and women. Abstract. Diabetologia 2002; 2: 94.
    474. American Diabetes Association: Concensus development conference on insulin resistance. Diabetes Care 1998: 310-314. Go to original source... Go to PubMed...
    475. Balletshofer BM, et al. Endothelial dysfunction is detectable in young normotensive first - degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784. Go to original source... Go to PubMed...
    476. Bergman RN, et al. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236: 667. Go to original source... Go to PubMed...
    477. Cauza E, Hanusch-Enserer U, Strassser B, et al. Effects of resistence training on glycemic control in type 2 diabetes mellitus. Diabetologia 2002; 2: 34.
    478. Cífková R. za členy společné pracovní skupiny: Prevence ischemické choroby srdeční v dospělém věku. Diab Metab Endokr Výž 2001; 1: 13-27.
    479. Češka R. Léčba diabetické dyslipoproteinémie. Kapitoly Kardiol 2001; 3/2: 14-19.
    480. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    481. De Fronzo RA, et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223. Go to original source... Go to PubMed...
    482. Despres JP, LaMarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957. Go to original source... Go to PubMed...
    483. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project randomised trial (CAPP). Lancet 1999; 353: 611-616.
    484. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116. Go to original source...
    485. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistence in essential hypertension. N Engl J Med 1987; 317: 317-350. Go to original source... Go to PubMed...
    486. Feskens EJM, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arterioscler Tromb 1994; 14: 1641-1647. Go to original source... Go to PubMed...
    487. Gaede P, Vedel P, Larsen N, et al. The Steno-2 study: intensified multifactorial intervention reduced the risk of cardiovascular disease in patients with Type 2 diabetes and microalbuminuria. Abstract. Diabetologia 2002; 45/2: 63.
    488. Haffner SM, Kennedy E, Gonzalez C, et al. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19/10: 1138-1141. Go to original source... Go to PubMed...
    489. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. Go to original source... Go to PubMed...
    490. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardivascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259. Go to original source...
    491. Helge JW, Dela F. Training and insulin sensitivity: effect of muscle phospholipid and triacylglycerol fatty acid composition and total muscle triacylglycerol content. Abstract. Diabetologia 2002; 45/2: 34.
    492. Hřebíček J, Janout B, Malinčíková J, et al. Detection of insulin resistence by simple quantitative sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metabol 2002; 87: 144-147. Go to original source...
    493. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25/7: 1129-1134. Go to original source... Go to PubMed...
    494. Hypertension Optimal Treatment Trial (HOT). Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    495. Chen W, Srinivasan SR, Elkasabany A, et al. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (syndrome X) between young parents and their offspring: the Bobalusa Heart Study. Atherosclerosis 1999; 145: 197-205. Go to original source... Go to PubMed...
    496. Chlup R. Současné možnosti prevence diabetes mellitus 1. a 2. typu. Kapitoly Kardiol 2001; 3/2: 36-39.
    497. Chlup R, Bruns W. Patofyziologický přístup k léčbě diabetu 2. typu. Interní Med 1999; 4: 27-35.
    498. Chlup R, Vaverková H, Bartek J: Complementary insulin therapy improves blood glucose and serum lipid perameters in type 2 (non-insulin-dependent) diabetic patients. I. Effect on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105/2: 70-73. Go to original source... Go to PubMed...
    499. Imperatore B, Ricardi G, Iovine C, et al. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998; 21: 549-654. Go to original source... Go to PubMed...
    500. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-865.
    501. Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: A simple, accurate method for assessing insulin sensitivity in humans. Clin Endocrinol Metabol 2000; 85/7: 2402-2410. Go to original source... Go to PubMed...
    502. Kernan WN, Inzucchi SE, Viscoli CM, et al. Insulin resistence and risk for stroke. Neurology 2002; 59/6: 809. Go to original source... Go to PubMed...
    503. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456. Go to original source... Go to PubMed...
    504. Lemieux I, Lamarche B, St-Pierre A, et al. Low HDL cholesterol without vs. with features of the atherogenic metabolic triad and its impact on IHD risk: the Québec cardiovascular study. Abstract. Diabetologia 2002; 45/2: 63-64.
    505. Lichnovská R, Gwozdziewiczová S, Hřebíček J. Gender differences in metabolic variables related to insulin resistance in elderly hyperlipemic non-diabetic subjects. Cardiovascular Diabetology v tisku.
    506. Linhart A, Paleček T, Aschermann M. Koronární postižení při diabetu - prevence a léčba. Kapitoly Kardiol 2001; 3/2: 20-26.
    507. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28/7: 412-419. Go to original source... Go to PubMed...
    508. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. J Amer Med Ass 2000; 283: 221-228. Go to original source... Go to PubMed...
    509. Meigs JB, Nathan DM, DÁgostino RB, et al. Fasting and postchallenge glycemia and cardiovascular disease risk. Diabetes Care 2002; 25: 1845-1850. Go to original source... Go to PubMed...
    510. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-1820. Go to original source... Go to PubMed...
    511. Nilsson PM. Hypertension in diabetes - favourable trends in clinical control in repeated national surveys from Sweden. Abstract. Diabetologia 2002; 45/2: 64.
    512. Oerry C. Report of 6th Scientific Meeting of the Hypertension in Diabetes (HID). Study Group of the EASD in Edinburgh. Abstract. Diabetologia 2001; 44/11: 57.
    513. Olšovský J. Vliv antihypertenzní terapie na inzulinovou rezistenci. Vnitřní Lék 1999; 45/11: 670-672.
    514. Pelikánová T. Ischemická choroba srdeční u nemocných s diabetem 2. typu. Diab Metab Endokr Výž 1999; 2/4: 161-169.
    515. Piarulli FN, Marolla ME, Bax G, et al. Insulin reduce progression of carotid stenosis in type 2 diabetes mellitus: a three years prospective study. Abstract. Diabetologia 2002; 45/2: 95.
    516. Reaven GM, Chen YDI, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92: 141-146. Go to original source... Go to PubMed...
    517. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistence and the sympathoadrenall system. N Engl J Med 1996; 334: 374-381. Go to original source... Go to PubMed...
    518. Ruige JB, Assendelft WJJ, Dekker JM, et al. Insulin and risk of cardiovascular disease. A meta-analysis. Circulation 1998; 97: 996-1991. Go to original source... Go to PubMed...
    519. Rybka J, Adamíková A. Syndrom diabetické nohy. Kapitoly Kardiol 2001; 3/2: 28-31.
    520. Shulman GI. Cellular mechanism of insulin resistence. J Clin Invest 2000; 106: 171-176. Go to original source... Go to PubMed...
    521. Scheen AJ, Van Gaal LF, et al. Need to optimize cardiovascular prevention in type 2 diabetic patients: the Belgian OCAPI Survey. Diabetologia 2002; 45/2: 63.
    522. Solerte SB, Fioravanti M. Human insulin up-regulates the release of Vascular Endothelial Growth Factor (VEGF) from immune cells in hyperinsulinemic microalbuminuria type 2 diabetic patients. Diabetologia 2002; 45/2: 35.
    523. Stout RW. Overview of the association between insulin and atherosclerosis. Metabolism 1985; 34/12 (Suppl. 1): 7-12. Go to original source... Go to PubMed...
    524. Turner R, Tchobroutsky G, Slama G, et al. Vascular complications of diabetes. Éditions pradel Paris 1994: 1-166.
    525. Šejda T. Rostlinné steroly a stanoly v prevenci ischemické choroby srdeční. Diab Metab Endokr Výž 2001; 4/2: 140-144.
    526. The Framingham Study. Circulation 1979; 59: 8-13. Go to original source... Go to PubMed...
    527. The UK Prospective Diabetes Study (UKPDS): Effect of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...
    528. The UK Prospective Diabetes Study (UKPDS): Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720. Go to original source...
    529. The UK Prospective Diabetes Study (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. Go to original source...
    530. The UK Prospective Diabetes Study (UKPDS) (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703713. Go to original source...
    531. Vaverková H, Chlup R, Ficker L, et al. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effect on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997; 105/2: 74-77. Go to original source... Go to PubMed...
    532. Welborn TA, Knuiman MW, Ward N, et al. Serum insulin is a risk marker for coronary heart disease mortality in men but not in women. Diabetes Res Clin Pract 1994; 26: 51-59. Go to original source... Go to PubMed...
    533. ###
    534. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes. (Účinek iniciální kombinované terapie sitagliptinem, inhibitorem dipeptidylpeptidázy-4 a metforminem při kontrole glykémie u pacientů s diabetes mellitus II. typu.) Diabetes Care 2007; 30 (8): 1979-1988. Go to original source... Go to PubMed...
    535. Honka M. Účinek fixní kombinace perindoprilu a indapamidu na makrovaskulární a mikrovaskulární komplikace u nemocných s diabetem 2. typu (studie Advance). Interní Med. 2008; 10 (5): 245-246.
    536. Honka M. Hypoglykémie u nemocných s diabetem 2. typu. Postgraduální medicína 2009; 11 (4): 423-427.
    537. Charvát J. Prevence kardiovaskulárních komplikací diabetu. Postgraduální medicína 2009; 11 (4): 433-438.
    538. Kvapil M. Perorální antidiabetika. Postgraduální medicína 2009; 11 (4): 407-412.
    539. Kvapil M. Terapie založená na účinku inkretinů. Postgraduální medicína 2009; 11 (4): 413-416.
    540. Mokáň M, Martinka E, Galajda P. Diabetes mellitus a vybrané metabolické ochorenia. Vydavateĺstvo P+M, 2008.
    541. Perušičová J. Perorální antidiabetika - současnost. Interní Med. 2008; 10 (1): 15-18.
    542. Piťhová P. Racionální léčba perorálními antidiabetiky. Interní Med. 2008; 10 (11): 495-497.
    543. Ravichandran S, MacEachern L Saxagliptin Added to Metformin Improves Glycemic Control in T2DM Patients 35th Annual Meeting of the American Association of Diabetes Educators. Washinton DC 2008.
    544. Rušavý Z. Nefarmakologická intervence diabetu 2. typu. Postgraduální medicína 2009; 11 (4): 399-406.
    545. Rybka J. Postavení thiazolidindionů v léčbě diabetu 2. typu - 2007. Interní Med. 2008; 10 (2): 50-53.
    546. Sosna T. Farmakoterapie diabetické retinopatie - zbožné přání nebo realita? Interní Med. 2008; 10 (11): 511-516.
    547. Sucharda P. Obezita a metabolický syndrom. Od syndromu inzulinové rezistence k, ,syndromu centrální obezity". Interní Med. 2008; 10 (4): 165-166.
    548. Šmahelová A. Volba antidiabetik s přihlédnutím k metabolickému syndromu. Interní Med. 2008; 10 (9): 380-383.
    549. Vítovec J, Špinar J. Použití betablokátorů u nemocných s diabetes mellitus. Interní Med. 2008; 10 (3): 126-128.
    550. Weber P. Diabetes mellitus - specifika a komplikace ve stáří. Interní Med. 2008; 10 (10): 456-460.
    551. www.dm2t.cz
    552. www.athero.cz
    553. www.tigis.cz/dmev/index.htm
    554. ###
    555. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86. Go to original source... Go to PubMed...
    556. Barnhorst DA, Barner HB. Prevalence of congenitally absent pedal pulses N Engl J Med, 1968; 278: 264-265. Go to original source... Go to PubMed...
    557. Bartoš V, Jirkovská A. Multidisciplinární přístup k prevenci amputací diabetické nohy. Diabetol. Metabol. Endokr. Výživa, 1998; 1: 3-5.
    558. Bartoš V, Jirkovská A, Kožnarová R. Rizika diabetické nohy pro příjemce renálních a pankreatických transplantátů. Čas. Lék. Čes., 1997; 136: 527-529.
    559. Belch JJF, et al. Critical issues in peripheral arterial disease. Detection and management. Arch. Intern. Med., 2003; 163: 884-892. Go to original source... Go to PubMed...
    560. Broulíková A. Etiopatogeneze a diferenciální diagnostika defektů dolních končetin. Ve: Angiologie 2007, trendy soudobé angiologie. Svazek 2, Galen, 2007: 11-13.
    561. Brunerová L, Anděl M. Ekonomické náklady syndromu diabetická noha v mezinárodním srovnání. Diabetol. Metabol. Endokr. Výživa, 2002; 3: 153-156.
    562. Bulvas M. Akutní uzávěry tepen a bypassů zásobujících dolní končetiny. Ve: Angiologie 2006, trendy soudobé angiologie. Svazek 1, Galén 2006: 27-41.
    563. Čechurová D, et al. Ekonomický pohled na léčbu syndromu diabetická noha. Diabetol. Metabol. Endokr. Výživa, 2001; 4: 4.
    564. Česká diabetologická společnost. Standardy péče o diabetes mellitus 2. typu. Prakt. Lék., 1997; 77: 401-408.
    565. Herman J. Chirurgická léčba claudicatio intermittens. Ve: Angiologie 2006, trendy soudobé angiologie. Svazek 1, Galén 2006: 23-25.
    566. Chochola M, Vařejka P, Heller S. Možnosti intervenční léčby onemocnění tepen dolních končetin. Interní medicína pro praxi, 2004; 6(11): 542-546.
    567. Jirkovská A. Klinický význam klasifikace syndromu diabetické nohy. Diabetol. Metabol. Endokr. Výživa, 2003; 1: 8-11.
    568. Jirkovská A, et al. Syndrom diabetické nohy. Praha: Maxdorf, 2006.
    569. Roztočil K. Medikamentózní léčba u nemocných s klaudikacemi. Ve: Angiologie 2006, trendy soudobé angiologie. Svazek 1, Galen, 2006: 15-18.
    570. Spáčil J, Svobodová J. Význam rehabilitace u nemocných s klaudikacemi. Ve: Angiologie 2006, trendy soudobé angiologie. Svazek 1, Galen, 2006: 19-21.
    571. Vodňanský P. Sonografická diagnostika onemocnění tepen dolních končetin. Interní Med. 2003; 5 (4): 165-170.
    572. Wosková V, Jirkovská A, Peregrin J, Skibová I. Hodnocení angiografických nálezů na dolních končetinách u diabetiků léčených v podiatrické ambulanci. Abstrakta. XXXlll. diabetologické dny v Luhačovicích, 1997: 77 s.
    573. Záhumenský E. Péče o diabetickou nohu a neuropatické defekty. Ve: Angiologie 2007, trendy soudobé angiologie. Svazek 2, Galen, 2007: 19-26.
    574. ###
    575. Faglia E, Mantero M, Caminiti M, et al. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. J. Intern. Med. 2002; 252(3): 225-232. Go to original source... Go to PubMed...
    576. Kožnar B, Peregrin JH. Perkutánní transluminální angioplastika (PTA) infrapopliteálních tepen. Čes. Radiol. 2004; 58 (3): 119-124.
    577. Krajina A, Hlava A. Angiografie. Hradec Králové, Nukleus HK, 1999.
    578. Krajina A, Peregrin JH, eds. Intervenční radiologie - miniinvazivní terapie. Grafické studio Olga Čermáková. Hradec Králové, 2005.
    579. ###
    580. Firt P, Hejnal J, Vaněk I. Cévní chirurgie. AVICENUM, 1990: 127-144.
    581. Kompendium rán a ich ošetrovania. PAUL HARTMAN AG 1999: 69-72, 81-84.
    582. Kozák P. Choroby obvodových cév. AVICENUM, 1981: 150-154.
    583. Wolfe, JHN. ABC cévních onemocnění. SCIENTIA MEDICA, 1996: 37-39.
    584. Nahodil V. Diabetické gangrény a flegmóny. SZN, 1967.
    585. Way, LW. a kolektiv. Současná cévní chirurgická diagnostika a léčba, I. díl. Grada, 1998: 927-928, 959-964.
    586. ###
    587. Bartoš V, Záhumenský E, Jirkovská A. Standardy péče o diabetickou nohu. Vnitř Lék, 1996; 42 (1): 54-56. Go to PubMed...
    588. Boulton AJM. Clinical presentation and management of diabetic neuropathy and foot ulceration. Diab Med, 1991; 8: 52-57. Go to original source... Go to PubMed...
    589. Bureš I. Rozdělení a základní přehled moderních obvazových materiálů. In Pomocník diabetologa - informační katalog. Praha: Geum, 2007: S.150-160.
    590. Caputo GM, Cavanagh PR, Albrecht JS, et al. Assesment and management of foot disease in patiens with diabetes. N Engl J Med, 1994; 29: 854-860. Go to original source... Go to PubMed...
    591. Coleman WC, Brand PW. The diabetic foot. In Davidson JK, Clinical Diabetes Mellitus. New York: Thieme Medical Publishers, 1991: 496-554.
    592. Edmonds M, Foster A. Diabetic foot clinic. In The diabetic foot. Levin M. et al. (eds.), Mosby Year Book, St. Luis, 1993: 587-604.
    593. Eldor R, Raz I, Ben Yehudat A, et al. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med 2004; 21: 1161-1173. Go to original source... Go to PubMed...
    594. Fife CE, Buyukcakir C, Otto GH, et al. The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospective analysis of 1 144 patients. Wound Repair Regen, 2002; 10: 198-207. Go to original source... Go to PubMed...
    595. Gray DG, White R, Cooper PJ, Kingsley A. Understanding Applied Wound Management. Wounds UK, 2005; 1(1): 62-68.
    596. Hoeldtke RT, Davis KM, Hshieh PB, et al. Are there two types of diabetic foot ulcers? J Diab Compl, 1994; 8: 117-125. Go to original source... Go to PubMed...
    597. Chlup R, Holá J, Kudlová P, et al. Co může vykonat diabetolog pro úspěšnou léčbu syndromu diabetické nohy. Trendy v medicíně, 2005; 6 (6): 41-51.
    598. Jeffcoat WJ, Price P, Harding KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev, 2004; 20 (Suppl 1): 78-89. Go to original source... Go to PubMed...
    599. Jirkovská, A. Hojení kožních afekcí u syndromu diabetické nohy při hospitalizaci. Vnitř Lék 2006; 52 (5): 459-464. Go to PubMed...
    600. Jirkovská A, et al. Syndrom diabetické nohy. Praha: Maxdorf, 2006. ISBN 80-7345-095-X.
    601. Kalani M, Brismar K, Fagrell B, et al. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care, 1999; 22: 147-151. Go to original source... Go to PubMed...
    602. Kudlová P. Edukace pacientů při terapii ran. In Management ran - komplexní přístup k léčbě a ošetřování, Olomouc, 9. června 2004 [online]. [Cit.2004-07-19]. Olomouc: FN, 2004. Dostupný z: <http://www.fnol.cz/akce.jsp?id=6>.
    603. Martinka E, Kurča E, et al. Komplexný pohľad na problém diabetickej nohy. Zdravotnické noviny, příloha Lékařské listy, 2003,14: 30-37.
    604. Mezinárodní pracovní skupina pro syndrom diabetické nohy. Syndrom diabetické nohy - Mezinárodní konsenzus.2000. vypracovaný Mezinárodní pracovní skupinou pro syndrom diabetické nohy. Jirkovská, A. (překlad a redakce). Praha: Galén, 2000. 102 s.
    605. Péče o rány - manuál. Příloha časopisu Sestra č. 6 a ZdN 2003; 25: 14-18.
    606. Rušavý Z, et al. Diabetická noha. Diagnostika a terapie v praxi. 1. vyd. Praha: Galén, 1998: 189 s.
    607. Souhrnně o Číselníku. Hojení ran, 2007; 1(1): 28-29.
    608. Stryja, J. Debridement v terapii ran. Šeflová, L (Ed.). Diagnostika a monitoring ran. Olomouc: FN a UP, 2005: S. 26-29.
    609. Stryja, J. Nebojme se nových klasifikací. Bureš I, pořadatel. Léčba rány. Praha: Galén, Edice Care, 2006.
    610. Švestková S. Hojení chronických ran. Sestra, 10 (8): 7.
    611. Tošenovský P, Edmonds ME, et al. Moderní léčba syndromu diabetické nohy. Praha: Galén, 2004.
    612. Výbor ČDS. Standardy léčby pacientů se syndromem diabetické nohy. 2005. [online]. [Cit. 2006-1-17]. Dostupný z: <http://www.diab.cz/modules/Standardy/dianoha.pdf>.
    613. ###
    614. Backonja MM. Use of anticonvulsant for treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med J 1993; 329 (14): 977-986. Go to original source... Go to PubMed...
    615. Diabetes Control and Complications Trial (DCCT) Research Group. Efect of intensive diabetes treatment on nerve conduction in the diabetes control and complications Trial. Ann Neurol 1995; 6: 869-880. Go to original source...
    616. Feldmann EL, Russel JW, Sullivan KA, Golovoy D. New insights into the patogenesis of diabetic neuropathy. Curr Opin Neurol 1999; 12 (5): 553-563. Go to original source... Go to PubMed...
    617. Gries FA, Cameron NE, Low PA, Ziegler A. Textbook of diabetic neuropathy. Thieme Stuttgart-New York, 1. vydání 2003. Go to original source...
    618. Mazanec R, Vyšata O, Bednařík J, Filová J. Sledování účinnosti preparátu Thioctacid v ambulantní léčbě diabetické neuropatie. Čes Slov Neurol Neurochir 2000; 63/96 (6): 400-405.
    619. Süsová J. Polyneuropatie. In Nevšímalová S. et al. Neurologie, Galén, 1. vydání 2002: 291-295.
    620. Vlachová I, Vaverková H, Urbánek K et al. Výskyt metabolických rizikových faktorů v rodinách mladých osob po ischemické cévní mozkové příhodě. Čes a Slov Neurol. Neurochir. 1998; 61/94 (4): 169-176.
    621. Vlachová I, Vaverková H, Urbánek K et al. Výskyt diabetes mellitus 2. typu, snížené glukózové tolerance a hyperinzulinémie v rodinách mladých osob po ischemické cévní mozkové příhodě. Čes Slov Neurol Neurochir 2001; 64/97 (4): 225-230.
    622. Vondrová H. Neurologické projevy diabetes mellitus. In: Vondrová H. Neurologické projevy endokrinních onemocnění. Praha: Geum, 2003: 40-127.
    623. Standardy diagnostiky a léčby diabetické neuropatie. Schváleno výborem České diabetologické společnosti ČLS JEP 6. 2. 2007. Diabetologie, metabolismus, endokrinologie, výživa 2007; 10: 215-220.
    624. ###
    625. Ambler Z. Diabetická neuropatie. In: Diabetická neuropatie. Konsenzuální konference, Žinkovy, 20.-22. března 1997. Praha: Galén, 1998: 9-22.
    626. American Diabetes Association. Standards of medical care in diabetes - 2006 (Position statement). Diabetes Care 2006; 29: S4-S42. Go to original source... Go to PubMed...
    627. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962. Go to original source... Go to PubMed...
    628. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes therapy on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38: 869-880. Go to original source... Go to PubMed...
    629. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41: 416-423. Go to original source... Go to PubMed...
    630. Dyck PJ. The near-future direction of research and medical care of human diabetic neuropathies. Neurosci Res Communication 1997; 21: 5-12. Go to original source...
    631. Dyrberg T, Benn J, Sandahl Christiansen J et al. Prevalence of diabetic autonomic neuropathy measured by simple bedside tests. Diabetologia 1981; 20: 190-194. Go to original source... Go to PubMed...
    632. Ewing DJ, Martyn CN, Young RJ, et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8: 491-498. Go to original source... Go to PubMed...
    633. Fraser DM, Campbell IW, Ewing DJ, et al. Peripheral and autonomic nerve function in newly diagnosed diabetes mellitus. Diabetes 1977; 26: 546-550. Go to original source... Go to PubMed...
    634. Kempler P, Váradi A, Szalay F, et al. Diabetic autonomic neuropathy. Br Med J 1990; 301: 1161. Go to original source... Go to PubMed...
    635. Krahulec B, Vozár J, Piják R, et al. Srdcová autonómna neuropatia u diabetikov 1. typu. Vnitřní Lék 1987; 33: 253-259.
    636. Kučera P, Goldenberg Z, Kurča E. Sympathetic skin response: review of the method and its clinical use. Bratislavské lekárské listy 2004; 105: 108-116. Go to PubMed...
    637. Lacigová S. Autonomní neuropatie. In: Diabetická neuropatie. Konsenzuální konference, Žinkovy, 20.-22. března 1997. Praha: Galén,1998: 56-69.
    638. Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004; 27: 2942-2947. Go to original source... Go to PubMed...
    639. O&Bacute;rien IA, McFadden JP, Corrall RJM. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991; 79: 495-502.
    640. Opavský J, Pumprla J, Salinger J, et al. Spektrální analýza variability srdeční frekvence - přínos pro diagnostiku diabetické autonomní neuropatie. Scripta medica Fac Med Univ Brunensis Masarykianae 1994; Tomus 67 (suppl 1): 29-32.
    641. Opavský J, Salinger J. Vyšetřovací metody funkcí autonomní nervové soustavy - přehled pro potřeby klinické praxe. Noninvasiv Cardiol 1995; 4: 139-153.
    642. Opavský J. Autonomní nervový systém a diabetická autonomní neuropatie. Klinické aspekty a diagnostika. Praha: Galén 2002.
    643. Rathmann W, Ziegler D, Jahnke M et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993; 10: 820-824. Go to original source... Go to PubMed...
    644. Standardy diagnostiky a léčby diabetické neuropatie. Schváleno výborem České diabetologické společnosti ČLS JEP 6. 2. 2007. Diabetologie, metabolismus, endokrinologie, výživa 2007; 10: 215-220.
    645. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996; 104: 311-316. Go to original source... Go to PubMed...
    646. Töyry JP, Niskanen LK, Mäntysaari MJ, et al. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Diabetes 1996; 45: 308-315. Go to original source... Go to PubMed...
    647. Ziegler D, Hanefeld M, Ruhnau KJ et al., The ALADIN Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-1433. Go to original source... Go to PubMed...
    648. Ziegler D, Schatz H, Conrad F, et al. The DEKAN Study Group. Effects of treatment with the antioxidant alpha-lipoic acid in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997; 20: 369-373. Go to original source... Go to PubMed...
    649. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes/Metabolism Reviews 1994; 10: 339-383. Go to original source... Go to PubMed...
    650. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocronol 2004; 3: 173-189. Go to original source... Go to PubMed...
    651. ###
    652. Patz A, Schatz H, Berkow JW, et al. Macular edema: an overlooked complication of diabetic retinopathy. Trans. Am. Acad. Opthal. Otolaryng., 1973; 77: 34-42.
    653. Photocoagulation in treatment of diabetic maculopathy. Interim report of a multicentre controlled study. Lancet, 1975; 2: 1110-1113.
    654. Klein R, Moss SE, Klein BEK, Davis MD, Mets DL. The Winconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Opthalmology, 1989; 96: 1501-1510. Go to original source... Go to PubMed...
    655. Bresnick GH. Diabetic macular edema. A review. Opthalmology, 1986; 93: 989-997. Go to original source... Go to PubMed...
    656. ###
    657. Bartoš V, Teplan V, Bouček P. Standardy péče při diabetické nefropatii. Vnitřní Lék 1998; 44: 727-731.
    658. Bartoš V. Možnosti ovlivnění progrese diabetické nefropatie. Vnitřní Lék 1998; 44: 428-430.
    659. Bartoš V, Pelikánová T. Praktická diabetologie. Praha, Maxdorf 1996: 376 s.
    660. Bouček P. Péče o nemocné s diabetickou nefropatií. ČLČ 1997; 136: 689-692.
    661. Hanssen KF. How tight must blood glucose control be to prevent diabetic nephropathy? Nephrol Dial Transplant 1994; 9: 226-227.
    662. Chábová V. Patofyziologie diabetické nefropatie. ČLČ 1999; 138: 392-395.
    663. Tesař V, Schück O. Klinická nefrologie. Praha, Grada Publishing 2006: 652 s.
    664. Tarnow L. Genetic pattern in diabetic nephropathy. Nephrol Dial Transplant 1996; 11: 410-412. Go to original source...
    665. Ruggenenti P, Fassi A., Parvano Ilieva A et al. Preventing microalbuminuria in type 2 diabetes. N Eng J Med 2004; 351: 1941-1951. Go to original source... Go to PubMed...
    666. Koch M, Gradaus F, Schoebel LC, et al. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant 1997; 12: 1187-1191. Go to original source... Go to PubMed...
    667. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219. Go to original source... Go to PubMed...
    668. Ritz E, Orth SROV. Nephropathy in patients with type 2 diabetes mellitus. N Eng J Med 1999; 341: 1127-1133. Go to original source... Go to PubMed...
    669. Rychlík I, Brunerová L. Diabetická nefropatie. Postgraduální medicína 2006; 8: 200-2006.
    670. American Diabetes Association: Diabetic Nephropathy. Diabetes Care 2002; 25(Supp 1): 85-89. Go to original source...
    671. Olšovský J. Hypertenze a diabetes mellitus. Lékařské listy 2002; 37: 14-18.
    672. Barnett AH, Bain SC, Bouter P. Angiotensin-receptor blokade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961. Go to original source... Go to PubMed...
    673. Ponťuch P. Diabetická nefropatie. Grada Publishing, Praha 2003: 139 s.
    674. Tesař V. Diabetická nefropatie - nové možnosti léčby. Interní Med. 2002; 2: 50-55.
    675. Passadakis P, Thodis E, Vargemezis V, et al. Long - term survival with peritoneal dialysis in ESRD due to diabetes. Clin Nephrol 2001; 56: 257-270. Go to PubMed...
    676. Rychlík I, Lopot F. Statistická ročenka dialyzační léčby v České republice 2006, Praha 2007: 28 s.
    677. ###
    678. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonyllureas or insulin. Diabetes Care. 2006; 29 (2): 254-258. Go to original source... Go to PubMed...
    679. Cottet V, Pariente A, Nalet B, Lafon J, Milan C, Olschwang S et al. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology. 2007; 133 (4): 1086-1092. Go to original source... Go to PubMed...
    680. Ehrmann J jr., Vavrušková N, Collan Y, Kolář Z. Peroxisome proliferator-activated receptors (PPARs) in health and desease. Biomed Pap Med Fac Univ Palacky Olomouc, 2002; 146: 11-14. Go to original source... Go to PubMed...
    681. Flood A, Mai V, Pfeiffer R, Kahle L, Remaley AT, Lanza E, Schatzkin A. Elevated serum concentrations of insulin glukose increase risk of recurrent colorectal adenomas. Gastroenterology. 2007; 133 (5): 1423-1429. Go to original source... Go to PubMed...
    682. Frič P, Zavoral M, Seifert B, Pokorný P, Suchánek Š. Screening sporadického kolorektálního karcinomu v ČR. Interní Med. 2007; 5: 221-224.
    683. Huxley R, Ansary-Moghaddam A, Berrington GA, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005; 92 (11): 2076-2083. Go to original source... Go to PubMed...
    684. Chari ST, Leibon CL, Rabe KG, Timmons LJ, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.
    685. Chlup R, Vaverková H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. Effect on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105(suppl 2): 70-73. Go to original source... Go to PubMed...
    686. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK. Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: A case-control study in Korea. Dis Colon rectum. 2008 Jan 25 (Zdroj PubMed před uvedením do tisku). Go to original source... Go to PubMed...
    687. Chung YW, Han DS, Park YK, Son BK, Paik CH, et al. Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea. Dig Liver Dis. 2006; 38 (9): 668-672. Go to original source... Go to PubMed...
    688. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, Biessy C, et al. Serum C-peptid, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007, 15; 121 (1): 368-376. Go to original source... Go to PubMed...
    689. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000, 4; 92 (19): 1592-600. Go to original source... Go to PubMed...
    690. Keku TO, Lund PK, Galanko J, Simmons JG, Woosley JT, Sander RS. Insulin resistence, apoptosis, and colorectal adenoma. Cancer Epidemiol Biomarkers Rev. 2005; 14 (9): 2076-2081. Go to original source... Go to PubMed...
    691. Ma J, Giovannucci E, Pollak M, Leavitt A., Tao Y, Gaziano JM, Stampfer MJ. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004; 96 (7): 546-553. Go to original source... Go to PubMed...
    692. Nagel JM, Göke B. Colorectal carcinoma screening in patients with type 2 diabetes mellitus. J Gastroenterol. 2006; 44 (11): 1153-1165. Go to original source...
    693. Otani T, Iwasaki M, Sasazuki S, et al. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer 2007, 1; 120 (9): 2007-2012. Go to original source... Go to PubMed...
    694. Procházka V, Chlup R. Kolorektální karcinom a diabetes mellitus. Vnitř lék 2008; 54(10): 979-984. Go to PubMed...
    695. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glukose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003; 12 (5): 412-418.
    696. Schiel R, Müller UA, Braun A, Stein G, Kath R. Risk of malignancies in patients with insulin-tread diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Eur J Med Res. 2005, 17; 10 (8): 339-344.
    697. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young - onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007, 12; 96 (3): 507-509. Go to original source... Go to PubMed...
    698. Svačina Šm Matoulek M, Svobodová Š et al. Nádory trávicího traktu a diabetes mellitus. Vnitř. lék 2004; 50: 386-391.
    699. Svačina Š, Matoušek M. Diabetes a kolorektální karcinom. In Perušičová J. Trendy soudobé diabetologie, svazek 7, 1. vydání, Praha Galén 2003.
    700. Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Amer J Epidemiol. 1998; 147 (9): 816-825. Go to original source... Go to PubMed...
    701. Winawer SJ, Zaber AG, Gerdes H, O&Bacute;rein MJ, Gottlieb LS, Sternberg SS, Bond JH, Waye JD, Schapiro M, Panish JF, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med. 1996, 16; 334 (20): 1339-1340. Go to original source... Go to PubMed...
    702. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004; 127 (4): 1044-1050. Go to original source... Go to PubMed...
    703. Zavoral M, Frič P. Screening kolorektálního karcinomu. Interní Med. 2007; 3: 149-150.
    704. ###
    705. Cox H. et al. Clinical application of nursing diagnosis. 4th ed. Philadelphia: F. A. Davis Company. 2002; 752 s.
    706. Doenges ME, Moorhouse MF. Kapesní průvodce zdravotní sestry; 2. vyd. Praha: Grada Publishing, 2001: 565 s.
    707. Elkin M, Perry A, Potter P. Nursing interventions and clinical skills. 3rd ed. St. Louis: Mosby, Inc. 2004: 1021 s.
    708. Gordon M. Nursing diagnoses: process and application. 2. vyd. St. Louis: McGraw-Hill, Inc., 1987: 515 s.
    709. Gordon M. et al. Nursing diagnoses: definitions & classification 2001-2002. Philadelphia: NANDA, 2001-2002: 256 s.
    710. Ralph SS, et al. NANDA. Nursing diagnoses: definitions & classification 2005-2006. Philadelphia: NANDA, 2005-2006: 240-250.
    711. Kim M, et al. Classification of nursing diagnoses. Proceedings of the 5th ed. National conference on the classification of nursing diagnoses. St. Louis: Mosby Company. 1984: 626 s.
    712. Kozier B, Erb G. Fundamentals of nursing. 3rd ed. California: Addison-Wesly Publishing Company, Inc. 1987: 1659 s.
    713. Kozierová B, Erbová G. Ošetrovateľstvo 1. a 2. díl. Martin: Osveta, 1991.
    714. Kudlová P, Marečková J. Ošetřovatelská dokumentace, plán ošetřovatelské péče - výstup 3. fáze ošetřovatelského procesu. In Ošetřovatelství perspektivní věda i umění. Ed. P. Kudlová, Olomouc: Grada Publishing, 2004: 388 s.
    715. Marečková J, Kudlová P. Pojmy užívané při prvním kroku ošetřovatelského procesu - Posouzení. In Ošetřovatelství perspektivní věda i umění. Ed. P. Kudlová, Olomouc: Grada Publishing, 2004: 388 s.
    716. Milliken M, Cambell G. Essential competencies for patient care. 1st ed. USA: Mosby, Inc. 1985: 826 s.
    717. Pacovský V. Ošetřovatelská diagnostika. Praha: UK, 1994.
    718. Trachtová E, a kol. Potřeby nemocného v ošetřovatelském procesu. Brno: IDVPZ, 1999.
    719. Herdman TH, et al. 2009. NANDA - I. Nursing Diagnoses: Definitions & Classification 2009-2011. Philadelphia: NANDA International, 2009. 435 p. ISBN 978-1-4051-8718-3.
    720. Herdman TH, et al. 2007. NANDA - I. Nursing Diagnoses: Definitions & Classification 2007-2008. Philadelphia: NANDA International, 2007. 339 p. ISBN 978-0-9788924-0-1.
    721. ###
    722. Směrnice č. 49/1967 Věstníku Ministerstva zdravotnictví, o posuzování zdravotní způsobilosti k práci, ve znění pozdějších předpisů.
    723. Vyhláška MD č. 101/1995 Sb., kterou se vydává Řád pro zdravotní a odbornou způsobilost osob při provozování dráhy a drážní dopravy, ve znění vyhlášky MDS č. 455/2000 Sb. a vyhlášky č. 194/2005 Sb.
    724. Vyhlášky č. 277/2004 Sb. Ministerstva zdravotnictví ČR o posuzování zdravotní způsobilosti k řízení motorových vozidel v platném znění.
    725. Brhel P, Manoušková M, Hrnčíř E, editors. Pracovní lékařství. Brno: NCO NZO; 2005, 338 s.
    726. Buchancová J, Mikulková R, Klimentová G, Javorková J, Buchanec J. Diabetes mellitus a profese - retrospektívna štúdia výskytu choroby, hodnoty BMI, glykemie a celkového cholesterolu v séru u vybraných skupin rizikových pracovníkov. Pracov. Lék., 2006; 58: 16-23.
    727. Cowen G, Richardson T, Cavan D, Kerr D. Insulin and driving: clinicians' advice and patients' practice. Abstract no. 2988, In: 18th International Diabetes Federation Congress [CD-ROM]. International Diabetes Federation: Paris, 2003, 24.-29. August 2003.
    728. De Backer G, Leynen F, Bacquer D, Clays E, Moreau M, Kornitzer M. Diabetes mellitus in middle-aged people is associated with increased sick leave: The Belstress study. Int J Occup Environ Health 2006; 12: 28-34. Go to original source... Go to PubMed...
    729. Nakládalová M, Bartoušek J, Pešáková L, Nakládal Z, Fialová J. Profesionální poškození nervus ulnaris v oblasti lokte. Čes a slov Neurol Neurochir. 2006; 69/102, 2: 132-135.
    730. Stork ADM, Schouten van der Velden, AP, Sels, J. WEM, Janssen, WH, Martens, MH, Erkelens, DW, Veneman, TF. Driving performance of patients with Type 2 diabetes mellitus during euglycaemia and moderate, symptomatic hypoglycaemia. Abstract no. 881, In: 18th International Diabetes Federation Congress, [CD-ROM]. International Diabetes Federation: Paris, 2003, 24.-29. August 2003.
    731. Syllaba J. Posuzování pracovní schopnosti při diabetes mellitus, s. 331-338. In: Kol. autorů: Kompendium lékařské posudkové činnosti II/ 1. Avicenum, 1981, 544 s.
    732. ###
    733. Banting FG, Best CH. Pancreatic extracts, J. Lab. Clin. Med. 1922; 7, 8 (May): 3-11.
    734. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922, 7 (2).
    735. Berger M, et al. Léčba inzulinem v každodenním životě. Victoria publishing, Praha 1995.
    736. Bliss M. The discovery of insulin Chicago: University of Chicago Press, 1982. Go to original source...
    737. Bliss M. J. J. R. Macleod and the discovery of insulin. Q. J. Exp. Physiol.1989, 74: 87-96. Go to original source... Go to PubMed...
    738. Bliss M. The history of diabetes. In, ,Textbook of Diabetes", Eds. Pickup, J. C. and Wiliams, C., Oxford Press 1993. Go to original source...
    739. Bober J. Nositelé Nobelovy ceny. Obzor, Bratislava, 1971.
    740. Engelhardt D. Diabetes - Its medical and cultural history. Springer-Verlag New York, Berlin, Heidelberg 1981.
    741. Foit R, Syllaba J, et al. Diabetes mellitus. Avicenum, Praha, 1970.
    742. Houssay BA. The discovery of pancreatic diabetes. The role of Oscar Minkowski. In: Engelhardt D. Diabetes its medical and cultural history. Springer-Verlag Berlin - Heidelberg - New York - London - Paris - Tokyo - Hongkong 1989. Go to original source...
    743. Chlup R. Nicolae C. Paulescu a objev inzulinu: torontská etika ve stínu, ,priority"? Zprav klin Farmakol Farmac 1997; 11 (2): 24-29.
    744. International Diabetes Federation. Report of the Special Commitee set up to present a written summary of work leading up to the discovery of insulin. News Bull. of the Int. Diab. Fed., 1974; 1: 29-40.
    745. Ionescu-Tirgoviste C. The re-discovery of insulin. Editura Geneze, Romania, 1996. ISBN 973-9099-32-7.
    746. Jörgens V, Minkowski HO. Past Masters Oskar Minkowski. Diabetologia 2005; 48 (8): A8.
    747. Korec R. 50. výročí objevu a izolace inzulinu, Banting, Best and Collip 1922. In: Čas Lék Čes 110: 416-418.
    748. Korec R. More comments on, ,Who discoverred insulin?" In: News in physiological sciences 1986: 211-212. Go to original source...
    749. Korec R. 75th anniversary of insulin discovery: NC Paulescuś and FG Bantingś with CH Best and JB Collip contribution to insulin discovery. Acta Diabetol Romana 1996; 22: 85-86.
    750. Korec R. Contribution of experimental diabetology to justification of intensification of intensived insulin therapy. Acta Diabetol Romana 1996; 22: 86-87.
    751. Martin E. Problems of priority in the discovery of insulin. Schweizerische medizinische Wochenschrifft 1971; 101: 164-167.
    752. Paulescu NC. Action de léxtrait pancreatique injecte dans le sang chez un animal diabetique. Comptes rendus des seances de la Societé de biologie 1921; 85(27): 556-559.
    753. Paulescu NC. Recherche sur le role du panréas dans lássimilation nutritive. Liege, Arch. Int. Physiol. 1921; 7: 85-109.
    754. Páv J. Historie světové priority začínající v Praze. In: Čas. Lék. Čes. 1986; 125: 784-785.
    755. Scott EL. On the influence of intravenous injection of an extract of the pancreas on experimental pancreatic diabetes. Amer. Jour. of Physiol., 1912: 306. Go to original source...
    756. Scott EL. The relation of pancreatic extract to the sugar of the blood. Soc. Exp. Bio. and Med., P. 1913: 101-103. Go to original source...
    757. Scott EL. Priority in discovery of a substance derived from the pancreas, active in carbohydrate metabolism. Jour. Amer. Med. Ass., 1923: 1303-1304. Go to original source...
    758. Von Mering O, Minkowski O. Diabetes mellitus nach Pankreasexstirpation. Arch. f. exp. Path. u. Pharm. 1890; 26: 371-387. Go to original source...
    759. Zuelzer GL. Experimentell Untersuchungen ueber den Diabetes. Berliner Klin. Woch., 1907: 475.
    760. Zuelzer GL. Ueber Versuche einer spezifischen Fermenttherapie. Des Diabetes Zeit. fur exp. Path. und Ther., 1908: 307.
    761. Zuelzer GL, Dohrn M, Marxer A. Neue Untersuchungen ueber den experimentellen Diabetes. Deutsch. Med. Woch., 1908:307. Go to original source...
    762. Berger M, Jörgens V, Chlup R. Léčba inzulinem v každodenním životě. Victoria Publishing, Praha, 1995: s. 293.
    763. Bruns W, Seige K, Menzel R, Panzram G. Die Entwicklung der Diabetologie im Osten Deutschlands von 1945 bis zur Wiedervereinigung. Deutsche Diabetesgesellschaft, WECOM, Hildesheim, ISBN 3-936453-31-4, 55 s.
    764. Diabetes Education Study Group. Basic curriculum for health professionals on diabetes therapeutic education. Report of DESG Working Group 2001, 62 stran.
    765. Goleman D. Emotional inteligence, Bloomsbury paperbacks, Great Britain, 1996, 352 s.
    766. Howorka K: Pícháte si inzulín? Kirchheim, Mainz, 1996: 155 s.
    767. Chlup R, Holešinská P, Chlupová L, Komenda S. Assessment of Postgraduate Education of Therapeutic Educators (PETE) at a university diabetes centre. In. Diabetes Metabolism. 18th Interantional Diabetes Federation Congress. Poster Displays. France: Paris, 24-29 August 2003.
    768. Chlup R, Janů K, Menzel R, Bruns W, Venháčová J. Léčba diabetu pomocí ručního dávkovače inzulínu MADI. Univerzita Palackého Olomouc, 1985: 63 s.
    769. Chlup R, Taton J, Neoral L, Day JL. The changing role of physician nurse dietitian teacher and social environment in the self-treatment of a diabetic patient. Vth European Workshop of Medical & Teaching Staff. Olomouc, 1991.
    770. Chlup R, Navrátilová L, Řehořová J, Vaverková H, Venháčová J, Bartek J, Ficker L, Slezáková L. Programová léčba diabetu. Galén, Praha 1996: 194 s.
    771. Jirkovská A, a kol. (1998) Jak (si) kontrolovat a léčit diabetes. Ed. PANAX Praha.
    772. Jörgens V, Grüsser M, Perger M, Kreze-Spirová E. Moja kniha o cukrovke. Eli Lilly, 1997: 121 s.
    773. Kodadský J. Praktické rady pro nemocné cukrovkou. GEUM Běstvina, 1999: 80 s.
    774. Kolektiv autorů: Diabetes mellitus - příčiny komplikace léčba. Příručka pro pacienty. IKEM, Praha, 1992.
    775. Kudlová P, Tomanová D. Didaktická vybavenost edukační lekce. In. Trendy v ošetřovatelství III. - Trends in Nursing III. Ostrava: Ostravská univerzita, Zdravotně sociální fakulta, 2004a: 93-102.
    776. Kudlová P, Tomanová D. Strukturní elementy edukace. In Kudlová, P. (Ed.) Ošetřovatelství perspektivní věda i umění. 1. vyd. Olomouc: Grada Publishing, 2004b: 388 s. 182-192.
    777. Menzel R. Insulin zum Leben. MEDICUS Verlag Gesundheit, Berlin, 1997: 204 stran.
    778. Mühlhauser I., Bruckner I, Berger M, Cheta D, Jörgens V, Ionescu-Tirgoviste C, Scholz V, Mincu I (1987) Evaluation of an intensified insulin treatment and teaching programme as routine management of type I (insulin-dependent) diabetes. Diabetologia 30: 681-690. Go to original source... Go to PubMed...
    779. Vávrovi H aj. Poezie dospívání. GEUM Praha, 2006.
    780. World Health Organisation. Therapeutic patient education. 1998: 76 s.
    781. ###
    782. Bartoš V, Pelikánová T. a kolektiv. Praktická diabetologie. 3. rozšířené vydání. Praha: Maxdorf, 2003: 479 s.
    783. Holešinská P. Edukace diabetika II. typu léčeného, mimo jiné, inzulinem. In Holešinská, P. (Ed.) Multioborová, interdisciplinární a mezinárodní kooperace v ošetřování. 1. vyd. Praha: GRADA Publishing, 2002; 376 s.
    784. Chlup R, a kol. Úvod do diagnostiky a léčby diabetu. Olomouc: VUP, 2000.
    785. Chlup R, et al. Programová léčba diabetu. 1. vyd. Praha: Galén, 1996: 196 s.
    786. Kalhous Z. Základy školní didaktiky. 1. vyd. Olomouc: VUP, 1995: 122 s.
    787. Kudlová P. Edukační program, distanční text v předmětu Ošetřovatelský proces u vybraných chorob. Olomouc: ÚTPO LF UP, LMS Unifor, 2003. Staženo 19. 02. 04. Dostupný z: http://serverl.upol.cz.
    788. Kudlová P, Tomanová D. Didaktická vybavenost edukační lekce. In. Trendy v ošetřovatelství III. - Trends in nursing III. Ostrava: Ostravská univerzita, Zdravotně sociální fakulta, 2004a: s. 93-102.
    789. Kudlová P, Tomanová D. Strukturní elementy edukace. In Ošetřovatelství perspektivní věda i umění. Kudlová, P. (Ed.) 1. vyd. Olomouc: Grada Publishing, 2004b: 388 s.
    790. Rybka J. Saintvincentská deklarace - váš průvodce k lepší léčbě diabetu. 1. vyd. Praha: Svaz osob s diabetem České republiky, 1994.
    791. Tomanová D. Edukační kompetence zdravotní sestry. In Multioborová, interdisciplinární a mezinárodní kooperace v ošetřování. Holešinská P. (Ed.) 1. vyd. Praha: GRADA Publishing, 2002. 376 s.
    792. ###
    793. Bartoš V, Pelikánová T. a kolektiv. Praktická diabetologie. 3. rozšířené vydání. Praha: Max dorf, 2003; 479 s.
    794. Chlup R, et. al. Programová léčba diabetu. 1. vyd. Praha, Galén, 1996; 194 s.
    795. Chlup R, a kol. Úvod do diagnostiky a léčby diabetu. Olomouc: VUP, 2000.
    796. Kudlová P, Chlup R. Pomůcky k aplikaci inzulinu. Interní Med. 2006; 8(6): 302-306.
    797. Vízner K, et al. Pomocník diabetologa 2008 - Informační katalog. Praha: Geum, 2008. 1. vyd.
    798. ###
    799. Expert committee on the diagnosis and classification of diabetes mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
    800. Silverstein J, et al. Care of children and adolescents with type 1 diabetes mellitus: a statement of the American Diabetes Association. Diabetes Care 2005; 28: 186-212. Go to original source... Go to PubMed...
    801. Standards of Medical Care in Diabetes - 2007. Diabetes Care 2007; 30 (Suppl. 1): S4-S41.
    802. Praktická diabetologie. Eds. V. Bartoš, T. Pelikánová a kol., Maxdorf 2003.
    803. ###
    804. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006; 49: 1711-1721. Go to original source... Go to PubMed...
    805. Praktická diabetologie. Eds. V. Bartoš, T. Pelikánová a spol., Maxdorf 2003. (3. vydání)
    806. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Cor Vasa 2005; 47: 3-14.
    807. Recommendations for the management of patients with type 2 diabetes mellitus in the central, Eastern and Southern European Region. Int. J. Posttrad. Train. Med. 2000: 8.
    808. Standards of medical care in diabetes - 2007, Diabetes Care 2006; 30 (Suppl. 1): S4-S41.
    809. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. European Heart Journal 2007; 28: 88-136.
    810. ###
    811. Anděl M, et al. Diabetes mellitus a další poruchy metabolismu. 1. vyd Galén Praha 2001: 210 s.
    812. Assal JP. The Diabetes Education Study Group of the European Association for the Study of Diabetes: 15 years devoted to improving patient management. 1994.
    813. Bakx J. Editorial: Health promoting hospitals. Patient Education and Counseling 2001; 45: 237-238. Go to original source...
    814. Berger M, Jörgens V, Chlup R. Léčba inzulinem v každodenním životě. Victoria Publishing. Praha 1995: 293 s.
    815. Bruns W. Zur Therapie des Typ-2 Diabetes - Ansätze für eine frühzeitig beginnende pathophysiologisch begründete Therapie mit Insulin. Diabetes Dialog 1998; 1-98: 9-13.
    816. Chlup R, et al. Programová léčba diabetu. Galén 1996; 194 s.
    817. Chlup R, Možíšová L. Léčba diabetiků pomocí inzulinové pumpy - teorie a praxe. Diabetologie-Metabolismus-EndokrinologieVýživa 2000; 3 (1): 3-17.
    818. Diabetes Education Study Group: Basic curriculum for health professionals on diabetes therapeutic educatioon. Report of a DESG Working Group, DESG 2001; 62 s.
    819. IDF Consultative Section on Diabetes Education: International Consensus of Practice for Diabetes Education. Class Publishing Barb House Berb Mews London W67PA UK 1997.
    820. Jirkovská A. Jak (si) kontrolovat a léčit diabetes: manuál pro edukaci diabetiků. Praha Panax 1999: 200 s.
    821. Kvapil M. Edukace diabetika - nezbytná součást léčby. Vnitřní lékařství 2001; 5: 293-297.
    822. Menzel R. Insullin zum Leben. Medicus Verlag Gesundh 1997: 204 s.
    823. Mlčák P, Chlup R, Boudová E, Bartek J, Zapletalová J. Vývoj koncentrace glukosy v intersticální tekutině u nediabtetiků s ohledam na detekci fenoménu svítání - pilotní studie. Klin. Metab 2003; 1: 44-49.
    824. Musil D, Heřman J. Přínos barevné duplexní ultrasonografie k předoperačnímu vyšetření nemocných s chronickou žilní insuficiencí. Vnitř. lék. 2001; 4: 227-231.
    825. Osterbrink B. für Ausschüssen und Arbeitsgruppen der Deutschen Diabetes-Gesellschaft. Neue Qualitätsstandards zur Anerkennung einer Behandlungseinrichtung für Typ 1- und Typ 2 - Diabetes mellitus. Diabetologie-Informationen (DDG) 2002; 24(6): 173-179.
    826. Perušičová J, Šmahelová A, Kvapil M, Rušavý Z. Inzulinová léčba diabetiků 1. typu - závěry workshopů českých diabetologů 1. část. Diabetologie-Metabolismus-Endokrinologie-Výživa 2002; 5 (4): 251-253.
    827. Rosak C. Insulinanaloga: Struktur, Eigenschaften und therapeutische Indikationen Teil 1: Kurzwirkende Insulinanaloga. Internist 2001; 42: 1523-1535. Go to original source... Go to PubMed...
    828. Rušavý Z, et al. Diabetická noha: diagnostika a terapie v praxi. Galén Praha 1998: 189 s.
    829. Škrha J. Standardy péče o diabetes mellitus 1. typu. Diabetologie-Metabolismus-Endokrinologie-Výživa 1999; 2 (2): 81-85.
    830. Šmahelová A, Perušičová J. Akutní komplikace diabetes mellitus. Interní medicina pro praxi 2000; 2 (10): 491-496.
    831. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruynink F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367. Go to original source... Go to PubMed...
    832. Weber P, Polcarová V. Jak léčíme diabetes (zejména s pozdními komplikacemi) ve vyšším věku? In: Čs. gerontologická a geriatrická společnost, Čs. společnost pro aterosklerózu, Společnost parenterální a enterální výživy, metabolismu a stárnutí: V. celostátní kongres s mezinárodní účastí na téma, ,Účelná farmakoterapie ve stáří". Hradec Králové 25.-26.11.1999. Souhrny přednášek a posterů. 1999.
    833. World Health Organization Regional Office for Europe: Therapeutic patient education. Report of a WHO working group 1998; 77s.
    834. World Health Organization, International Diabetes Federation: Saintvincentská deklarace - Váš průvodce k lepší léčbě diabetu. Svaz diabetiků České republiky Praha 1994.
    835. ###
    836. Vaverková H, Soška V, Rosolová H, Češka R, Cífková R, Freiberger T, Piha J, Poledne R, Štulc T, Urbanová Z, Vráblík M. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracovaná výborem české společnosti pro aterosklerózu. Vnitřní lék 2007; 53(2): 181-197.
    837. Cífková R, Býma S, Češka R, Horký K, Karen I, Kunešová M, Králíková E, Rosolová H, Roztočil K, Soška V, Škrha J. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Cor Vasa 2007; 49(3): K73-K86.
    838. Cífková R, Býma S, Češka R, Horký K, Karen I, Kunešová M, Králíková E, Rosolová H, Roztočil K, Soška V, Škrha J. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Čas Lék čes 2007; 146(6): I-XV.
    839. Cífková R, Býma S, Češka R, Horký K, Karen I, Kunešová M, Králíková E, Rosolová H, Roztočil K, Soška V, Škrha J. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. DMEV 2007; 10(2): 106-120.
    840. Cífková R, Býma S, Češka R, Horký K, Karen I, Kunešová M, Králíková E, Rosolová H, Roztočil K, Soška V, Škrha J. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Vnitřní lék 2005; 51: 1021-1036.
    841. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Four Joint Task Force of European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehab 2007; 14 (Suppl 2): E1-E40.
    842. ###
    843. Berger M, Jörgens V, Chlup R. Léčba inzulinem v každodenním životě. Victoria Publishing, Praha, 1995; 293 s.
    844. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Y, Shahinfar S, for the RENAAL Study Investigators (... Chlup R...). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001; 345 (12): 861-869. Go to original source... Go to PubMed...
    845. Bruns W, Chlup R, Philipp A, Worms F, Lundershausen R. Pathophysiologisch begründete Therapie der postprandialen Hyperglykämie - unter Berücksichtigung der zirkadianen Insulindefizite bei Typ-2-Diabetes - Untersuchungen unter Nutzung des sogenannten Basalratentests. Diabetes Stoffw 2001; 10 (Suppl 2): 7 (Abstrakt).
    846. Felsing W, Menzel R, Alt P, Chlup R, Bruns W. Erste Erfahrungen mit dem MADI in der DDR. In: W Bruns (ed) Lehrgang über aktuelle Probleme des Diabetes mellitus Berlin 24.-28. 11. 1986 (Kongressberichte) Edn Akademie für ärztliche Fortbildung der DDR, p 60.
    847. Holešinská P, Chlup R. Kdo má edukovat diabetiky? Zprav klin Farmakol Farmac 1998; 12 (4): 29-33. Go to original source...
    848. Hřebíček J, Janout V, Malinčíková J, Horáková D, Čížek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index Quicki for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002; 87 (1): 144-147. Go to original source... Go to PubMed...
    849. Chlup R. Přínos a praktické provádění intenzivní léčby u diabetiků 1. a 2. typu. In: Abstrakta XI. Diabetologické dny v Trenčíně s medzinárodnou účasťou 7.-9. 6. 2001, (nestr) (Abstrakt).
    850. Chlup R, Bartek J, Malá E, Doubravová B, Pukowietz L, Zatloukal P, Chlupová L, Zapletalová J. Uživatelská studie o správnosti a přesnosti měření glukometrů Advance, Card a Optium. Klin Biochem Metab 2004; 12 (3): v tisku.
    851. Chlup R, Bartek J, Řezníčková M, Zapletalová J, Doubravová B, Chlupová L, Sečkař P, Dvořáčková S, Šimánek V. Determination of glycaemic index of selected foods (white bread and cereal bars) in healthy persons. Biomed Papers 2003; 147: v tisku. Go to original source...
    852. Chlup R, Beránková I, Boudová E, Ďurajková E, Faltýnková J, Fišarová S, Gajdošová M, Grecmanová M, Holá J, Holešinská P, Hrubá V, Kmoníčková A, Konštacká L, Pevná Z, Řehořová J, Strnadová J, Šeflová L. Doporučení pro léčbu inzulinem u dospělých diabetiků při hospitalizaci - návrh standardu. Klin Farmakol Farm 2003; 17 (1): 34-42.
    853. Chlup R, Holešinská P, Chlupová L, Komenda S. Assessment of postgraduate education of therapeutic educators (PETE) at a university diabetes centre. Diabetes Metab 2003; 29: 4S385 (Abstract).
    854. Chlup R, Janů K, Menzel R, Bruns W, Venháčová J. Léčba diabetu pomocí ručního dávkovače inzulinu MADI. Univerzita Palackého v Olomouci, Olomouc, 1985; 64 s.
    855. Chlup R, Janů K, Venháčová J, Bartek J. Six models of a new insulin pen (MADI): description and first clinical trial. Practical Diabetes International 1995; 12 (1): 32-35. Go to original source...
    856. Chlup R, Křikal Z, Flašarová B, Gazárek F. Diabetes a těhotenství matky. Čes Gynek 1976; 41: 113-115.
    857. Chlup R, Maršálek E, Bruns W. Prospective study of the hazards of multiple use of disposable syringes and needles in intensified insulin therapy. Diabetic Medicine 1990; 7: 624-627. Go to original source... Go to PubMed...
    858. Chlup R, Menzel R, Hildmann W, Eisner B, Heinke P, Jutzi E. Co přináší noční dávka insulinu? In: Abstrakta XXVI. diabetologické dny v Luhačovicích, 24.-27. dubna 1990, 20 s.
    859. Chlup R, Menzel R, Kolesár P, Rybka J, Svoboda Z, Škarpová O, Venháčová J, Zander E, Abel P, Rosenfeld R, Hildebrandt R, Janů K, Jutzi E. Erste Erfahrungen mit dem MADI - multizentrische technische und klinische Studie. VIII. internationales DonauSymposium über Diabetes mellitus, Bratislava, 18.-21. Juni 1985. Wien: Robidruck 1985; Abstrakt 79 P, (nestr).
    860. Chlup R, Mlčák P, Boudová E, Fialová J, Bartek J. Kontinuální monitorování koncentrace glukosy v intersticiální tekutině - naše první zkušenosti. Klin Biochem Metab 2003; 11 (32): 37-43.
    861. Chlup R, Možíšová L. Léčba diabetiků pomocí inzulinové pumpy - teorie a praxe. Diabet Metabol Endokrin Výž 2000; 3 (1): 3-17.
    862. Chlup R, Navrátilová L, Řehořová J, Vaverková H, Venháčová J, Bartek J, Ficker L, Slezáková L. Programová léčba diabetu. Galén, Praha 1996: 196 s.
    863. Chlup R, Neoral L. Methods for retrospective assessment of the unusual behavior of a person with diabetes: ebrietas alcoholica and/or hypoglycaemia? Biomed Papers 2003; 147: v tisku.
    864. Chlup R, Rancová A, Both P, Axmannová M, Vaverková H, Bartek J. Intensive komplementäre Insulintherapie bei adipösen Typ-2Diabetikern hat meistens eine Gewichtsreduktion zur Folge. Diabetes und Stoffwechsel 1999; 8 (Suppl): 17 (Abstrakt).
    865. Chlup R, Táncosová S, Malá E, Boudová E. Co stojí léčba diabetu? In: Abstrakta XII. Diabetologické dni v Trenčíně s medzinárodnou účasťou 5.-8. 6. 2002, (nestr) (Abstrakt).
    866. Chlup R, Vaverková H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. I. Effects on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105 (Suppl 2): 70-73. Go to original source... Go to PubMed...
    867. Chlup R, Vaverková H, Bartek J. Long-Term Benefits of Complementary Insulin Therapy on Body Mass and Hemoglobin A1c in Obese Type 2 Diabetic Patients. Diabetes Research and Clinical Practice 2000; 50 (Suppl 1): S66-S67 (Abstract). Go to original source...
    868. Chlup R, Zander E, Hildmann W, Bartek J, Jutzi E. Vliv tělesného tréninku na metabolizmus sacharidů a tuků u diabetiků 1. typu. In: E Horniak (ed) Sport ve zdraví a nemoci: Práce IV. Evropského kongresu sportovního lékařství, Praha 25. 3.-28. 3. 1985, 1. díl, 245-251.
    869. Chlup R, Zapletalová J, Sečkař P, Chlupová L, Táncosová S, Řezníčková M. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 diabetes treated by means of an insulin pump. Biomed Papers 2003; 147: v tisku. Go to original source...
    870. Janů K, Chlup R. Konstrukční řešení ručního dávkovače inzulinu MADI. Jemná mechanika a optika 1992; 37 (1): 14-15.
    871. Loyková V, Chlup R, Pumprla J, Bartek J. Intenzivní inzulinová léčba pomocí MADI u dospělých. In: Abstrakta XXIV. diabetologické dny v Luhačovicích, 24.-27. dubna 1990, 30 s.
    872. Menzel R, Chlup R, Felsing W, Witte K, Alt E, Jutzi E. Insulininjection devices connected to the body by subcutaneous catheter - a cheap alternative to highly sophisticated insulin pumps? Diabetologia 1988; 31: 520 A (Abstract).
    873. Menzel R, Chlup R, Jutzi E, Hildmann W., ,Catheter-Pens" - an alternative to insulin pump treatment? Exp Clin Endocrinol 1990; 95: 157-64. Go to original source... Go to PubMed...
    874. Nakládalová M, Kapoun S. Zdravotní způsobilost k práci u osob s diabetem. Pracov Lék 2004; 56: 13-16.
    875. Neoral L, Chlup R, Loyková V, Franková M, Zedníková K, Bartek J, Mazochová J. Vliv inzulinu na metabolizmus etylakoholu a vliv etylalkoholu na glykemii u diabetiků 1. typu. Protialkoholický obzor 1991; 26 (6): 329-337.
    876. Rybka J, Brázdová L, Jirkovská A, Chlup R, Lacigová S, Lebl J, Vavřinec J, Podroužková B, Šimurda J, Rušavý Z. Edukace diabetika. In: Sborník XXX. jubilejní diabetologické dny v Luhačovicích, 21.-23. 4. 1994, 40-49.
    877. Vaverková H, Chlup R, Ficker L, Novotný D, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients: II. Effects on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997; 105 (Suppl 2): 74-77. Go to original source... Go to PubMed...
    878. World Health Organization Regional Office for Europe. Therapeutic patient education. Continuing education programmes for healthcare providers in the field of prevention of chronic diseases. Report of a WHO Working Group 1998: 77 s.
    879. Zander E, Bruns W, Wulfert P, Besch W, Lubs D, Chlup R, Schulz B. Muscular Exercise in Type 1-Diabetics. Exp Clin Endocrinol 1983; 82 (1): 78-90. Go to original source... Go to PubMed...
    880. Zander E, Schulz B, Chlup R, Woltansky P, Lubs D. Muscular exercise in Type-1-Diabetics: II. Hormonal and metabolic responses to moderate exercise. Exp Clin Endocrinol 1985; 85 (1): 95-104. Go to original source... Go to PubMed...
    881. ###
    882. Cox DR, Oakes D. Analysis of survival data. Chapman & Hall, USA 1998.
    883. Faber E, Koza V, et al. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry. Neoplasma 2007; 54 (5): 443-446. Go to PubMed...
    884. Faber E, Vondráková J, et al. Prognostic factors for survival of patiens with non-Hodgkin's lymphoma (NHL) after autologous peripheral stem cell transplantation (APSCT) - dingle center experience. Biology of Blood and Marrow Transplantation 2006; 12 (2): 344. Go to original source...
    885. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203-223. Go to original source... Go to PubMed...
    886. Hanefeld M, Julius U, et al. Die Diabetesinterventionsstudie (DIS) Diabetesverlauf und Mortalität, eine Bilanz 11 Jahre nach Diagnosestellung, Diabetes und Stoffwechsel 1996; 5: 39-45.
    887. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Ass 1958; 53: 457-481. Go to original source...
    888. Karvonen M, Tuomilehto J, et al. A review of the recent epidemiological data on the worldwide incidence of Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 883-892. Go to original source... Go to PubMed...
    889. Klein JP, Moeschberger ML. Survival analysis: Techniques for censored and truncated data. Springer, New York 1997.
    890. Kleinbaum DG. Survival analysis. Springer-Verlag, New York 1996. Go to original source...
    891. Michaelis D, Jutzi E, Heinke P. 30jährige Inzidenz - und Prävalenztrend des juvenilen Typ I - Diabetes in der ostdeutschen Bevölkerung. Diab Stoffw 1993; 2: 245-250.
    892. Perušičová J, Neuwirt K. Epidemiology of diabetes mellitus in Prague. Kvarta 1992, Praha.
    893. Procházka V, Trněný M, et al. Peripheral T-cell lymphoma, unspecified - the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomed Pap 2007; 151 (1): 103-107. Go to original source... Go to PubMed...
    894. Ratzmann K, Gorr K, Schneider H. Prävalenz diabetesbedingter Erblindungen. Diabetes und Stoffwechsel 1994; 3: 261-264.
    895. Schneider H, Lischinski M, Jutzi E. Survival time after onset of diabetes: 29-year follow-up mortality study in a diabetes cohort from a rural district. Diabete & Metabolisme 1993; 19: 152-158. Go to PubMed...
    896. Schneider H, Lischinski M, Jutzi E. Überlebenszeit von Diabetikern im 30-Jahres-Follow-up innerhalb einer geschlossenen Population. Diabetes 1993; 87: 323-327.
    897. Snedecor GW, Cochrane WG. Statistical Methods. Ames, The Iowa State University Press, 1967.
    898. Škrha J. Diabetes mellitus 2002 v České republice - epidemiologická studie. Diabetol Metab Endokrinol výž 2005; 8 (1): 5-12.
    899. Ústav zdravotnických informací a statistiky ČR. Péče o nemocné cukrovkou 2006 in.: Zdravotnická statistika http://www.uzis.cz.
    900. Zvárová J. Základy statistiky pro biomedicínské obory, Karolinum, Praha 2004.
    901. ###
    902. Standardy péče o diabetes mellitus v těhotenství, Diab Metabol Endokrin Výž., 2007; 10(4): 229-231.
    903. Bartoš V, Pelikánová T, et al., Praktická diabetologie, II. vydání 2000: 345-365.
    904. Barron MW, Lindheimer MD. Medical disorders during pregnancy, Mosby 2000, 3rd edition, 71-101.
    905. James DK, Steer PJ, Werner CP, Gonik B, High risk pregnancy management options, W. B. Saunders II.nd edition, London, 665-685.
    906. Chlup R, Gazárek F, Křikal Z, Flašarová B. Diabetes a těhotenství matky, Čes. Gynekol. 1976; 41(2): 113-115.
    907. Čech E. a kol. Porodnictví. Grada 2006, II. vydání.
    908. Kudela M, a kol. Základy gynekologie a porodnictví pro posluchače lékařské fakulty, LF UP Olomouc, 2004: 242-243.
    909. Winn NH, Hobbins JC. Clinical Maternal-Fetal Medicíně, Parthenon Publishing, New York 2002: 395-402.
    910. Queenan JT, Spong CY, Lockwood CJ, Management of High-Risk Pregnancy, Blackwell Publishing, Vth edition, 2007, 182-186. Go to original source...
    911. Boulvain M, Stan C, Irion O. Elective delivery in diabetic pregnant women. Cochrane Pregnancy and Childbirth Group. Cochrane Databáze Syst rev 2006; 2: CD 000451.
    912. Unzeitig V, Andělová K, Stará S. Doporučený postup k provádění screeningu poruch glukózové tolerance v graviditě, www.perinatologie.cz, 2009.
    913. ###
    914. Bartoš V, Pelikánová T, a kol. Praktická diabetologie, 3. vydání. Maxdorf, Praha 2003: 479 s.
    915. Cinek O, Šumník Z, Vavřinec J. Dětský diabetes mellitus v České republice: stále více a čím dál dříve. Čas. Lék. čes. 2005; 144: 266-271.
    916. Eurodiab ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000; 355 (9207): 873-8763. Go to original source...
    917. Frier BM. Defining hypoglycaemia: What level has clinical relevance? Diabetologia 2009; 52: 31-34. Go to original source... Go to PubMed...
    918. IS3 Clinical Practice Consensus Guidelines 2006-2007. www.ispad.org.
    919. Lebl J, Průhová Š, a kol. Abeceda diabetu. 3. rozšířené vydání, Maxdorf, Praha 2008: 184 s.
    920. Phillip M, Batelino T, Rodriguez H, et al. Use of Insulin Pump Therapy in the Pediatric Age-Group. Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007; 30(6): 1653-1662. Go to original source... Go to PubMed...
    921. Workgroup on Hypoglycemia ADA. Defining and reporting hypoglycemia in diabetes: a report from American Diabetes Association Workgroup on hypoglycemia. Diabetes Care 2005; 28: 1245-1249. Go to original source... Go to PubMed...
    922. ###
    923. Chlup, R. et al. Programová léčba diabetu. Praha: Galén, 1996. 190 s.
    924. Chlup, R., Možíšová, L. Léčba diabetiků pomocí inzulinové pumpy - teorie a praxe. DMEV. 2000, 3(1).
    925. Jirkovská, A. a kol. Jak si léčit a kontrolovat diabetes - Manuál pro edukaci diabetiků. Praha: PANAX, 2003.
    926. Kupčík, V. Implantabilní inzulinová pumpa s dálkovým ovladačem. Prezentace firmy Medtronic Minimed - únor 2006.
    927. Perušičová, J. Analoga Inzulinu. Klinická Farmakologie a Farmacie, 2006; 20 (1).
    928. Pomocník diabetologa 2005 - Informační katalog. Praha: Geum, 2005. 1. vyd.
    929. ###
    930. Abraira C, Henderson WG, Colwell JA, Nuttall FQ, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998; 21: 574-579. Go to original source... Go to PubMed...
    931. Berger M, Jörgens V, Chlup R. Léčba inzulinem v každodenním životě. Victoria Publishing Praha 1995.
    932. Bruns W. Zur Therapie des Typ-2-Diabetes - Ansätze für eine früzeitig beginnende pathophysiologisch begründete Therapie mit Insulin. Diabetes Dialog 1998; 1: 9-13.
    933. Bruns W, Heinz F, Altmann B, Lundershausen R, Menzel R, Worms F, von Kriegstein E. Insulintherapie bei Typ 2 - Diabetes. Science. 1. 2004 Auflage - Bremen: UNI-MED.
    934. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marrat G, Quagliaro L, Piconi L, Assaloni R, Motz E. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabetea UK Diabetic Medicine 2004; 21: 171-175. Go to original source... Go to PubMed...
    935. Consensus Statement. Recxommendation for the management of patients with type 2 diabetes mellitus in the central, eastern and southern european region. Int J Postgr Train Med 2001; 13: 1-20.
    936. Davies MJ, Metcalfe J, Gray JL, et al. Insulin deficiency rather than hyperinsulinemia in newly diagnosed type-2 diabetes mellitus. Diab. Med. 1992; 10: 305-312. Go to original source...
    937. Del Prato S, Bruttomesso D. Clinical aspects of beta-cell dysfunction in NIDDM. Exc. Med. Boehringer Mannheim 1996; 17 (1): 1-5.
    938. Fischer S, Bruns W, Kohler C, Melchert P, Gudat U, Frank M, Hanefeld M. Substitution der Frühphase der postprandialen Insulinsekretion mit Lispro bzw. Normalinsulin bei Typ-2-Diabetikern. Abstrakt. Diabetes und Stoffwechsel 1999; 8 (Suppl 1): 22.
    939. Gerich JE. Novel insulins: Expanding options in diabetes management. Am J Med 2002; 113: 308-316. Go to original source... Go to PubMed...
    940. Gudat U, Kühn C, Kazda C, Lehnert H. Insulin lispro bei übergewichtigen Patienten mit Diabetes mellitus Typ 2. Diabetes und Stoffwechsel 2003; 12: 3-7.
    941. Chapman TM, Noble S, Goa KL. Insulin aspart: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 2002; 62: 1945-1981. Go to original source... Go to PubMed...
    942. Chlup R, Bruns W. Patofyziologický přístup k léčbě diabetu 2. typu. Interní Med. 1999; 4: 27-35.
    943. Chlup R, et al. Programová léčba diabetu. Galén, Praha 1996.
    944. Chlup R, Vaverková H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipids parameters in type 2 (non-insulin-dependent) diabetic patients. I. Effects on blood glucose control. Exp. Clin. Endocrinol. Diabetes 1997; 105 (Suppl. 2): 70-73. Go to original source... Go to PubMed...
    945. Kalfhaus J, Berger M. Supplementare Insulintherapie (SII) - wie effektiv und sicher ist die Gabe von praeprandialem Normalinsulin als Therapie-Alternative bei Typ-2-Diabetes? Abstrakt. Diabetes und Stoffwechsel 1999; 8 (Suppl 1): 44.
    946. Kazlauskaite R, Fogelfeld L, Orlowski JM. Insulin therapy in type 2 diabetes. Dis. Mon., 2003; 49: 373-420. Go to original source... Go to PubMed...
    947. Klimeš I. Súčasné možnosti prevencie diabetu 2. typu. Diabetes a obezita 2004; 4 (7): 13-38.
    948. Koehler C, Fischer S, Bruns W, Melchert J, Gudat U, Pfuetzner A, Frank M, Hanefeld M. Einfluss des Koerpergewichts auf die Glykaemielage bei Typ-2-Diabetikern nach kleinen Dosen Lispro-Insulin oder Normalinsulin. Abstrakt. Diabetes und Stoffwechsel 1999; 8 (Suppl 1): 49.
    949. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin. Pharmacokinet. 2001; 40: 641-659. Go to original source... Go to PubMed...
    950. Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp. Clin. Endocrinol. Diabetes, 2002; 110: 416-419. Go to original source...
    951. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patints with diabetes mellitus. DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Brit med. 1997; J 314: 1512-1515. Go to original source... Go to PubMed...
    952. Ohkubo Y, Kishikawa H, Araki E, Miyata R, et al. Intensive insulin therapy prevents the progressions of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pact. 2000; 28: 103-117. Go to original source... Go to PubMed...
    953. Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diab. Med. 1996; 13: 19-24. Go to original source...
    954. Ratzmann KP. Kumulative Häufigkeit des Sekundärversagens einer Sulfonylharnstoff Therapie. Diabetes Stoffw 1994; 3: 348-352.
    955. Sawicki PT, Berger M. Pharmacological treatment of diabetic patents with cardiovascular complications. J. Intern. Med. 1998; 243: 181-189. Go to original source... Go to PubMed...
    956. Scherbaum WA, Landgraf R. Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Diabetes und Stoffwechsel, 2003; 12: 13-31.
    957. Standl E. Insulin analogues - State of the art. Horm. Res., 2002; 57: 40-45. Go to original source... Go to PubMed...
    958. UK Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998; 352: 854-865. Go to original source... Go to PubMed...
    959. UK Prospective Diabetes Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352: 837-853. Go to original source... Go to PubMed...
    960. UK Prospective Diabetes Study (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit. med. J. 1998; 317: 703-713. Go to original source...
    961. Vaverková H, Chlup R, Ficker L, Novotný D, Bartek J. Complementary insulin therapy improves blood glucose and serum lipids parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins. Exp. Clin. Endocrinol. Diabetes 1997; 105 (Suppl. 2): 74-77. Go to original source... Go to PubMed...
    962. Vozár J, Uličiansky V, Tkáč I, Martinka E, Michálek J, Krahulec B, Porubská M, Okapcová J (2004) Racionálna liečba diabetes mellitus 2. typu. Diabetes a Obezita 4 (7): 79-91.
    963. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, et al. (1992) Comparison of insulin regimens in patients with nen-insulin-dependent diabetes mellitus. N Engl J Med 327: 1426-1433. Go to original source... Go to PubMed...
    964. ###
    965. Chlup R, Zapletalová J, Sečkař P, Malá E, Doubravová B, Táncosová S, Chlupová L, Pukowietz L, Zatloukal P. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. Diab Technol Therap 2006; 9(3): 223-231. Go to original source... Go to PubMed...
    966. Kvapil M, Rušavý Z, Olšovský J. DM II z hlediska klinické praxe. Nakl. Adéla Plzeň 2007; 173 s.
    967. Nathan D, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. (Léčba hyperglykemie u diabetu 2. typu: konsenzuální algoritmus pro zahájení a úpravu léčby). Diabetologia 2006; 49: 1711-1721. [Český překlad: Revue Endokrinologie 2006; 2(1): 1-15]. Go to original source...
    968. Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE(TM) study. Int J Clin Pract 2009; 63(3): 425-452. Go to original source... Go to PubMed...
    969. www.diab.cz
    970. www.diazivot.cz
    971. www.diabetik.cz
    972. www.dm2t.cz
    973. www.athero.cz
    974. www.tigis.cz/dmev/index.htm
    975. ###
    976. DeVries JK, et al. Refining basal unsulin therapy: what have we learned in the age of analogues? Diabetes Metabolism Research&Reviews 2007. Go to original source...
    977. Dornhorst A et al. Safety and efficacy of insulin detemir in clinical practice: 14week follow-up data from type 1 and 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007; 61: 523-528. Go to original source... Go to PubMed...
    978. Hermansen K, et al. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007; 9 (3): 209-217. Go to original source... Go to PubMed...
    979. Klein O, et al. Albumin bound basal insulin analogues (insulin detemir and NN 344): Comparable time-action profiles, but less variability than glargine in type 2 diabetes. Diabetes, Obesity and Metabolism 2006. Go to original source... Go to PubMed...
    980. Luddeke HJ, Sreenan S, et al, PREDICTIVE Study Group. PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes, baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab. 2007; 9: 428-434. Go to original source... Go to PubMed...
    981. Muggeo M, et al, Diabetes Care 2006.
    982. Philis-Tsimikas, et al. Comparison of once daily insulin detemir added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin. Ther., 2006; 28 (10). Go to original source... Go to PubMed...
    983. Raslova T, et al. Insulin detemir results in less weight gain than NPH insulin when in basal-bolus therapy for type 2 diabetes mellitus. Clin Drug Investig. 2007; 27 (4): 279-285. Go to original source... Go to PubMed...
    984. SPC Levemir, 2007.
    985. Standard léčby diabetu 2. typu, Česká diabetologická společnost, Výbor 2007-08-16.
    986. Stratton IM, Adler AI, et al. Association of glycaemia with macrovascular and microvascular complications of type diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321 (17258): 405-412. Go to original source... Go to PubMed...
    987. ###
    988. ADA. National Standards for Diabetes Self-Management Education. Diabetes Care, 2006, vol. 29, p. 78-85. Go to original source...
    989. ADA. Standards of Medical Care in Diabetes. Position Statement. Diabetes Care, January 1, 2006, vol. 29 (suppl. 1), p. 4-42. ISSN 0149-5992. Go to original source...
    990. Bartoš V. et al. Praktická diabetologie. 2. vyd. Praha: Maxdorf, 2000. 473 s. ISBN 80-8591217-1.
    991. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J, Langová K, Chlupová L. Continuous glucose monitoring - a novel upproach to the determination of the glycaemic index of foods (DEGIF 1). Exp Clin Endocrinol Diabetes 2006, 114: 68-74. Go to original source... Go to PubMed...
    992. Chlup R, Mlčák P, Boudová E, Bartek J. Kontinuální monitorování glukosy v intersticiální tekutině - naše první zkušenosti. Klin. Biochem. Metab., 2003, roč. 11, s. 37-43.
    993. Kožnarová R. Kontinuální senzory glykemie. Sestra v diabetologii, 2005, roč. 1. č. 1, s. 15-16.
    994. Kudlová P, Stanislavová A. Edukace zdravých probandů v souvislosti s určováním glykemického indexu potravin (Education of healthy volunteers for the determination of glycaemic index of foods). In Čáp J, Žiaková K, Nemčeková M, Holmanová E. (eds.). Teoria, výskum a vzdelávanie v ošetrovatelstve, First Edition. S. 363-372, Martin: JLF UK Martin, 2005. ISBN 80-88866-32-4.
    995. Ladýř M. Velký přehled glukometrů. Diastyl, 2005, roč. 2, č. 1, s. 30-31.
    996. Perušičová J, et al. Diabetes mellitus 2. typu. 1. vyd. Praha: Galén, 1996. 127 s. ISBN 8085824-33-7.
    997. Pomocník diabetologa 2005 - Informační katalog. Praha: Geum, 2005. 1. vyd. ISBN 8086256-42-1.
    998. Úhrady VZP (online). (Cit. 2006-02-20). Dostupný z: <http://www.mte.cz/vzp.htm.
    999. Výbor České diabetologické společnosti. Standardy péče o diabetes mellitus 1. typu, 2. typu, o diabetes mellitus v těhotenství. Laboratorní diagnostika a sledování stavu diabetu mellitu (online). (Cit. 2006-02-20). Dostupný z: <http://www.diab.cz/modules.php?name=Standardy.
    1000. ###
    1001. Amir O, Cihen O, Zilberstein S, Gabis E, Karasin A. The First Non-Invasive CGMS Profiler. Diabetes 2007; 56 (Suppl 1): A118 (P442).
    1002. Bailey T. Diabetes data management in the clinic. J Diab Sci Tech 2007; 1 (6): 888-891. Go to original source... Go to PubMed...
    1003. Bernhardt JKM, Block U, Freeman B, Lenosky T, Lipson J, Lipson JM, McNamara RP, Petrasek D. Noninvasive continuous monitoring of glucose concentration using Raman spectroscopy: Result of a glucose clamp study. VII. Diab Technol Meeting, San Francisco, 2007: A9.
    1004. Brauker J, Kamath A, Li Y, Zisser H, Schwartz S, Ratner R, Wise J, Bailey T. Time Lag of a Seven-Day Transcutaneous Glucose Sensor Compared to YSI Blood Glucose Values. Diabetes 2007; 56 (Suppl 1): A119 (P448).
    1005. Bugler JR, Pryor H, Harris C. Performance of FreeStyle Navigator against standards for continuous glucose monitoring system and ISO 15197 system accuracy blood glucose meter guidelines. Diabetologia 2007; 50 (Suppl. 1): S419 (A1014).
    1006. Burgler J, Buell H. MAGE analysis of the FreeStyle Navigator continuous glucose monitoring system. Diabetes 2007; 56 (Suppl 1): A111 (P419).
    1007. Caduff A, Talary M, Donath M, Dewarrat F, Huber D, Stahel WA, Falco L, Klisic J. Tracking glucose excursion with a multisensor platform for noninvasive glucose monitoring. VII. Diab. Technol. Meeting, San Francisco, 2007: A17. Go to original source...
    1008. Cameron BD, Li Y. Polarization-based diffuse reflectance imaging for noninvasive measurement of glucose. J Diab Sci Tech 2007; 1 (6): 873-878. Go to original source... Go to PubMed...
    1009. Chase JG, Hann CHE, Shaw GM, Wong J, Lim J, Hons BE, Lotz T, LeCompte A, Lonergan T: Overview of glycemic control in critical care: Relating performance and clinical results. J Diab Sci Tech 2007; 1 (1): 82-91. Go to original source... Go to PubMed...
    1010. Chlup R, Janů K, Venháčová J, Bartek J. Six models of a new insulin pen (MADI): description and first clinical trial. Practical Diabetes International 1995,12 (1): 32-35. Go to original source...
    1011. Chlup R, Payne M, Zapletalová J, Komenda S, Doubravová B, Řezníčková M, Chlupová L, Sečkař P. Results of selfmonitoring on glucometer systems Advance and Optium in daily routine. Biomed Papers 2005; 149: 127-139. Go to original source...
    1012. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Chlupová L, Bartek J. Function and accuracy of glucose sensors beyond their stated expiry date. Diabetes Technology et Therapeutics. 2005; 8 (4): 495-504. Go to original source... Go to PubMed...
    1013. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J. Continuous glucose monitoring - a novel approach to the determination of the glycaemic index of foods (DEGIF 1). Exp Clin Endocrinol Diabetes. 2006; 114: 68-74. Go to original source... Go to PubMed...
    1014. Chlup R, Sečkař P, Zapletalová J, Langová K, Kudlová P, Chlupová K, Bartek J, Jelenová D. Automated computation of glycaemic index for foodstuffs using continuous glucose monitoring. J Diabetes Sci Technol 2008; 2 (1): 67-75. Go to original source... Go to PubMed...
    1015. Chlupová K, Kohnert KD, Heinke P, Augstein P, Chlup R. Salzsieder E. Resultate kontinuerlicher Glukosemessungen (CGMS) unter ambulanten Bedingungen zur Beurteilung der Stoffwechseleinstellung bei T2DM. Diabetologie und Stoffwechsel. 2006; 1 (Suppl 1): 94 (Abstract). Go to original source...
    1016. Clarke WL, Kovatchev B. Continuous glucose sensors: continuing questions about clinical accuracy. J Diab Sci Tech 2007; 1 (3): 669-675. Go to original source... Go to PubMed...
    1017. Cooke D, Steed L, Hurel SJ, Nunn A, Ahlquist J, Weaver J, Kerr D, Barnard M, Newman S. Use and acceptability of two minimally invasive continuous blood monitors. Diabetologia 2007; 50 (Suppl. 1): S418 (A1012).
    1018. DeBlock CH, Keenoy BM, Rogiers P, Van Gaal L. Continuous glucose monitoring highlights stress hyperglycemia at the intentive care unit: need for expert diabetes supervision? Diabetes 2007; 56 (Suppl. 1): A118 (P443).
    1019. Deiss D, Bolinder J, Riveline JP, Battelino T, Bost E, Tubiana-Rufi N, Kerr D, Phillip M. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diab. Care 2006; 29 (12): 2730-2732. Go to original source... Go to PubMed...
    1020. Ellis SI, Voelmle M, Gottlieb P, Gutin R, Garg S.. Improved glycemic control with real-time continuous glucose sensors in patients with type 1 diabetes. Diabetologia 2007; 50 (Suppl. 1): S418 (A1010).
    1021. Fachinetti A, Sparacino G, Cobelli C. Recontruction of glucose in plasma from interstitial fluid continuous glucose monitoring data: role of sensor calibration. J Diab Sci Tech 2007; 1 (5): 617-623. Go to original source... Go to PubMed...
    1022. Fajkusová Z, Jadviščoková T, Pallayová M, Luža J, Kuzmina G. Glycaemic index of selected foodstuffs in healthy persons. Biomed Papers 2007; 151 (2): 257-261. Go to original source... Go to PubMed...
    1023. Farrell B. Microformats: Three proposed standards for solving the need for standard data presentation. J Diab Sci Tech 2007; 1 (2): 245-250. Go to original source... Go to PubMed...
    1024. Freckmann G, Hagenlocher S, Baumstark A, Jendrike N, Gillen RC, Rössner K, Haug C. Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals. J Diab Sci Tech 2007; 1 (5): 695-703. Go to original source... Go to PubMed...
    1025. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values. Diab Care 2006; 29 (12): 2644-2649. Go to original source... Go to PubMed...
    1026. Garraugh GV. Detection of hypoglycaemia in patients with TIDM using the FreeStyle Navigator continuous monitoring system and traditional blood glucose monitoring. Diabetologia 2007; 50 (Suppl.1): S417 (A1009).
    1027. Ge X, Lam H, Modi SJ, LaCourse WR, Rao G, Tolosa L. Comparing the performance of the optical glucose assay based on glucose binding protein with high-performance anion-exchange chromatography with pulsed electrochemical detection: effors to design a low-cost point-of-care glucose sensor. J Diab Sci Tech 2007; 1 (6): 864-872. Go to original source... Go to PubMed...
    1028. Ghevondian N, Nguyen H, Jones T, Skladnev V. Comparison of the overnight and daytime physiological responses of children with type 1 diabetes using the HypoMon - results of the glucose-vlamp studies. Diabetes 2007; 56 (Suppl1): A117 (P439).
    1029. Gravesen P, Poulsen KR, Dirac H. Lab-on-a-chip technology for continuous glucose monitoring. J Diab Sci Tech 2007; 1 (3): 372-374. Go to original source... Go to PubMed...
    1030. Heinemann L, the Glucose monitoring study group: Continuous glucose monitoring by means of the microdialysis technique: underlying fundamental aspects. Diabetes Technol Ther 2003; 5: 545-561. Go to original source... Go to PubMed...
    1031. Heinemann L. Noninvasive glucose monitoring systems: will we ever have such sensors for practical use? J Diab Sci Tech 2007; 1(6): 936-939. Go to original source... Go to PubMed...
    1032. Hsieh YCH, Zahn JD. On-chip microdialysis system with flow-through glucose sensing capabilities. J Diab Sci Tech 2007; 1 (3): 373-383. Go to original source... Go to PubMed...
    1033. Jadviščoková T, Fajkusová Z, Pallayová M, Luža J, Kuzmina G. Occurence of adverse events due to continuous glucose monitoring. Biomed Pap Med Fac Univ Palacký Olomouc Czech Rep. 2007; 151 (2): 263-266. Go to original source... Go to PubMed...
    1034. Klonoff DC. The benefits of implanted glucose sensors. J Diab Sci Tech 2007; 1 (6): 797-800. Go to original source... Go to PubMed...
    1035. Kudlová P, Chlup R. Pomůcky k aplikaci inzulinu. Interní Med 2006; 8 (6): 302-306.
    1036. Kudlová P, Chlup R. Selfmonitoring u osob s diabetem. Interní Med 2006; 8 (12): 539-544.
    1037. Kudlová P, Stanislavová A. Edukace zdravých probandů v souvislosti s určováním glykemického indexu potravin (Czech: Education of healthy volunteers for the determination of glycemic index of foods). 1st ed. In: Čáp J, Žiaková K, Nemčeková M, Holmanová E, ed. Teoria, výskum a vzdelávanie v ošetrovatelstve (Theory, research and education in nursing). Univerzita Komenského Bratislava, Jeseniova Lekárska Fakulta Martin, Ústav ošetrovatelstva, SR, Lékařská fakulta Univerzity Palackého Olomouc, Ústav teorie a praxe ošetřovatelství, ČR, Občianské združenie pre rozvoj zdravotníckeho vzdelávania v Martine.2005: 363-372.
    1038. Lee SW, Sweeney T, Clausen D, Kolbach C, Haasen A, Firek A, Brinegar Ch, Petrofsky J. Combined insulin pump therapy with real-time continuous glucose monitoring significantly improves glycemic control compared to multiple daily injection therapy in pump na ve patients with type 1 diabetes; Single center pilot study experience. J Diab Sci Tech 2007; 1 (3): 400-404. Go to original source... Go to PubMed...
    1039. Mastrototaro J, Soundararajan G, Cooper K, Shah R. Accuracy of real-time continuous glucose monitoring in the MiniMed Paradigm System. Diabetes 2007; 56 (Suppl. 1): A112 (P422).
    1040. Miller M, White NH, Chase H. Continuous glucose monitoring system glycaemic variability in pediatric type 1 diabetes patients in basal insulin prandial insulin: utility of Fourier analysis. Diabetologia 2007; 50 (Suppl. 1): S420 (A1015).
    1041. Mlčák P, Fialová J, Trnková K, Chlup R. A continuous glucose monitoring system (CGMS) - A promising approach for improving metabolic control in person with type 1 diabetes mellitus treated by insulin pumps. Biomed Pap Med Fac Univ Palacký Olomouc Czech Rep. 2004; 148: 33-38. Go to original source...
    1042. Nichols JH, Klonoff DC. The need for performance standards for continuous glucose monitors. J Diab Sci Tech 2007; 1 (1): 92-74. Go to original source... Go to PubMed...
    1043. Nielsen JK, Gravholt CH, Djurhuus CHB, Brandt D, Becker J, Heinemann L, Christiansen JS. Continuous subcutaneous glucose monitoring shows a close correlation between mean glucose and time spent in hyperglycemia and hemoglobin A1c. J Diab Sci Tech 2007; 1 (6): 857-963. Go to original source... Go to PubMed...
    1044. Peterson K, Chlup R, Langová K, Zapletalová J, Kudlová P, Přibylová H. Benefits of continuous glucose monitoring transmitted to Paradigm 722. Diabetes 2006; 55 (Suppl. 1): A531.
    1045. Sacks DB. Correlation between hemoblobin A1c (HbA1c) and average blood glucose: can HbA1c be reported as estimated blood glucose concentration. J Diab Sci Tech 2007; 1 (6): 801-803. Go to original source... Go to PubMed...
    1046. Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGerraugh GV. Accuracy of the 5-day FreeStyle Navigator continuous glucose monitoring system. Diabetes Care 2007; 30 (5): 1125-1130. Go to original source... Go to PubMed...
    1047. Wriss R, Lazar I. The need for continuous blood glucose monitoring in the intensive care unit. J Diab Sci Tech 2007; 1 (3): 412-414. Go to original source... Go to PubMed...
    1048. Zoupas CS, Kefaloyannis N, Pappas A, Kepaptzoglou O, Kyrlaki E, Taraoune I, Giannakopoulos F, Garoutsou P, Vasilopoulos H. Evaluation of continuous use of real-time glucose monitoring, alone and after combined insulin pump therapy, as a mean to normalise glycaemic control in IDDM. Diabetologia 2007; 50 (Suppl. 1): S418 (A1011).
    1049. www.abbott.com
    1050. www.dexcom.com
    1051. www.minimed.com
    1052. ###
    1053. Bartoš V, et al. Praktická diabetologie. 2. vyd. Praha: Maxdorf, 2000; 473 s.
    1054. Brand-Mileler J, Wolever TMS, Colagiuri S, Foster-Powell K. The glucose revolution. The autoritative guide to the glycemic index. 3th ed., New York: Marlowe and company, 1999.
    1055. ČDS. Doporučení k edukaci diabetika [online]. [Cit. 2005-12-15]. Dostupný z: <http://www.diab.cz/modules/Standardy/edukace.pdf>.
    1056. FAO/WHO. Carbohydrates in human nutrition. Report of a joint FAO/WHO report. Rome 144 - 18. 4. 1997, Paper 66. 1998. FAO Food and Nutrition.
    1057. Foster H. Dieta GI. Glykemický index - nižší hmotnost a více energie. 1. vyd. Praha: Ottovo nakladatelství, s. r. o., 2004; 128 s.
    1058. Foster-Powell K, Holt S, Brand-Miller JC. International table of glycemic index and glycemic load. American Journal of Clinical Nutricion, 2002; July 76: 5-56. Go to original source... Go to PubMed...
    1059. Frost G, Leeds AA, Dore CJ, Madeiros S, et al. Glycemic index as a determinant of serum HDL-cholesterol concentration. Lancet, 1999; 353: 1045-1048. Go to original source... Go to PubMed...
    1060. Chantelau E. Diät-Liberalisierung bei Typ-I-Diabetes mellitus. Ergebnisse intensivierter Insulintherapie. Urban&Schwarzenberg München-Wien-Baltimore, 1988: 120 s.
    1061. Chlup R, Bartek J, Řezníčková M, Zapletalová J, Doubravová B, Chlupová L, Sečkař P, Dvořáčková S, Šimánek V. Determination of glycaemic index of selected foods (white bread and cereal bars) in healthy persons. Biomed Papers, 2004; 148: 17-25. Go to original source...
    1062. Chlup R, et al. Úvod do diagnostiky a léčby diabetu. 1. vyd. Olomouc: Univerzita Palackého v Olomouci, 2000.
    1063. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Bartek J. Function and accuracy of glucose sensors beyond their stated expiry date. Diabetes, 2005; 54 (Suppl 1), A138 (Abstract).
    1064. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J, Langová K, Chlupová L. Continuous glucose monitoring - a novel approach to the Determination of the Glycaemic Index of Foods (DEGIF 1). Exp Clin Endocrinol Diab, 2006; 114: 68-74. Go to original source... Go to PubMed...
    1065. Lebl J, Burgerová R. Velká dia knížka o jídle. Praha: Sdružení rodičů a přátel diabetických dětí v ČR, 2004.
    1066. Ludwig DS. Dietary glycemic index and obesity. J Nutr, 2000; 130: 280S-283S. Go to original source... Go to PubMed...
    1067. Kudlová P, Chlup R. Nové trendy ve výživě u osob s diabetem. Diagnóza v ošetřovatelství, 2006, 2(7): 259-262.
    1068. Páv J, Klusoňová H, Štorková H. Jak žít a co jíst při cukrovce. 4. vyd. Praha: Avicenum, 1985; 269 s.
    1069. Pelikánová T. Diabetologie a vybrané kapitoly z metabolismu. 1. vyd. Praha: Triton, 2003; s. 18-19, 25-27, 34-36, 38-40, 44, 47-50, 51-57.
    1070. Rušavý Z, Kreuzbergová J. Glykemický index potravin. Postgraduální medicína, 2002; 6.
    1071. Výbor ČDS. Standardy dietní léčby pacientů s diabetem [online]. [Cit. 2005-12-15]. Dostupný z: <http://www.diab.cz/modules/Standardy/dieta.pdf>.
    1072. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999; 354: 617-621. Go to original source...
    1073. Turek B, Ježková D, Procházková R. Glykemický index. Praha: SZÚ, 2003.
    1074. Wolever TMS, Jenkins DJA, Jenkins AL, Josse RG. The glycemic index: metodology and clinical implications. Am J Clin Nutr, 1991; 54: 846-854. Go to original source... Go to PubMed...
    1075. ###
    1076. Ball SD, Keller KR, Moyer-Mileur LJ, Ding YW, Donaldson D, Jackson WD. Prolongation of satiety after low versus moderately high glycemic index meals in obese adolescents. Pediatrics 2003; 111: 488-494. Go to original source... Go to PubMed...
    1077. Berger M. Diabetes mellitus I. First Edition, p. 135-157, Urban & Schwarzenberg, München Wien Baltimore, 1995.
    1078. Brand-Miller JC, Holt SH, Pawlak DB, McMillan J. Glycemic index and obesity. American Journal of Clinical Nutrition 2002; 76: 2815-2855. Go to original source...
    1079. Chlup R, Bartek J, Malá E, Doubravová B, Pukowietz L, Zatloukal P, Chlupová L, Zapletalová J. User-oriented study on accuracy and precision of glucometer systems Advance, Card and Optium. Klin Biochem Metab 2004; 12: 171-178.
    1080. Chlup R, Bartek J, Řezníčková M, Zapletalová J, Doubravová B, Chlupová L, Sečkař P, Dvořáčková S, Šimánek V. Determination of glycaemic index of selected foods (white bread and cereal bars) in healthy persons. Biomed Papers 2004; 148: 17-25. Go to original source...
    1081. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Bartek J. Function and accuracy of glucose sensors beyond their stated expiry date. Diabetes 2005; 54 Suppl 1: A138 (Abstract).
    1082. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J, Langová K, Chlupová L. Continuous glucose monitoring - a novel approach to the Determination of the Glycaemic Index of Foods (DEGIF 1). Exp Clin Endocrinol Diab 2006: in press. Go to original source... Go to PubMed...
    1083. Food and Agriculture Organization/World Health Organization: Carbohydrates in human nutrition: report of a Joint FAO/WHO expert consultation. FAO Food and Nutrition Paper 1998; 66: 1-140. Go to PubMed...
    1084. Foster-Powell K, Holt SH, Brand-Miller JC. International table of glycemic index and glycemic load values. American Journal of Clinical Nutrition 2002; 76: 5-56. Go to original source... Go to PubMed...
    1085. Gannon MC, Nuttall FQ, Krezowski PA, Billington CJ, S. Parker. The serum insulin and plasma glucose responses to milk and fruit products in type-2 (non-insulin-dependent) diabetic patients. Diabetologia 1986; 29: 784-791. Go to original source... Go to PubMed...
    1086. Heilbrann LK, Noakes M, Clifton PM. The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. Journal of the American College of Nutrition 2002; 21: 120-127. Go to original source... Go to PubMed...
    1087. Hodge AM, English DR, O&Dacute;ea K, Giles GG. Glycemic index and dietary fiber and the risk of type 2 diabetes. Diabetes Care 2004; 27: 2701-2706. Go to original source... Go to PubMed...
    1088. Jenkins AL, Jenkins DJ, Zdravkovitz U, Wursch P, Vuksan V. Depression of glycemic index by high levels of beta-glucan fiber in two functional foods tested in type 2 diabetes. Europan Journal of Clinical Nutrition 2002; 56: 622-628. Go to original source... Go to PubMed...
    1089. Jenkins DJ, Kendall CW, Augustin LS, Franceschi S, Hamidi M, Marchie A, Jenkins AL, Axelsen M. Glycemic index: overview of implications in health and disease. American Journal of Clinical Nutrition 2002; 76: 2665-2673. Go to original source...
    1090. Jenkins DJ, Kendall CW, Augustin LS, Vuksan V. High-complex carbohydrate or lente carbohydrate foods? American Journal of Medicine 2002; 113 Suppl 98: 30S-37S. Go to original source... Go to PubMed...
    1091. Kabir M, Oppert JM, Vidal H, Bruzzo F, Fiquet C, Wursch P, Slama G, Rizkalla SW. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. Metabolism. Clinical & Experimental 2002; 51: 819-826. Go to original source... Go to PubMed...
    1092. Kudlová P, Stanislavová A. Edukace zdravých probandů v souvislosti s určováním glykemického indexu potravin (Education of healthy volunteers for the determination of glycaemic index of foods). In: Čáp J, Žiaková K, Nemčeková M, Holmanová E (eds.). Teoria, výskum a vzdelávanie v ošetrovatelstve, First Edition. pp. 363-372, Univerzita Komenského Bratislava, Jeseniova Lekárska Fakulta Martin, Ústav ošetrovatelstva, SR, Lékařská fakulta Univerzity Palackého Olomouc, Ústav teorie a praxe ošetřovatelství, ČR, Občianské sdruženie pre rozvoj zdravotníckeho vzdelávania v Martine, Martin, 2005.
    1093. Liu S, Willett WC. Dietary glycemic load and atherotrombotic risk. Current Atherosclerosis Reports 2002; 4: 454-61. Go to original source... Go to PubMed...
    1094. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002; 287: 2414-2423. Go to original source... Go to PubMed...
    1095. Nakládalová M, Kapoun S. Zdravotní způsobilost k práci u osob s diabetem. Pracovní Lék 2004; 56: 13-6.
    1096. Payne M. Hypoguard Advance Micro-draw performance. Klin Biochem Metab 2004; 12: 202 (Letter).
    1097. Raben A. Should obese patients be counselled to follow a low-glycemic index diet? No. Obesity Reviews 2002; 3: 245-256. Go to original source... Go to PubMed...
    1098. Sheard NF, Clark NG, Brand-Miller JC, Franz MJ, Pi-Sunyer FX, Mayer-Davis E, Kulkarni K, Geil P. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the American Diabetes Association. Diabetes Care 2004; 27: 2266-2271. Go to original source... Go to PubMed...
    1099. Sievpiper JL, Jenkins AL, Whitham DL, Vuksan V. Insulin resistance: concepts, controversies, and role of nutrition. Canadian Journal of Dietetic Practice & Research 2002; 63: 20-32. Go to original source... Go to PubMed...
    1100. Wolever TMS, Mehling C. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr 2002; 76: 5-56.
    1101. Zemlin C, Lüder W, Vetter K, Bruns W, Menzel R. Diät bei Diabetes mellitus. Med aktuell 1989; 15: 49-52.
    1102. ###
    1103. Fajkusová Z, Jadviščoková T, Pallayová M, Matušková V, Luža J, Kuzmina G. Glycaemic index of selected foodstuffs in healthy persons. Biomed Pap Med Fac Univ Palacky Olomouc. 2007; 151(2): 257-261. Go to original source... Go to PubMed...
    1104. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Chlupová L, Bartek J. Function and Accuracy of glucose sensors beyond their stated expiry date. Diab Technol Therap 2006; 8(4): 495-504. Go to original source... Go to PubMed...
    1105. Chlup R, Sečkař P, Zapletalová J, Langová K, Kudlová P, Chlupová K, Bartek J, Jelenová D. Automated computation of glycemic index for foodstuffs using continuous glucose monitoring. J Diab Sci Techn 2008; 2(1): 67-75. Go to original source... Go to PubMed...
    1106. Jadviščoková T, Fajkusová Z, Pallayová M, Luža J, Kuzmina G: Occurence of adverse events due to continuous glucose monitoring. Biomed Pap Med Fac Univ Palacký Olomouc. 2007; 151(2): 263-266. Go to original source... Go to PubMed...
    1107. Lippaiová N, Pallayová M, Kuzmina G, Peterson K, Fajkošová L, Luža J. Safety of new algorithms for premeal insulin boluses in high glycaemic index meals in persons with type 1 diabetes mellitus using insulin pumps. Biomed Pap Med Fac Univ Palacky Olomouc. 2008; 152(I): 73-77. Go to original source... Go to PubMed...
    1108. Peterson K, Lippaiová N, Chlup R, Pallayová M, Langová K. Efficiency of simple algorithms for premeal boluses in high glycemic index meals in persons with type 1 diabetes mellitus using insulin pumps and sensors. Diabetes 2008; 57 (Suppl 1): A471 (Abstract). Go to original source... Go to PubMed...
    1109. Přibylová H, Pallayová M, Hučíková J, Luža J. Evaluation of the new software program DEGIFXL4 in the determination of the glycaemic indices of foodstuffs. Biomed Pap Med Fac Univ Palacky Olomouc. 2008; 152(I): 65-71. Go to original source... Go to PubMed...
    1110. Chlup R, Peterson K, Zapletalova J, Langova K, Seckar P, Kudlova P. Relation between glycemic index of ingested foods and mean plasma glucose concentration measured by CGMS in healthy persons. Abstracts 2nd International Conference on Advanced Techologies and Treatments for Diabetes (Athens 2009). www.kenes.com/attd: Abstract No 204. Go to original source...
    1111. ###
    1112. Brand-Miller JC, Pang E, Bramall L. Rice - a low or high glycaemic food. Am J Clin Nutr 1991; 56: 1034-1036. Go to original source... Go to PubMed...
    1113. Brand-Miller JC, Pang E, Broomhead L. Glycaemic index of foods containing sugars: comparison of foods with naturally occuring versus added sugars. Br J Nutr 1995; 73: 613-623. Go to original source... Go to PubMed...
    1114. Brand-Miller J, Colagiuri S, Foster-Powell K. The glycaemic index is easy and works in practice. Letter Diabetes Care 1997; 2: 1628-1629. Go to original source... Go to PubMed...
    1115. Buyken EA, Heitkamp G, Toeller M. and the EURODIAB Complications Study Group. Dietary glycemic indices in European outpatients with type-1 diabetes: Relations to HbA1c, and serum lipids. Abstracts. Booklet of abstracts. Versailles/France: 17th Annual Symposium of the Diabetes and Nutrition Study Group of the EASD; 1999.
    1116. Capani F, Casalini G, Consoli A, DÉmilio A, Lanave GF, Loragno M, Vitacolonna E, Zappone G, Sensi S. Variability of the efficacy of a small subsucateous insulin bolus in CSII-treated type-1 diabetic subjects. Diab Nutr Metab 1988; 1: 297-301.
    1117. Capani F, Casalini G, Consoli A, DÉmilio A, Lanave G, Loragno M, Vitacolonna E, Zappone G. Insulin requirement of simple and complex carbohydrate foods in type-1 (insulin-dependent) CSII-treated diabetic subjects obtained by Biostator. Correlation with glycaemic index. Acta diabetol Lat 1991; 28: 47-53. Go to original source... Go to PubMed...
    1118. Chantelau E. The glycaemic index of carbohydrate foods: an update from a diabetologistś perspective. Aktuel Ernaehr Med 2000; 25: 176-185.
    1119. Chantelau E, Kronsbein P, Kempf U, Berger M. Untersuchung zum Mahlzeiten-bezogenen Insulinbedarf von Linsen und Kartoffeln bei Patienten mit Typ-1 Diabetes mellitus. Aktuel Ernaehr Med 1989; 14: 175-178.
    1120. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J, Langová K, Chlupová L. Continuous Glucose Monitoring - A Novel Approach to the Determination of the Glycaemic Index of Foods (DEGIF 1). Exp Clin Endocrinol Diabetes 2006; 114: 68-74. Go to original source... Go to PubMed...
    1121. Chlup R, Jelenová D, Chlupová K, Zapletalová J, Chlupová L, Bartek J. Function and Accuracy of Glucose Sensors beyond their stated Expiry Date. Diabetes Technology & Therapeutics 2006; 8 (4) 495-504. Go to original source... Go to PubMed...
    1122. Chlup R, Kudlová P., Bartek J, Sečkař P, Langová K. Základní předpoklady a ekonomika pro stanovení glykemického indexu potravin. Diabet Metabol Endokrin Výž 2006; 9 (Suppl 2): 24-26 (Abstract).
    1123. Chlup R, Zapletalová J, Jelenová D, Chlupová K, Bartek J, Řehořová J. Glykemický index hořké čokolády, ovocného jogurtu, jablečné přesnídávky a rýžových chlebíčků u zdravých osob. Diab Obezita 2006; 11: 103-112.
    1124. Chlup R, Jelenová D, Kudlová P, Bartek J, Nakládalová M, Sečkař P, Zapletalová J Langová K, Pukowietz L, Chlupová K. Konventionelle Bestimmung des glykämischen Indexes verschiedener Nahrungsmittel (Schokolade, Apfelmuss, Reisbrot, Yoghurt) bei pumpenbehandelten Typ-1 Diabetikern. Diabetologie und Stoffwechsel 2006; 1 (Suppl 1): 154 (Abstract). Go to original source...
    1125. Chlup R, Kudlová P, Sečkař P, Zapletalová J, Bartek J, Chlupová K, Luža J. Glycaemic index of foods in healthy persons vs persons with type 1 diabetes mellitus. Diabetes 2006; 55 (Suppl 1): A593 (Abstract).
    1126. Frost G. The relevance of the glycaemic index to our understanding of dietary carbohydrates. Diabetic Med 2000; 17: 336-345. Go to original source... Go to PubMed...
    1127. Goldschmied A, Shani J, Zurkowski S. Range-related glycaemic response to increasing load of carbohydrates. Pharmacology 1980; 21: 355-362. Go to original source... Go to PubMed...
    1128. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21: 1910-1914. Go to original source... Go to PubMed...
    1129. Hollenbeck CB, Coulston AM, Donner CC, Williams RA, Reaven GM. The effect of variations in percent of naturally occuring complex and simple carbohydrates on plasma glucose and insulin response in individuals with non-insulin-dependent diabetes mellitus. Diabetes 1985; 34: 151-153. Go to original source... Go to PubMed...
    1130. Ionescu-Tirgoviste C, Popa E, Santu E, Mihalache N, Cheta D, Mincu I. Blood glucose and plasma insulin responses to various carbohydrates in type 2 (non-insulin-dependent) diabetes. Diabetologia 1983; 24: 80-84. Go to original source... Go to PubMed...
    1131. Ionescu-Tirgoviste C. Reproducibility of a standard test meal in type 2 diabetic patients. Letter to the Editor. Klin Wochenschr 1991; 69: 91. Go to original source... Go to PubMed...
    1132. Jenkins DJA, Wolever TMS, Taylor RH, Barker H, Fielden H, Baldwin JM, Bowling AC, Newman HC, Jenkins AL, Goff DV. Glycemic index of foods: a physiological basis for carbohydrate exchange. Amer J Clin Nutr 1981; 34: 362-366. Go to original source... Go to PubMed...
    1133. Katan MB. Are there good and bad carbohydrates for HDL-cholesterol? The Lancet 1999; 353: 1029-1030. Go to original source... Go to PubMed...
    1134. LeFloch JP, Baudin E, Escuyer P, Wirquin E, Nillus P, Perlemuter L. Influence of non-carbohydrate foods on glucose and insulinresponses to carbohydrates of different glycaemic index in type-2 diabetic patients. Diab Med 1992; 9: 44-48. Go to original source... Go to PubMed...
    1135. Ludwig DS, Majzoub JA, Al-Zahrani A, Dallal GE, Blanco I, Roberts SB. High glycaemic index foods, overeating and obesity. Pediastrics 1999; 103: E 26. Go to original source... Go to PubMed...
    1136. Nielsen PH, Nielsen GL. Preprandial blood glucose values: influence on glycaemic response studies. Am J Clin Nutr 1989; 49: 1243-1246. Go to original source... Go to PubMed...
    1137. Otto H, Bleyer M, Pennartz M, Sabin G, Schauberger G, Spaethe R. Kohlenhydrat-Austausch nach biologischen Äquivalenten. In: Otto H, Spaethe R (Hrsg): Diätetik bei Diabetes mellitus. Bern, Stuttgart, Wien: Verlag Hans Huber; 1973: 41-50.
    1138. Otto H, Niklas L. Differences dáction sur la glycemie dáliments contenant des hydrates de carbone. Consequences pour le traitement dietetique du diabete sucre. Med et Hyg 1980; 38: 3424-3429.
    1139. Rasmussen O, Hermansen K. Preprandial blood glucose values and glycemic responses in insulin-dependent diabetes mellitus at constant insulinaemia. Am J Clin Nutr 1991; 53: 520-523. Go to original source... Go to PubMed...
    1140. Rasmussen O. Dose-dependency of the glycemic response to starch-rich meals in non-insulin-dependent diabetic subjects: studies with varying amounts of white rice. Metabolism 1993; 42: 214-217. Go to original source... Go to PubMed...
    1141. Rasmussen O. Dose-dependency of the glycemic response to starch-rich meals in insulin-dependent diabetic subjects: studies at constant insulinemie. Metabolism 1993; 42: 710-713. Go to original source... Go to PubMed...
    1142. Samanta A, Burden AC, Jones GR. Plasma glucose responses to glucose, sucrose, and honey in patients with diabetes mellitus: an analysis of glycaemic and peak incremental indices. Diab Med 1985; 2: 371-373. Go to original source... Go to PubMed...
    1143. Weyman-Daum M, Fort P, Recker B, Lanes R, Lifshitz F. Glycemic response in children with insulin-dependent diabetes mellitus after high- or low-glycemic-index breakfasts. Am J Clin Nutr 1987; 46: 798-803. Go to original source... Go to PubMed...
    1144. Wolever TMS, Jenkins DJA, Jenkins AL, Josse RG. The glycamic index: methodology and clinical implications. Am J Clin Nutr 1991; 54: 846-854. Go to original source... Go to PubMed...
    1145. ###
    1146. Astrand PO, Rodahl K. Texbook of work physiology. Physiological base of exercise. McGrawHill Book Company, N. York, London, Düsseldorf 1977; IInd edition: 331-365.
    1147. Berger M, Berchtold P, Cüppers HJ, Drost H, Kley HK, Müller WA, Wiegelmann W, Zimmermann-Teschlow H, Gries FA, Krüskemper HL, Zimmermann H. Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. Diabetologia 1777; 13: 355. Go to original source... Go to PubMed...
    1148. Brož J. Sportování s inzulínem. Sanvitalia s.r.o. 2007, 1. vydání: 46 s.
    1149. Chassin LJ, Wilinska ME, Hovorka R. Intense exercise in type 1 diabetes: Exploring the role of continuous glucose monitoring. J Diab Sci Technol 2007; 1 (4): 570-573. Go to original source... Go to PubMed...
    1150. Chlup R, Bartek J, Hildmann W, Lubs D, Wodrig W, Jutzi E, Zander E. Die Effektivität eines Trainingsprogramms auf den Insulinbedarf und die Stoffwechseleinstellung von Typ-1-Diabetikern. In: Wiedermann B, Bibergeil H (eds), Symposium Diabetes a fyzická zátěž - Diabetes und Muskelbelastung, Olomouc, ČSSR, 21.-23. 1. 1982. Univerzita Palackého v Olomouci, Olomouc, pp.36-37.
    1151. Chlup R, Zander E, Hildmann W, Bartek J, Jutzi E Vliv tělesného tréninku na metabolismus sacharidů a tuků u diabetiků I. typu. In: E Horniak (ed) Sport ve zdraví a nemoci: Práce IV. Evropského kongresu sportovního lékařství, Praha 25. 3. - 28. 3. 1985, 1. díl, pp.245-251.
    1152. Felig P. Glucose-Alanin-Zyklus. Metabolism 1973; 22: 179. Go to original source... Go to PubMed...
    1153. Lefebvre PJ. Naturally labeled 13C-glucose: A new tool to measure oxidation rates of exogenous glucose. Diabetes 1979; 28: 63. Go to original source... Go to PubMed...
    1154. Lopata L, Piroch V, Techlová R. Při diabetu cvičte denně. Olympia, Praha, 1977, 2. vyd.
    1155. Pirnay F. et al. Eur J Appl Physiol. 1977; 36: 247. Go to original source... Go to PubMed...
    1156. Ribisl PM, Lang W, Jaramillo S, Jakicic JM, Stewart KJ, Bahnson J, Bright R, Curtis J, Crow R, Soberman JE. On behalf on the Look AHEAD Research Group: Exercise capacity and cardiovascular/metabolic characteristic of overweight and obese individuals with type 2 diabetes. Diabetes Care 2007; 30 (10): 2679-2689. Go to original source... Go to PubMed...
    1157. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients. Diabetes Care 2006; 29 (11): 2518-2527. Go to original source... Go to PubMed...
    1158. Vranic M, Berger M. Exercise and diabetes mellitus. Diabetes 1979; 28: 147. Go to original source... Go to PubMed...
    1159. Zander E, Bruns W, Wulfert P, Besch W, Lubs D, Chlup R, Schulz B. Muscular Exercise in type 1-diabetics. Exp Clin Endocrinol 1983; 82 (1): 78-90. Go to original source... Go to PubMed...
    1160. Zander E, Schulz B, Chlup R, Woltansky P, Lubs D. Muscular exercise in type-1-diabetics: II. Hormonal and metabolic responses to moderate exercise. Exp Clin Endocrinol 1985; 85 (1): 95-104. Go to original source... Go to PubMed...
    1161. ###
    1162. Almdal T, Scharling H, Jensen JS, et al. Type II diabetes is an independent risk factor for myocardial infarction and death from ischemic heart disease in man and women. Abstract. Diabetologia 2002; 2: 94.
    1163. American Diabetes Association: Concensus development conference on insulin resistance. Diabetes Care 1998: 310-314. Go to original source... Go to PubMed...
    1164. Balletshofer BM, et al. Endothelial dysfunction is detectable in young normotensive first - degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784. Go to original source... Go to PubMed...
    1165. Bergman RN, et al. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236: 667. Go to original source... Go to PubMed...
    1166. Cauza E, Hanusch-Enserer U, Strassser B, et al. Effects of resistence training on glycemic control in type 2 diabetes mellitus. Diabetologia 2002; 2: 34.
    1167. Cífková R. za členy společné pracovní skupiny: Prevence ischemické choroby srdeční v dospělém věku. Diab Metab Endokr Výž 2001; 1: 13-27.
    1168. Češka R. Léčba diabetické dyslipoproteinémie. Kapitoly Kardiol 2001; 3/2: 14-19.
    1169. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    1170. De Fronzo RA, et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223. Go to original source... Go to PubMed...
    1171. Despres JP, LaMarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957. Go to original source... Go to PubMed...
    1172. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project randomised trial (CAPP). Lancet 1999; 353: 611-616.
    1173. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116. Go to original source...
    1174. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistence in essential hypertension. N Engl J Med 1987; 317: 317-350. Go to original source... Go to PubMed...
    1175. Feskens EJM, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arterioscler Tromb 1994; 14: 1641-1647. Go to original source... Go to PubMed...
    1176. Gaede P, Vedel P, Larsen N, et al. The Steno-2 study: intensified multifactorial intervention reduced the risk of cardiovascular disease in patients with Type 2 diabetes and microalbuminuria. Abstract. Diabetologia 2002; 45/2: 63.
    1177. Haffner SM, Kennedy E, Gonzalez C, et al. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19/10: 1138-1141. Go to original source... Go to PubMed...
    1178. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. Go to original source... Go to PubMed...
    1179. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardivascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259. Go to original source...
    1180. Helge JW, Dela F. Training and insulin sensitivity: effect of muscle phospholipid and triacylglycerol fatty acid composition and total muscle triacylglycerol content. Abstract. Diabetologia 2002; 45/2: 34.
    1181. Hřebíček J, Janout B, Malinčíková J, et al. Detection of insulin resistence by simple quantitative sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metabol 2002; 87: 144-147. Go to original source...
    1182. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25/7: 1129-1134. Go to original source... Go to PubMed...
    1183. Hypertension Optimal Treatment Trial (HOT). Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    1184. Chen W, Srinivasan SR, Elkasabany A, et al. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (syndrome X) between young parents and their offspring: the Bobalusa Heart Study. Atherosclerosis 1999; 145: 197-205. Go to original source... Go to PubMed...
    1185. Chlup R. Současné možnosti prevence diabetes mellitus 1. a 2. typu. Kapitoly Kardiol 2001; 3/2: 36-39.
    1186. Chlup R, Bruns W. Patofyziologický přístup k léčbě diabetu 2. typu. Intern Med 1999; 4: 27-35.
    1187. Chlup R, Vaverková H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid perameters in type 2 (non-insulin-dependent) diabetic patients. I. Effect on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105/2: 70-73. Go to original source... Go to PubMed...
    1188. Imperatore B, Ricardi G, Iovine C, et al. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998; 21: 549-654. Go to original source... Go to PubMed...
    1189. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-865.
    1190. Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: A simple, accurate method for assessing insulin sensitivity in humans. Clin Endocrinol Metabol 2000; 85/7: 2402-2410. Go to original source... Go to PubMed...
    1191. Kernan WN, Inzucchi SE, Viscoli CM, et al. Insulin resistence and risk for stroke. Neurology 2002; 59/6: 809. Go to original source... Go to PubMed...
    1192. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456. Go to original source... Go to PubMed...
    1193. Lemieux I, Lamarche B, St-Pierre A, et al. Low HDL cholesterol without vs. with features of the atherogenic metabolic triad and its impact on IHD risk: the Québec cardiovascular study. Abstract. Diabetologia 2002; 45/2: 63-64.
    1194. Lichnovská R, Gwozdziewiczová S, Hřebíček J. Gender differences in metabolic variables related to insulin resistance in elderly hyperlipemic non-diabetic subjects. Cardiovascular Diabetology v tisku.
    1195. Linhart A, Paleček T, Aschermann M. Koronární postižení při diabetu - prevence a léčba. Kapitoly Kardiol 2001; 3/2: 20-26.
    1196. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28/7: 412-419. Go to original source... Go to PubMed...
    1197. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. J Amer Med Ass 2000; 283: 221-228. Go to original source... Go to PubMed...
    1198. Meigs JB, Nathan DM, DÁgostino RB, et al. Fasting and postchallenge glycemia and cardiovascular disease risk. Diabetes Care 2002; 25: 1845-1850. Go to original source... Go to PubMed...
    1199. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-1820. Go to original source... Go to PubMed...
    1200. Nilsson PM. Hypertention in diabetes - favourable trends in clinical control in repeated national surveys from Sweden. Abstract. Diabetologia 2002; 45/2: 64.
    1201. Oerry C. Report of 6th Scientific Meeting of the Hypertension in Diabetes (HID). Study Group of the EASD in Edinburgh. Abstract. Diabetologia 2001; 44/11: 57.
    1202. Olšovský J. Vliv antihypertenzní terapie na inzulinovou rezistenci. Vnitřní Lék 1999; 45/11: 670-672.
    1203. Pelikánová T. Ischemická choroba srdeční u nemocných s diabetem 2. typu. Diab Metab Endokr Výž 1999; 2/4: 161-169.
    1204. Piarulli FN, Marolla ME, Bax G, et al. Insulin reduce progression of carotid stenosis in type 2 diabetes mellitus: a three years prospective study. Abstract. Diabetologia 2002; 45/2: 95.
    1205. Reaven GM, Chen YDI, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92: 141-146. Go to original source... Go to PubMed...
    1206. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistence and the sympathoadrenall system. N Engl J Med 1996; 334: 374-381. Go to original source... Go to PubMed...
    1207. Ruige JB, Assendelft WJJ, Dekker JM, et al. Insulin and risk of cardiovascular disease. A meta-analysis. Circulation 1998; 97: 996-1991. Go to original source... Go to PubMed...
    1208. Rybka J, Adamíková A. Syndrom diabetické nohy. Kapitoly Kardiol 2001; 3/2: 28-31.
    1209. Shulman GI. Cellular mechanism of insulin resistence. J Clin Invest 2000; 106: 171-176. Go to original source... Go to PubMed...
    1210. Scheen AJ, Van Gaal LF, et al. Need to optimize cardiovascular prevention in type 2 diabetic patients: the Belgian OCAPI Survey. Diabetologia 2002; 45/2: 63.
    1211. Solerte SB, Fioravanti M. Human insulin up-regulates the release of Vascular Endothelial Growth Factor (VEGF) from immune cells in hyperinsulinemic microalbuminuria type 2 diabetic patients. Diabetologia 2002; 45/2: 35.
    1212. Stout RW. Overview of the association between insulin and atherosclerosis. Metabolism 1985; 34/12 (Suppl. 1): 7-12. Go to original source... Go to PubMed...
    1213. Turner R, Tchobroutsky G, Slama G, et al. Vascular complications of diabetes. Éditions pradel Paris 1994: 1-166.
    1214. Šejda T. Rostlinné steroly a stanoly v prevenci ischemické choroby srdeční. Diab Metab Endokr Výž 2001; 4/2: 140-144.
    1215. The Framingham Study. Circulation 1979; 59: 8-13. Go to original source... Go to PubMed...
    1216. The UK Prospective Diabetes Study (UKPDS): Effect of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...
    1217. The UK Prospective Diabetes Study (UKPDS): Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720. Go to original source...
    1218. The UK Prospective Diabetes Study (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. Go to original source...
    1219. The UK Prospective Diabetes Study (UKPDS) (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713. Go to original source...
    1220. Vaverková H, Chlup R, Ficker L, et al. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effect on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997; 105/2: 74-77. Go to original source... Go to PubMed...
    1221. Welborn TA, Knuiman MW, Ward N, et al. Serum insulin is a risk marker for coronary heart disease mortality in men but not in women. Diabetes Res Clin Pract 1994; 26: 51-59. Go to original source... Go to PubMed...
    1222. ###
    1223. Adámková R. Akutní infarkt myokardu a diabetes mellitus. Interní Med 2008; 10(9): 402-406.
    1224. Kvapil M. Těsná kompenzace glykemie a vaskulární komplikace u pacientů. Interní Med. 2008; 10(10): 479-480.
    1225. Kvapil M. Studie Advance v kontextu ostatních morbi-mortalitních studií u pacientů s diabetem 2. typu. Interní Med. 2008; 10(12): 583-587.
    1226. Mokáň M, Martinka E, Galajda P. Diabetes mellitus a vybrané metabolické ochorenia. Vydavateľstvo P+M, Martin 2008.
    1227. Rybka J. Diabetes mellitus II. typu, co víme a v co věříme (stručný nástin etiopatogenetických poznatků). Diabetes a obezita 2008; 8(16): 31-39.
    1228. Sucharda P. Obezita a metabolický syndrom. Od syndromu inzulinové rezistence k, ,syndromu centrální obezity". Interní Med. 2008; 10(4): 165-166.
    1229. Weber P. Diabetes mellitus - specifika a komplikace ve stáří. Interní Med. 2008; 10(10): 456-460.
    1230. www.dm2t.cz
    1231. www.athero.cz
    1232. www.tigis.cz/dmev/index.htm
    1233. ###
    1234. Almdal T, Scharling H, Jensen JS, et al. Type II diabetes is an independent risk factor for myocardial infarction and death from ischemic heart disease in man and women. Abstract. Diabetologia 2002; 2: 94.
    1235. American Diabetes Association: Concensus development conference on insulin resistance. Diabetes Care 1998: 310-314. Go to original source... Go to PubMed...
    1236. Balletshofer BM, et al. Endothelial dysfunction is detectable in young normotensive first - degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784. Go to original source... Go to PubMed...
    1237. Bergman RN, et al. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236: 667. Go to original source... Go to PubMed...
    1238. Cauza E, Hanusch-Enserer U, Strassser B, et al. Effects of resistence training on glycemic control in type 2 diabetes mellitus. Diabetologia 2002; 2: 34.
    1239. Cífková R. za členy společné pracovní skupiny: Prevence ischemické choroby srdeční v dospělém věku. Diab Metab Endokr Výž 2001; 1: 13-27.
    1240. Češka R. Léčba diabetické dyslipoproteinémie. Kapitoly Kardiol 2001; 3/2: 14-19.
    1241. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    1242. De Fronzo RA, et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223. Go to original source... Go to PubMed...
    1243. Despres JP, LaMarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957. Go to original source... Go to PubMed...
    1244. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project randomised trial (CAPP). Lancet 1999; 353: 611-616.
    1245. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116. Go to original source...
    1246. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistence in essential hypertension. N Engl J Med 1987; 317: 317-350. Go to original source... Go to PubMed...
    1247. Feskens EJM, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arterioscler Tromb 1994; 14: 1641-1647. Go to original source... Go to PubMed...
    1248. Gaede P, Vedel P, Larsen N, et al. The Steno-2 study: intensified multifactorial intervention reduced the risk of cardiovascular disease in patients with Type 2 diabetes and microalbuminuria. Abstract. Diabetologia 2002; 45/2: 63.
    1249. Haffner SM, Kennedy E, Gonzalez C, et al. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19/10: 1138-1141. Go to original source... Go to PubMed...
    1250. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. Go to original source... Go to PubMed...
    1251. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardivascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259. Go to original source...
    1252. Helge JW, Dela F. Training and insulin sensitivity: effect of muscle phospholipid and triacylglycerol fatty acid composition and total muscle triacylglycerol content. Abstract. Diabetologia 2002; 45/2: 34.
    1253. Hřebíček J, Janout B, Malinčíková J, et al. Detection of insulin resistence by simple quantitative sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metabol 2002; 87: 144-147. Go to original source...
    1254. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25/7: 1129-1134. Go to original source... Go to PubMed...
    1255. Hypertension Optimal Treatment Trial (HOT). Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    1256. Chen W, Srinivasan SR, Elkasabany A, et al. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (syndrome X) between young parents and their offspring: the Bobalusa Heart Study. Atherosclerosis 1999; 145: 197-205. Go to original source... Go to PubMed...
    1257. Chlup R. Současné možnosti prevence diabetes mellitus 1. a 2. typu. Kapitoly Kardiol 2001; 3/2: 36-39.
    1258. Chlup R, Bruns W. Patofyziologický přístup k léčbě diabetu 2. typu. Interní Med 1999; 4: 27-35.
    1259. Chlup R, Vaverková H, Bartek J: Complementary insulin therapy improves blood glucose and serum lipid perameters in type 2 (non-insulin-dependent) diabetic patients. I. Effect on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105/2: 70-73. Go to original source... Go to PubMed...
    1260. Imperatore B, Ricardi G, Iovine C, et al. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998; 21: 549-654. Go to original source... Go to PubMed...
    1261. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-865.
    1262. Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: A simple, accurate method for assessing insulin sensitivity in humans. Clin Endocrinol Metabol 2000; 85/7: 2402-2410. Go to original source... Go to PubMed...
    1263. Kernan WN, Inzucchi SE, Viscoli CM, et al. Insulin resistence and risk for stroke. Neurology 2002; 59/6: 809. Go to original source... Go to PubMed...
    1264. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456. Go to original source... Go to PubMed...
    1265. Lemieux I, Lamarche B, St-Pierre A, et al. Low HDL cholesterol without vs. with features of the atherogenic metabolic triad and its impact on IHD risk: the Québec cardiovascular study. Abstract. Diabetologia 2002; 45/2: 63-64.
    1266. Lichnovská R, Gwozdziewiczová S, Hřebíček J. Gender differences in metabolic variables related to insulin resistance in elderly hyperlipemic non-diabetic subjects. Cardiovascular Diabetology v tisku.
    1267. Linhart A, Paleček T, Aschermann M. Koronární postižení při diabetu - prevence a léčba. Kapitoly Kardiol 2001; 3/2: 20-26.
    1268. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28/7: 412-419. Go to original source... Go to PubMed...
    1269. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. J Amer Med Ass 2000; 283: 221-228. Go to original source... Go to PubMed...
    1270. Meigs JB, Nathan DM, DÁgostino RB, et al. Fasting and postchallenge glycemia and cardiovascular disease risk. Diabetes Care 2002; 25: 1845-1850. Go to original source... Go to PubMed...
    1271. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-1820. Go to original source... Go to PubMed...
    1272. Nilsson PM. Hypertension in diabetes - favourable trends in clinical control in repeated national surveys from Sweden. Abstract. Diabetologia 2002; 45/2: 64.
    1273. Oerry C. Report of 6th Scientific Meeting of the Hypertension in Diabetes (HID). Study Group of the EASD in Edinburgh. Abstract. Diabetologia 2001; 44/11: 57.
    1274. Olšovský J. Vliv antihypertenzní terapie na inzulinovou rezistenci. Vnitřní Lék 1999; 45/11: 670-672.
    1275. Pelikánová T. Ischemická choroba srdeční u nemocných s diabetem 2. typu. Diab Metab Endokr Výž 1999; 2/4: 161-169.
    1276. Piarulli FN, Marolla ME, Bax G, et al. Insulin reduce progression of carotid stenosis in type 2 diabetes mellitus: a three years prospective study. Abstract. Diabetologia 2002; 45/2: 95.
    1277. Reaven GM, Chen YDI, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92: 141-146. Go to original source... Go to PubMed...
    1278. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistence and the sympathoadrenall system. N Engl J Med 1996; 334: 374-381. Go to original source... Go to PubMed...
    1279. Ruige JB, Assendelft WJJ, Dekker JM, et al. Insulin and risk of cardiovascular disease. A meta-analysis. Circulation 1998; 97: 996-1991. Go to original source... Go to PubMed...
    1280. Rybka J, Adamíková A. Syndrom diabetické nohy. Kapitoly Kardiol 2001; 3/2: 28-31.
    1281. Shulman GI. Cellular mechanism of insulin resistence. J Clin Invest 2000; 106: 171-176. Go to original source... Go to PubMed...
    1282. Scheen AJ, Van Gaal LF, et al. Need to optimize cardiovascular prevention in type 2 diabetic patients: the Belgian OCAPI Survey. Diabetologia 2002; 45/2: 63.
    1283. Solerte SB, Fioravanti M. Human insulin up-regulates the release of Vascular Endothelial Growth Factor (VEGF) from immune cells in hyperinsulinemic microalbuminuria type 2 diabetic patients. Diabetologia 2002; 45/2: 35.
    1284. Stout RW. Overview of the association between insulin and atherosclerosis. Metabolism 1985; 34/12 (Suppl. 1): 7-12. Go to original source... Go to PubMed...
    1285. Turner R, Tchobroutsky G, Slama G, et al. Vascular complications of diabetes. Éditions pradel Paris 1994: 1-166.
    1286. Šejda T. Rostlinné steroly a stanoly v prevenci ischemické choroby srdeční. Diab Metab Endokr Výž 2001; 4/2: 140-144.
    1287. The Framingham Study. Circulation 1979; 59: 8-13. Go to original source... Go to PubMed...
    1288. The UK Prospective Diabetes Study (UKPDS): Effect of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...
    1289. The UK Prospective Diabetes Study (UKPDS): Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720. Go to original source...
    1290. The UK Prospective Diabetes Study (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. Go to original source...
    1291. The UK Prospective Diabetes Study (UKPDS) (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703713. Go to original source...
    1292. Vaverková H, Chlup R, Ficker L, et al. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effect on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997; 105/2: 74-77. Go to original source... Go to PubMed...
    1293. Welborn TA, Knuiman MW, Ward N, et al. Serum insulin is a risk marker for coronary heart disease mortality in men but not in women. Diabetes Res Clin Pract 1994; 26: 51-59. Go to original source... Go to PubMed...
    1294. ###
    1295. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes. (Účinek iniciální kombinované terapie sitagliptinem, inhibitorem dipeptidylpeptidázy-4 a metforminem při kontrole glykémie u pacientů s diabetes mellitus II. typu.) Diabetes Care 2007; 30 (8): 1979-1988. Go to original source... Go to PubMed...
    1296. Honka M. Účinek fixní kombinace perindoprilu a indapamidu na makrovaskulární a mikrovaskulární komplikace u nemocných s diabetem 2. typu (studie Advance). Interní Med. 2008; 10 (5): 245-246.
    1297. Honka M. Hypoglykémie u nemocných s diabetem 2. typu. Postgraduální medicína 2009; 11 (4): 423-427.
    1298. Charvát J. Prevence kardiovaskulárních komplikací diabetu. Postgraduální medicína 2009; 11 (4): 433-438.
    1299. Kvapil M. Perorální antidiabetika. Postgraduální medicína 2009; 11 (4): 407-412.
    1300. Kvapil M. Terapie založená na účinku inkretinů. Postgraduální medicína 2009; 11 (4): 413-416.
    1301. Mokáň M, Martinka E, Galajda P. Diabetes mellitus a vybrané metabolické ochorenia. Vydavateĺstvo P+M, 2008.
    1302. Perušičová J. Perorální antidiabetika - současnost. Interní Med. 2008; 10 (1): 15-18.
    1303. Piťhová P. Racionální léčba perorálními antidiabetiky. Interní Med. 2008; 10 (11): 495-497.
    1304. Ravichandran S, MacEachern L Saxagliptin Added to Metformin Improves Glycemic Control in T2DM Patients 35th Annual Meeting of the American Association of Diabetes Educators. Washinton DC 2008.
    1305. Rušavý Z. Nefarmakologická intervence diabetu 2. typu. Postgraduální medicína 2009; 11 (4): 399-406.
    1306. Rybka J. Postavení thiazolidindionů v léčbě diabetu 2. typu - 2007. Interní Med. 2008; 10 (2): 50-53.
    1307. Sosna T. Farmakoterapie diabetické retinopatie - zbožné přání nebo realita? Interní Med. 2008; 10 (11): 511-516.
    1308. Sucharda P. Obezita a metabolický syndrom. Od syndromu inzulinové rezistence k, ,syndromu centrální obezity". Interní Med. 2008; 10 (4): 165-166.
    1309. Šmahelová A. Volba antidiabetik s přihlédnutím k metabolickému syndromu. Interní Med. 2008; 10 (9): 380-383.
    1310. Vítovec J, Špinar J. Použití betablokátorů u nemocných s diabetes mellitus. Interní Med. 2008; 10 (3): 126-128.
    1311. Weber P. Diabetes mellitus - specifika a komplikace ve stáří. Interní Med. 2008; 10 (10): 456-460.
    1312. www.dm2t.cz
    1313. www.athero.cz
    1314. www.tigis.cz/dmev/index.htm
    1315. ###
    1316. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86. Go to original source... Go to PubMed...
    1317. Barnhorst DA, Barner HB. Prevalence of congenitally absent pedal pulses N Engl J Med, 1968; 278: 264-265. Go to original source... Go to PubMed...
    1318. Bartoš V, Jirkovská A. Multidisciplinární přístup k prevenci amputací diabetické nohy. Diabetol. Metabol. Endokr. Výživa, 1998; 1: 3-5.
    1319. Bartoš V, Jirkovská A, Kožnarová R. Rizika diabetické nohy pro příjemce renálních a pankreatických transplantátů. Čas. Lék. Čes., 1997; 136: 527-529.
    1320. Belch JJF, et al. Critical issues in peripheral arterial disease. Detection and management. Arch. Intern. Med., 2003; 163: 884-892. Go to original source... Go to PubMed...
    1321. Broulíková A. Etiopatogeneze a diferenciální diagnostika defektů dolních končetin. Ve: Angiologie 2007, trendy soudobé angiologie. Svazek 2, Galen, 2007: 11-13.
    1322. Brunerová L, Anděl M. Ekonomické náklady syndromu diabetická noha v mezinárodním srovnání. Diabetol. Metabol. Endokr. Výživa, 2002; 3: 153-156.
    1323. Bulvas M. Akutní uzávěry tepen a bypassů zásobujících dolní končetiny. Ve: Angiologie 2006, trendy soudobé angiologie. Svazek 1, Galén 2006: 27-41.
    1324. Čechurová D, et al. Ekonomický pohled na léčbu syndromu diabetická noha. Diabetol. Metabol. Endokr. Výživa, 2001; 4: 4.
    1325. Česká diabetologická společnost. Standardy péče o diabetes mellitus 2. typu. Prakt. Lék., 1997; 77: 401-408.
    1326. Herman J. Chirurgická léčba claudicatio intermittens. Ve: Angiologie 2006, trendy soudobé angiologie. Svazek 1, Galén 2006: 23-25.
    1327. Chochola M, Vařejka P, Heller S. Možnosti intervenční léčby onemocnění tepen dolních končetin. Interní medicína pro praxi, 2004; 6(11): 542-546.
    1328. Jirkovská A. Klinický význam klasifikace syndromu diabetické nohy. Diabetol. Metabol. Endokr. Výživa, 2003; 1: 8-11.
    1329. Jirkovská A, et al. Syndrom diabetické nohy. Praha: Maxdorf, 2006.
    1330. Roztočil K. Medikamentózní léčba u nemocných s klaudikacemi. Ve: Angiologie 2006, trendy soudobé angiologie. Svazek 1, Galen, 2006: 15-18.
    1331. Spáčil J, Svobodová J. Význam rehabilitace u nemocných s klaudikacemi. Ve: Angiologie 2006, trendy soudobé angiologie. Svazek 1, Galen, 2006: 19-21.
    1332. Vodňanský P. Sonografická diagnostika onemocnění tepen dolních končetin. Interní Med. 2003; 5 (4): 165-170.
    1333. Wosková V, Jirkovská A, Peregrin J, Skibová I. Hodnocení angiografických nálezů na dolních končetinách u diabetiků léčených v podiatrické ambulanci. Abstrakta. XXXlll. diabetologické dny v Luhačovicích, 1997: 77 s.
    1334. Záhumenský E. Péče o diabetickou nohu a neuropatické defekty. Ve: Angiologie 2007, trendy soudobé angiologie. Svazek 2, Galen, 2007: 19-26.
    1335. ###
    1336. Faglia E, Mantero M, Caminiti M, et al. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. J. Intern. Med. 2002; 252(3): 225-232. Go to original source... Go to PubMed...
    1337. Kožnar B, Peregrin JH. Perkutánní transluminální angioplastika (PTA) infrapopliteálních tepen. Čes. Radiol. 2004; 58 (3): 119-124.
    1338. Krajina A, Hlava A. Angiografie. Hradec Králové, Nukleus HK, 1999.
    1339. Krajina A, Peregrin JH, eds. Intervenční radiologie - miniinvazivní terapie. Grafické studio Olga Čermáková. Hradec Králové, 2005.
    1340. ###
    1341. Firt P, Hejnal J, Vaněk I. Cévní chirurgie. AVICENUM, 1990: 127-144.
    1342. Kompendium rán a ich ošetrovania. PAUL HARTMAN AG 1999: 69-72, 81-84.
    1343. Kozák P. Choroby obvodových cév. AVICENUM, 1981: 150-154.
    1344. Wolfe, JHN. ABC cévních onemocnění. SCIENTIA MEDICA, 1996: 37-39.
    1345. Nahodil V. Diabetické gangrény a flegmóny. SZN, 1967.
    1346. Way, LW. a kolektiv. Současná cévní chirurgická diagnostika a léčba, I. díl. Grada, 1998: 927-928, 959-964.
    1347. ###
    1348. Bartoš V, Záhumenský E, Jirkovská A. Standardy péče o diabetickou nohu. Vnitř Lék, 1996; 42 (1): 54-56. Go to PubMed...
    1349. Boulton AJM. Clinical presentation and management of diabetic neuropathy and foot ulceration. Diab Med, 1991; 8: 52-57. Go to original source... Go to PubMed...
    1350. Bureš I. Rozdělení a základní přehled moderních obvazových materiálů. In Pomocník diabetologa - informační katalog. Praha: Geum, 2007: S.150-160.
    1351. Caputo GM, Cavanagh PR, Albrecht JS, et al. Assesment and management of foot disease in patiens with diabetes. N Engl J Med, 1994; 29: 854-860. Go to original source... Go to PubMed...
    1352. Coleman WC, Brand PW. The diabetic foot. In Davidson JK, Clinical Diabetes Mellitus. New York: Thieme Medical Publishers, 1991: 496-554.
    1353. Edmonds M, Foster A. Diabetic foot clinic. In The diabetic foot. Levin M. et al. (eds.), Mosby Year Book, St. Luis, 1993: 587-604.
    1354. Eldor R, Raz I, Ben Yehudat A, et al. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med 2004; 21: 1161-1173. Go to original source... Go to PubMed...
    1355. Fife CE, Buyukcakir C, Otto GH, et al. The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospective analysis of 1 144 patients. Wound Repair Regen, 2002; 10: 198-207. Go to original source... Go to PubMed...
    1356. Gray DG, White R, Cooper PJ, Kingsley A. Understanding Applied Wound Management. Wounds UK, 2005; 1(1): 62-68.
    1357. Hoeldtke RT, Davis KM, Hshieh PB, et al. Are there two types of diabetic foot ulcers? J Diab Compl, 1994; 8: 117-125. Go to original source... Go to PubMed...
    1358. Chlup R, Holá J, Kudlová P, et al. Co může vykonat diabetolog pro úspěšnou léčbu syndromu diabetické nohy. Trendy v medicíně, 2005; 6 (6): 41-51.
    1359. Jeffcoat WJ, Price P, Harding KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev, 2004; 20 (Suppl 1): 78-89. Go to original source... Go to PubMed...
    1360. Jirkovská, A. Hojení kožních afekcí u syndromu diabetické nohy při hospitalizaci. Vnitř Lék 2006; 52 (5): 459-464. Go to PubMed...
    1361. Jirkovská A, et al. Syndrom diabetické nohy. Praha: Maxdorf, 2006. ISBN 80-7345-095-X.
    1362. Kalani M, Brismar K, Fagrell B, et al. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care, 1999; 22: 147-151. Go to original source... Go to PubMed...
    1363. Kudlová P. Edukace pacientů při terapii ran. In Management ran - komplexní přístup k léčbě a ošetřování, Olomouc, 9. června 2004 [online]. [Cit.2004-07-19]. Olomouc: FN, 2004. Dostupný z: <http://www.fnol.cz/akce.jsp?id=6>.
    1364. Martinka E, Kurča E, et al. Komplexný pohľad na problém diabetickej nohy. Zdravotnické noviny, příloha Lékařské listy, 2003,14: 30-37.
    1365. Mezinárodní pracovní skupina pro syndrom diabetické nohy. Syndrom diabetické nohy - Mezinárodní konsenzus.2000. vypracovaný Mezinárodní pracovní skupinou pro syndrom diabetické nohy. Jirkovská, A. (překlad a redakce). Praha: Galén, 2000. 102 s.
    1366. Péče o rány - manuál. Příloha časopisu Sestra č. 6 a ZdN 2003; 25: 14-18.
    1367. Rušavý Z, et al. Diabetická noha. Diagnostika a terapie v praxi. 1. vyd. Praha: Galén, 1998: 189 s.
    1368. Souhrnně o Číselníku. Hojení ran, 2007; 1(1): 28-29.
    1369. Stryja, J. Debridement v terapii ran. Šeflová, L (Ed.). Diagnostika a monitoring ran. Olomouc: FN a UP, 2005: S. 26-29.
    1370. Stryja, J. Nebojme se nových klasifikací. Bureš I, pořadatel. Léčba rány. Praha: Galén, Edice Care, 2006.
    1371. Švestková S. Hojení chronických ran. Sestra, 10 (8): 7.
    1372. Tošenovský P, Edmonds ME, et al. Moderní léčba syndromu diabetické nohy. Praha: Galén, 2004.
    1373. Výbor ČDS. Standardy léčby pacientů se syndromem diabetické nohy. 2005. [online]. [Cit. 2006-1-17]. Dostupný z: <http://www.diab.cz/modules/Standardy/dianoha.pdf>.
    1374. ###
    1375. Backonja MM. Use of anticonvulsant for treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med J 1993; 329 (14): 977-986. Go to original source... Go to PubMed...
    1376. Diabetes Control and Complications Trial (DCCT) Research Group. Efect of intensive diabetes treatment on nerve conduction in the diabetes control and complications Trial. Ann Neurol 1995; 6: 869-880. Go to original source...
    1377. Feldmann EL, Russel JW, Sullivan KA, Golovoy D. New insights into the patogenesis of diabetic neuropathy. Curr Opin Neurol 1999; 12 (5): 553-563. Go to original source... Go to PubMed...
    1378. Gries FA, Cameron NE, Low PA, Ziegler A. Textbook of diabetic neuropathy. Thieme Stuttgart-New York, 1. vydání 2003. Go to original source...
    1379. Mazanec R, Vyšata O, Bednařík J, Filová J. Sledování účinnosti preparátu Thioctacid v ambulantní léčbě diabetické neuropatie. Čes Slov Neurol Neurochir 2000; 63/96 (6): 400-405.
    1380. Süsová J. Polyneuropatie. In Nevšímalová S. et al. Neurologie, Galén, 1. vydání 2002: 291-295.
    1381. Vlachová I, Vaverková H, Urbánek K et al. Výskyt metabolických rizikových faktorů v rodinách mladých osob po ischemické cévní mozkové příhodě. Čes a Slov Neurol. Neurochir. 1998; 61/94 (4): 169-176.
    1382. Vlachová I, Vaverková H, Urbánek K et al. Výskyt diabetes mellitus 2. typu, snížené glukózové tolerance a hyperinzulinémie v rodinách mladých osob po ischemické cévní mozkové příhodě. Čes Slov Neurol Neurochir 2001; 64/97 (4): 225-230.
    1383. Vondrová H. Neurologické projevy diabetes mellitus. In: Vondrová H. Neurologické projevy endokrinních onemocnění. Praha: Geum, 2003: 40-127.
    1384. Standardy diagnostiky a léčby diabetické neuropatie. Schváleno výborem České diabetologické společnosti ČLS JEP 6. 2. 2007. Diabetologie, metabolismus, endokrinologie, výživa 2007; 10: 215-220.
    1385. ###
    1386. Ambler Z. Diabetická neuropatie. In: Diabetická neuropatie. Konsenzuální konference, Žinkovy, 20.-22. března 1997. Praha: Galén, 1998: 9-22.
    1387. American Diabetes Association. Standards of medical care in diabetes - 2006 (Position statement). Diabetes Care 2006; 29: S4-S42. Go to original source... Go to PubMed...
    1388. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962. Go to original source... Go to PubMed...
    1389. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes therapy on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38: 869-880. Go to original source... Go to PubMed...
    1390. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41: 416-423. Go to original source... Go to PubMed...
    1391. Dyck PJ. The near-future direction of research and medical care of human diabetic neuropathies. Neurosci Res Communication 1997; 21: 5-12. Go to original source...
    1392. Dyrberg T, Benn J, Sandahl Christiansen J et al. Prevalence of diabetic autonomic neuropathy measured by simple bedside tests. Diabetologia 1981; 20: 190-194. Go to original source... Go to PubMed...
    1393. Ewing DJ, Martyn CN, Young RJ, et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8: 491-498. Go to original source... Go to PubMed...
    1394. Fraser DM, Campbell IW, Ewing DJ, et al. Peripheral and autonomic nerve function in newly diagnosed diabetes mellitus. Diabetes 1977; 26: 546-550. Go to original source... Go to PubMed...
    1395. Kempler P, Váradi A, Szalay F, et al. Diabetic autonomic neuropathy. Br Med J 1990; 301: 1161. Go to original source... Go to PubMed...
    1396. Krahulec B, Vozár J, Piják R, et al. Srdcová autonómna neuropatia u diabetikov 1. typu. Vnitřní Lék 1987; 33: 253-259.
    1397. Kučera P, Goldenberg Z, Kurča E. Sympathetic skin response: review of the method and its clinical use. Bratislavské lekárské listy 2004; 105: 108-116. Go to PubMed...
    1398. Lacigová S. Autonomní neuropatie. In: Diabetická neuropatie. Konsenzuální konference, Žinkovy, 20.-22. března 1997. Praha: Galén,1998: 56-69.
    1399. Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004; 27: 2942-2947. Go to original source... Go to PubMed...
    1400. O&Bacute;rien IA, McFadden JP, Corrall RJM. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991; 79: 495-502.
    1401. Opavský J, Pumprla J, Salinger J, et al. Spektrální analýza variability srdeční frekvence - přínos pro diagnostiku diabetické autonomní neuropatie. Scripta medica Fac Med Univ Brunensis Masarykianae 1994; Tomus 67 (suppl 1): 29-32.
    1402. Opavský J, Salinger J. Vyšetřovací metody funkcí autonomní nervové soustavy - přehled pro potřeby klinické praxe. Noninvasiv Cardiol 1995; 4: 139-153.
    1403. Opavský J. Autonomní nervový systém a diabetická autonomní neuropatie. Klinické aspekty a diagnostika. Praha: Galén 2002.
    1404. Rathmann W, Ziegler D, Jahnke M et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993; 10: 820-824. Go to original source... Go to PubMed...
    1405. Standardy diagnostiky a léčby diabetické neuropatie. Schváleno výborem České diabetologické společnosti ČLS JEP 6. 2. 2007. Diabetologie, metabolismus, endokrinologie, výživa 2007; 10: 215-220.
    1406. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996; 104: 311-316. Go to original source... Go to PubMed...
    1407. Töyry JP, Niskanen LK, Mäntysaari MJ, et al. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Diabetes 1996; 45: 308-315. Go to original source... Go to PubMed...
    1408. Ziegler D, Hanefeld M, Ruhnau KJ et al., The ALADIN Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-1433. Go to original source... Go to PubMed...
    1409. Ziegler D, Schatz H, Conrad F, et al. The DEKAN Study Group. Effects of treatment with the antioxidant alpha-lipoic acid in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997; 20: 369-373. Go to original source... Go to PubMed...
    1410. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes/Metabolism Reviews 1994; 10: 339-383. Go to original source... Go to PubMed...
    1411. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocronol 2004; 3: 173-189. Go to original source... Go to PubMed...
    1412. ###
    1413. Patz A, Schatz H, Berkow JW, et al. Macular edema: an overlooked complication of diabetic retinopathy. Trans. Am. Acad. Opthal. Otolaryng., 1973; 77: 34-42.
    1414. Photocoagulation in treatment of diabetic maculopathy. Interim report of a multicentre controlled study. Lancet, 1975; 2: 1110-1113.
    1415. Klein R, Moss SE, Klein BEK, Davis MD, Mets DL. The Winconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Opthalmology, 1989; 96: 1501-1510. Go to original source... Go to PubMed...
    1416. Bresnick GH. Diabetic macular edema. A review. Opthalmology, 1986; 93: 989-997. Go to original source... Go to PubMed...
    1417. ###
    1418. Bartoš V, Teplan V, Bouček P. Standardy péče při diabetické nefropatii. Vnitřní Lék 1998; 44: 727-731.
    1419. Bartoš V. Možnosti ovlivnění progrese diabetické nefropatie. Vnitřní Lék 1998; 44: 428-430.
    1420. Bartoš V, Pelikánová T. Praktická diabetologie. Praha, Maxdorf 1996: 376 s.
    1421. Bouček P. Péče o nemocné s diabetickou nefropatií. ČLČ 1997; 136: 689-692.
    1422. Hanssen KF. How tight must blood glucose control be to prevent diabetic nephropathy? Nephrol Dial Transplant 1994; 9: 226-227.
    1423. Chábová V. Patofyziologie diabetické nefropatie. ČLČ 1999; 138: 392-395.
    1424. Tesař V, Schück O. Klinická nefrologie. Praha, Grada Publishing 2006: 652 s.
    1425. Tarnow L. Genetic pattern in diabetic nephropathy. Nephrol Dial Transplant 1996; 11: 410-412. Go to original source...
    1426. Ruggenenti P, Fassi A., Parvano Ilieva A et al. Preventing microalbuminuria in type 2 diabetes. N Eng J Med 2004; 351: 1941-1951. Go to original source... Go to PubMed...
    1427. Koch M, Gradaus F, Schoebel LC, et al. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant 1997; 12: 1187-1191. Go to original source... Go to PubMed...
    1428. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219. Go to original source... Go to PubMed...
    1429. Ritz E, Orth SROV. Nephropathy in patients with type 2 diabetes mellitus. N Eng J Med 1999; 341: 1127-1133. Go to original source... Go to PubMed...
    1430. Rychlík I, Brunerová L. Diabetická nefropatie. Postgraduální medicína 2006; 8: 200-2006.
    1431. American Diabetes Association: Diabetic Nephropathy. Diabetes Care 2002; 25(Supp 1): 85-89. Go to original source...
    1432. Olšovský J. Hypertenze a diabetes mellitus. Lékařské listy 2002; 37: 14-18.
    1433. Barnett AH, Bain SC, Bouter P. Angiotensin-receptor blokade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961. Go to original source... Go to PubMed...
    1434. Ponťuch P. Diabetická nefropatie. Grada Publishing, Praha 2003: 139 s.
    1435. Tesař V. Diabetická nefropatie - nové možnosti léčby. Interní Med. 2002; 2: 50-55.
    1436. Passadakis P, Thodis E, Vargemezis V, et al. Long - term survival with peritoneal dialysis in ESRD due to diabetes. Clin Nephrol 2001; 56: 257-270. Go to PubMed...
    1437. Rychlík I, Lopot F. Statistická ročenka dialyzační léčby v České republice 2006, Praha 2007: 28 s.
    1438. ###
    1439. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonyllureas or insulin. Diabetes Care. 2006; 29 (2): 254-258. Go to original source... Go to PubMed...
    1440. Cottet V, Pariente A, Nalet B, Lafon J, Milan C, Olschwang S et al. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology. 2007; 133 (4): 1086-1092. Go to original source... Go to PubMed...
    1441. Ehrmann J jr., Vavrušková N, Collan Y, Kolář Z. Peroxisome proliferator-activated receptors (PPARs) in health and desease. Biomed Pap Med Fac Univ Palacky Olomouc, 2002; 146: 11-14. Go to original source... Go to PubMed...
    1442. Flood A, Mai V, Pfeiffer R, Kahle L, Remaley AT, Lanza E, Schatzkin A. Elevated serum concentrations of insulin glukose increase risk of recurrent colorectal adenomas. Gastroenterology. 2007; 133 (5): 1423-1429. Go to original source... Go to PubMed...
    1443. Frič P, Zavoral M, Seifert B, Pokorný P, Suchánek Š. Screening sporadického kolorektálního karcinomu v ČR. Interní Med. 2007; 5: 221-224.
    1444. Huxley R, Ansary-Moghaddam A, Berrington GA, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005; 92 (11): 2076-2083. Go to original source... Go to PubMed...
    1445. Chari ST, Leibon CL, Rabe KG, Timmons LJ, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.
    1446. Chlup R, Vaverková H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. Effect on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105(suppl 2): 70-73. Go to original source... Go to PubMed...
    1447. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK. Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: A case-control study in Korea. Dis Colon rectum. 2008 Jan 25 (Zdroj PubMed před uvedením do tisku). Go to original source... Go to PubMed...
    1448. Chung YW, Han DS, Park YK, Son BK, Paik CH, et al. Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea. Dig Liver Dis. 2006; 38 (9): 668-672. Go to original source... Go to PubMed...
    1449. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, Biessy C, et al. Serum C-peptid, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007, 15; 121 (1): 368-376. Go to original source... Go to PubMed...
    1450. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000, 4; 92 (19): 1592-600. Go to original source... Go to PubMed...
    1451. Keku TO, Lund PK, Galanko J, Simmons JG, Woosley JT, Sander RS. Insulin resistence, apoptosis, and colorectal adenoma. Cancer Epidemiol Biomarkers Rev. 2005; 14 (9): 2076-2081. Go to original source... Go to PubMed...
    1452. Ma J, Giovannucci E, Pollak M, Leavitt A., Tao Y, Gaziano JM, Stampfer MJ. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004; 96 (7): 546-553. Go to original source... Go to PubMed...
    1453. Nagel JM, Göke B. Colorectal carcinoma screening in patients with type 2 diabetes mellitus. J Gastroenterol. 2006; 44 (11): 1153-1165. Go to original source...
    1454. Otani T, Iwasaki M, Sasazuki S, et al. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer 2007, 1; 120 (9): 2007-2012. Go to original source... Go to PubMed...
    1455. Procházka V, Chlup R. Kolorektální karcinom a diabetes mellitus. Vnitř lék 2008; 54(10): 979-984. Go to PubMed...
    1456. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glukose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003; 12 (5): 412-418.
    1457. Schiel R, Müller UA, Braun A, Stein G, Kath R. Risk of malignancies in patients with insulin-tread diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Eur J Med Res. 2005, 17; 10 (8): 339-344.
    1458. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young - onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007, 12; 96 (3): 507-509. Go to original source... Go to PubMed...
    1459. Svačina Šm Matoulek M, Svobodová Š et al. Nádory trávicího traktu a diabetes mellitus. Vnitř. lék 2004; 50: 386-391.
    1460. Svačina Š, Matoušek M. Diabetes a kolorektální karcinom. In Perušičová J. Trendy soudobé diabetologie, svazek 7, 1. vydání, Praha Galén 2003.
    1461. Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Amer J Epidemiol. 1998; 147 (9): 816-825. Go to original source... Go to PubMed...
    1462. Winawer SJ, Zaber AG, Gerdes H, O&Bacute;rein MJ, Gottlieb LS, Sternberg SS, Bond JH, Waye JD, Schapiro M, Panish JF, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med. 1996, 16; 334 (20): 1339-1340. Go to original source... Go to PubMed...
    1463. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004; 127 (4): 1044-1050. Go to original source... Go to PubMed...
    1464. Zavoral M, Frič P. Screening kolorektálního karcinomu. Interní Med. 2007; 3: 149-150.
    1465. ###
    1466. Cox H. et al. Clinical application of nursing diagnosis. 4th ed. Philadelphia: F. A. Davis Company. 2002; 752 s.
    1467. Doenges ME, Moorhouse MF. Kapesní průvodce zdravotní sestry; 2. vyd. Praha: Grada Publishing, 2001: 565 s.
    1468. Elkin M, Perry A, Potter P. Nursing interventions and clinical skills. 3rd ed. St. Louis: Mosby, Inc. 2004: 1021 s.
    1469. Gordon M. Nursing diagnoses: process and application. 2. vyd. St. Louis: McGraw-Hill, Inc., 1987: 515 s.
    1470. Gordon M. et al. Nursing diagnoses: definitions & classification 2001-2002. Philadelphia: NANDA, 2001-2002: 256 s.
    1471. Ralph SS, et al. NANDA. Nursing diagnoses: definitions & classification 2005-2006. Philadelphia: NANDA, 2005-2006: 240-250.
    1472. Kim M, et al. Classification of nursing diagnoses. Proceedings of the 5th ed. National conference on the classification of nursing diagnoses. St. Louis: Mosby Company. 1984: 626 s.
    1473. Kozier B, Erb G. Fundamentals of nursing. 3rd ed. California: Addison-Wesly Publishing Company, Inc. 1987: 1659 s.
    1474. Kozierová B, Erbová G. Ošetrovateľstvo 1. a 2. díl. Martin: Osveta, 1991.
    1475. Kudlová P, Marečková J. Ošetřovatelská dokumentace, plán ošetřovatelské péče - výstup 3. fáze ošetřovatelského procesu. In Ošetřovatelství perspektivní věda i umění. Ed. P. Kudlová, Olomouc: Grada Publishing, 2004: 388 s.
    1476. Marečková J, Kudlová P. Pojmy užívané při prvním kroku ošetřovatelského procesu - Posouzení. In Ošetřovatelství perspektivní věda i umění. Ed. P. Kudlová, Olomouc: Grada Publishing, 2004: 388 s.
    1477. Milliken M, Cambell G. Essential competencies for patient care. 1st ed. USA: Mosby, Inc. 1985: 826 s.
    1478. Pacovský V. Ošetřovatelská diagnostika. Praha: UK, 1994.
    1479. Trachtová E, a kol. Potřeby nemocného v ošetřovatelském procesu. Brno: IDVPZ, 1999.
    1480. Herdman TH, et al. 2009. NANDA - I. Nursing Diagnoses: Definitions & Classification 2009-2011. Philadelphia: NANDA International, 2009. 435 p. ISBN 978-1-4051-8718-3.
    1481. Herdman TH, et al. 2007. NANDA - I. Nursing Diagnoses: Definitions & Classification 2007-2008. Philadelphia: NANDA International, 2007. 339 p. ISBN 978-0-9788924-0-1.
    1482. ###
    1483. Směrnice č. 49/1967 Věstníku Ministerstva zdravotnictví, o posuzování zdravotní způsobilosti k práci, ve znění pozdějších předpisů.
    1484. Vyhláška MD č. 101/1995 Sb., kterou se vydává Řád pro zdravotní a odbornou způsobilost osob při provozování dráhy a drážní dopravy, ve znění vyhlášky MDS č. 455/2000 Sb. a vyhlášky č. 194/2005 Sb.
    1485. Vyhlášky č. 277/2004 Sb. Ministerstva zdravotnictví ČR o posuzování zdravotní způsobilosti k řízení motorových vozidel v platném znění.
    1486. Brhel P, Manoušková M, Hrnčíř E, editors. Pracovní lékařství. Brno: NCO NZO; 2005, 338 s.
    1487. Buchancová J, Mikulková R, Klimentová G, Javorková J, Buchanec J. Diabetes mellitus a profese - retrospektívna štúdia výskytu choroby, hodnoty BMI, glykemie a celkového cholesterolu v séru u vybraných skupin rizikových pracovníkov. Pracov. Lék., 2006; 58: 16-23.
    1488. Cowen G, Richardson T, Cavan D, Kerr D. Insulin and driving: clinicians' advice and patients' practice. Abstract no. 2988, In: 18th International Diabetes Federation Congress [CD-ROM]. International Diabetes Federation: Paris, 2003, 24.-29. August 2003.
    1489. De Backer G, Leynen F, Bacquer D, Clays E, Moreau M, Kornitzer M. Diabetes mellitus in middle-aged people is associated with increased sick leave: The Belstress study. Int J Occup Environ Health 2006; 12: 28-34. Go to original source... Go to PubMed...
    1490. Nakládalová M, Bartoušek J, Pešáková L, Nakládal Z, Fialová J. Profesionální poškození nervus ulnaris v oblasti lokte. Čes a slov Neurol Neurochir. 2006; 69/102, 2: 132-135.
    1491. Stork ADM, Schouten van der Velden, AP, Sels, J. WEM, Janssen, WH, Martens, MH, Erkelens, DW, Veneman, TF. Driving performance of patients with Type 2 diabetes mellitus during euglycaemia and moderate, symptomatic hypoglycaemia. Abstract no. 881, In: 18th International Diabetes Federation Congress, [CD-ROM]. International Diabetes Federation: Paris, 2003, 24.-29. August 2003.
    1492. Syllaba J. Posuzování pracovní schopnosti při diabetes mellitus, s. 331-338. In: Kol. autorů: Kompendium lékařské posudkové činnosti II/ 1. Avicenum, 1981, 544 s.
    1493. ###
    1494. Banting FG, Best CH. Pancreatic extracts, J. Lab. Clin. Med. 1922; 7, 8 (May): 3-11.
    1495. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922, 7 (2).
    1496. Berger M, et al. Léčba inzulinem v každodenním životě. Victoria publishing, Praha 1995.
    1497. Bliss M. The discovery of insulin Chicago: University of Chicago Press, 1982. Go to original source...
    1498. Bliss M. J. J. R. Macleod and the discovery of insulin. Q. J. Exp. Physiol.1989, 74: 87-96. Go to original source... Go to PubMed...
    1499. Bliss M. The history of diabetes. In, ,Textbook of Diabetes", Eds. Pickup, J. C. and Wiliams, C., Oxford Press 1993. Go to original source...
    1500. Bober J. Nositelé Nobelovy ceny. Obzor, Bratislava, 1971.
    1501. Engelhardt D. Diabetes - Its medical and cultural history. Springer-Verlag New York, Berlin, Heidelberg 1981.
    1502. Foit R, Syllaba J, et al. Diabetes mellitus. Avicenum, Praha, 1970.
    1503. Houssay BA. The discovery of pancreatic diabetes. The role of Oscar Minkowski. In: Engelhardt D. Diabetes its medical and cultural history. Springer-Verlag Berlin - Heidelberg - New York - London - Paris - Tokyo - Hongkong 1989. Go to original source...
    1504. Chlup R. Nicolae C. Paulescu a objev inzulinu: torontská etika ve stínu, ,priority"? Zprav klin Farmakol Farmac 1997; 11 (2): 24-29.
    1505. International Diabetes Federation. Report of the Special Commitee set up to present a written summary of work leading up to the discovery of insulin. News Bull. of the Int. Diab. Fed., 1974; 1: 29-40.
    1506. Ionescu-Tirgoviste C. The re-discovery of insulin. Editura Geneze, Romania, 1996. ISBN 973-9099-32-7.
    1507. Jörgens V, Minkowski HO. Past Masters Oskar Minkowski. Diabetologia 2005; 48 (8): A8.
    1508. Korec R. 50. výročí objevu a izolace inzulinu, Banting, Best and Collip 1922. In: Čas Lék Čes 110: 416-418.
    1509. Korec R. More comments on, ,Who discoverred insulin?" In: News in physiological sciences 1986: 211-212. Go to original source...
    1510. Korec R. 75th anniversary of insulin discovery: NC Paulescuś and FG Bantingś with CH Best and JB Collip contribution to insulin discovery. Acta Diabetol Romana 1996; 22: 85-86.
    1511. Korec R. Contribution of experimental diabetology to justification of intensification of intensived insulin therapy. Acta Diabetol Romana 1996; 22: 86-87.
    1512. Martin E. Problems of priority in the discovery of insulin. Schweizerische medizinische Wochenschrifft 1971; 101: 164-167.
    1513. Paulescu NC. Action de léxtrait pancreatique injecte dans le sang chez un animal diabetique. Comptes rendus des seances de la Societé de biologie 1921; 85(27): 556-559.
    1514. Paulescu NC. Recherche sur le role du panréas dans lássimilation nutritive. Liege, Arch. Int. Physiol. 1921; 7: 85-109.
    1515. Páv J. Historie světové priority začínající v Praze. In: Čas. Lék. Čes. 1986; 125: 784-785.
    1516. Scott EL. On the influence of intravenous injection of an extract of the pancreas on experimental pancreatic diabetes. Amer. Jour. of Physiol., 1912: 306. Go to original source...
    1517. Scott EL. The relation of pancreatic extract to the sugar of the blood. Soc. Exp. Bio. and Med., P. 1913: 101-103. Go to original source...
    1518. Scott EL. Priority in discovery of a substance derived from the pancreas, active in carbohydrate metabolism. Jour. Amer. Med. Ass., 1923: 1303-1304. Go to original source...
    1519. Von Mering O, Minkowski O. Diabetes mellitus nach Pankreasexstirpation. Arch. f. exp. Path. u. Pharm. 1890; 26: 371-387. Go to original source...
    1520. Zuelzer GL. Experimentell Untersuchungen ueber den Diabetes. Berliner Klin. Woch., 1907: 475.
    1521. Zuelzer GL. Ueber Versuche einer spezifischen Fermenttherapie. Des Diabetes Zeit. fur exp. Path. und Ther., 1908: 307.
    1522. Zuelzer GL, Dohrn M, Marxer A. Neue Untersuchungen ueber den experimentellen Diabetes. Deutsch. Med. Woch., 1908:307. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.